<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id><journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id><journal-title-group><journal-title>Frontiers in Immunology</journal-title></journal-title-group><issn pub-type="epub">1664-3224</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC12101089</article-id><article-id pub-id-type="doi">10.3389/fimmu.2025.1567459</article-id><article-categories><subj-group subj-group-type="heading"><subject>Immunology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Interferon and immunity: the role of microRNA in viral evasion strategies</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bayat</surname><given-names>Mobina</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2903831/overview"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Nahid-Samiei</surname><given-names>Rahil</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Sadri Nahand</surname><given-names>Javid</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/1036371/overview"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Naghili</surname><given-names>Behrouz</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2033448/overview"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>Infectious and Tropical Diseases Research Center, Tabriz University of Medical Sciences</institution>, <addr-line>Tabriz</addr-line>, <country>Iran</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>Molecular Medicine Research Center, Tabriz University of Medical Sciences</institution>, <addr-line>Tabriz</addr-line>, <country>Iran</country>
</aff><aff id="aff3">
<sup>3</sup>
<institution>Department of Virology, School of Medicine, Iran University of Medical Sciences</institution>, <addr-line>Tehran</addr-line>, <country>Iran</country>
</aff><author-notes><fn fn-type="edited-by"><p>Edited by: Won Fen Wong, University of Malaya, Malaysia</p></fn><fn fn-type="edited-by"><p>Reviewed by: Wenting Lu, Houston Methodist Research Institute, United States</p><p>Henry Puerta-Guardo, Universidad Aut&#x000f3;noma de Yucat&#x000e1;n, Mexico</p></fn><corresp id="fn001">*Correspondence: Javid Sadri Nahand, <email xlink:href="mailto:Javidsadri65@gmail.com">Javidsadri65@gmail.com</email>; <email xlink:href="mailto:sadrij@tbzmed.ac.ir">sadrij@tbzmed.ac.ir</email>; Behrouz Naghili, <email xlink:href="mailto:naghilyb@tbzmed.ac.ir">naghilyb@tbzmed.ac.ir</email>
</corresp></author-notes><pub-date pub-type="epub"><day>09</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>16</volume><elocation-id>1567459</elocation-id><history><date date-type="received"><day>27</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>26</day><month>3</month><year>2025</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2025 Bayat, Nahid-Samiei, Sadri Nahand and Naghili</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Bayat, Nahid-Samiei, Sadri Nahand and Naghili</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>Interferons (IFNs) are indispensable innate antiviral cytokines that orchestrate the vertebrate immune response against viral incursions. Nearly every cell possesses the remarkable ability to release IFNs upon detecting viral threats, triggering a robust signaling cascade that alerts neighboring cells and halts viral propagation via paracrine communication. The intricate influence of IFNs is mediated by an extensive network of proteins activated through the Jak-STAT pathways, facilitating the swift transcription of over 300 interferon-stimulated genes (ISGs) that fortify cellular defenses against replication. However, the cunning nature of viruses has led to the evolution of sophisticated evasion strategies, notably through the manipulation of host microRNAs (miRNAs) that disrupt vital components of the IFN signaling machinery. This review delves into the intricate interplay between viral infections and both host- and viral-derived miRNAs, exploring their potent roles in modulating RIG-I-like receptors, Toll-like receptors, IFN receptors, and the JAK/STAT pathway, ultimately shaping the landscape of antiviral immunity.</p></abstract><kwd-group><kwd>microRNA</kwd><kwd>virus</kwd><kwd>interferon</kwd><kwd>innate immune response</kwd><kwd>viral-encoded miRNA</kwd></kwd-group><funding-group><funding-statement>The author(s) declare that no financial support was received for the research and/or publication of this article.</funding-statement></funding-group><counts><fig-count count="4"/><table-count count="1"/><equation-count count="0"/><ref-count count="211"/><page-count count="23"/><word-count count="12909"/></counts><custom-meta-group><custom-meta><meta-name>section-in-acceptance</meta-name><meta-value>Viral Immunology</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><label>1</label><title>Introduction</title><p>The innate immune system serves as the initial defense mechanism encountering viral infections. Host cells employ pattern recognition receptors (PRRs) to detect conserved structures associated with pathogens, which subsequently engage various adaptor proteins that facilitate downstream signaling and activate the interferon (IFN) response (<xref rid="B1" ref-type="bibr">1</xref>). The IFN system is universally found in vertebrates and plays a pivotal role in antiviral defense mechanisms (<xref rid="B2" ref-type="bibr">2</xref>). Interferons are categorized into three distinct families based on their receptor interactions, mode of induction, biological functions, and amino acid homology (<xref rid="B3" ref-type="bibr">3</xref>): type I, II, and III IFNs. Type I IFNs (IFN-I) were initially identified by their antiviral activity (<xref rid="B4" ref-type="bibr">4</xref>) and in mammals, IFN-I response is critical for innate antiviral responses (<xref rid="B2" ref-type="bibr">2</xref>).</p><p>Viruses use several mechanisms to bypass the host IFN responses in order to replicate and continue their infectious cycle (<xref rid="B4" ref-type="bibr">4</xref>). One such mechanism is the deregulation of host microRNAs (miRNAs), which specifically target key factors involved in the IFN signaling pathway. This manipulation of miRNA expression levels allows viruses to disrupt the normal functioning of the IFN-mediated antiviral response, thereby gaining a selective advantage and ultimately contributing to their persistence within the host. MicroRNAs, characterized by their diminutive size and non-coding functionality, wield a significant influence on gene expression as key regulators. With an average length of approximately 22 nucleotides, these molecules exhibit a remarkable capacity for precision in their interactions with specific mRNA targets, binding to the 3&#x02019;-untranslated regions (UTRs) and thereby precipitating either a diminution of mRNA translation or the degradation of the mRNA itself. This profound impact on gene expression serves to modulate the phenotypic outcomes of cellular processes (<xref rid="B5" ref-type="bibr">5</xref>&#x02013;<xref rid="B8" ref-type="bibr">8</xref>). MicroRNAs, by virtue of their far-reaching influence on protein-coding genes, exert a profound impact on regulatory networks, including the host immune response (<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B10" ref-type="bibr">10</xref>) (<xref rid="f1" ref-type="fig">
<bold>Figure&#x000a0;1</bold>
</xref>). Notably, these non-coding RNAs have been confirmed to play a vital role in modulating the IFN cell signaling pathway, with numerous studies highlighting their contribution to this process (<xref rid="B11" ref-type="bibr">11</xref>&#x02013;<xref rid="B16" ref-type="bibr">16</xref>). Intriguingly, viruses have evolved mechanisms to subvert the regulatory function of host miRNAs, while also encoding their own miRNAs to evade the host&#x02019;s immune response. Notably, miRNAs exert fine-tuned control over the PRR-IFN signaling axis, where they can amplify or dampen antiviral signaling cascades to dynamically calibrate the host&#x02019;s response to viral invasion (<xref rid="B17" ref-type="bibr">17</xref>). In fact, viruses have adapted the host transcriptional machinery to their advantage, enabling them to produce viral miRNAs that serve their own interests (<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B19" ref-type="bibr">19</xref>). This review aims to elucidate how viruses manipulate the IFN signaling pathway by disrupting host miRNAs and deploying viral miRNAs. By shedding light on these mechanisms, we hope to provide insights into the development of more effective strategies for preventing and treating diverse viral infections.</p><fig position="float" id="f1"><label>Figure&#x000a0;1</label><caption><p>Overview of the roles of miRNAs in cellular functions. They function primarily through post-transcriptional regulation by binding to target mRNAs and guiding the RNA-induced silencing complex (RISC) for degradation or translation inhibition. miRNAs impact the cell cycle, apoptosis, stress responses, immune functions, metabolism, and epigenetic regulation. Additionally, they facilitate intercellular communication by being packaged into extracellular vesicles that influence recipient cells, contributing to tissue remodeling and immune modulation.</p></caption><graphic xlink:href="fimmu-16-1567459-g001" position="float"/></fig></sec><sec id="s2"><label>2</label><title>Innate immune system</title><p>The immune system encompasses a diverse array of cells, chemicals, and processes that work synergistically to safeguard the skin, respiratory pathways, gastrointestinal tract, and other regions from foreign antigens, including microbes (such as bacteria, fungi, and parasites), viruses, neoplastic cells, and toxins. In addition to structural and chemical barriers that offer initial protection against infections, the immune system can be broadly conceptualized as comprising two primary &#x0201c;lines of defense&#x0201d;: innate immunity and adaptive immunity (<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B21" ref-type="bibr">21</xref>). The innate immune response constitutes the primary, frontline defense against invading pathogens, providing an antigen-independent, non-specific mechanism of defense that is promptly deployed by the host upon antigen encounter. This immediate and non-specific response enables the host to rapidly and effectively counteract the incursion of pathogens, thereby safeguarding against the establishment of infection (<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B23" ref-type="bibr">23</xref>).</p><p>The innate immune system serves as a universal and fundamental defense mechanism against infectious diseases, employing various recognition strategies to detect the presence of pathogens. A key mechanism involves pattern recognition receptors (PRRs), which identify conserved microbial structures that are characteristic of entire classes of microorganisms. These receptors are adept at recognizing metabolic byproducts unique to specific microbial classes, such as lipopolysaccharides found in Gram-negative bacteria (<xref rid="B24" ref-type="bibr">24</xref>).</p><p>In the case of viral pathogens, the absence of distinct molecular components in host cells shifts the focus of innate immune recognition to viral nucleic acids. The innate immune system has evolved to recognize specific structural features of viral RNA and DNA that differentiate them from host nucleic acids. This includes the detection of long double-stranded RNA (dsRNA), RNA with 5&#x02019;-triphosphate groups, and unmethylated CpG motifs present in viral DNA genomes. However, recognizing these features alone is not enough to reliably differentiate between host and viral nucleic acids. Thus, the innate immune response relies on additional factors and context to accurately determine the origin of the nucleic acids it encounters [see (<xref rid="B24" ref-type="bibr">24</xref>)].</p><p>The mechanisms of innate immune recognition can be divided into two primary categories: cell-intrinsic and cell-extrinsic, based on whether the response is initiated by infected cells or by those that remain uninfected. Cell-intrinsic recognition occurs mainly within infected cells and is facilitated by cytosolic sensors such as NOD-like receptors (NLRs) and RIG-I-like receptors (RLRs). These receptors are expressed broadly, allowing for the detection of viral pathogens that can infect various cell types. In contrast, cell-extrinsic recognition involves transmembrane receptors, such as Toll-like receptors (TLRs) and C-type lectins (CLRs), which do not necessitate the infection of the cells expressing them. This form of recognition is predominantly carried out by specialized immune cells, including plasmacytoid dendritic cells, macrophages, and conventional dendritic cells, which are essential for initiating and coordinating the immune response (<xref rid="B24" ref-type="bibr">24</xref>).</p><p>The viral recognition by the innate immune system leads to two primary outcomes. First, it triggers the innate antiviral mechanisms, which are largely mediated by type-I interferons (IFNs). Second, it activates the adaptive immune response, which offers a more targeted, antigen-specific, and long-lasting antiviral immunity. An essential tactic in the host&#x02019;s defense against viral infections is the removal of cells that have been infected by the virus (<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B25" ref-type="bibr">25</xref>). This elimination may occur through intrinsic mechanisms driven by IFN-I within the infected cells or through the activation of cytotoxic lymphocytes, particularly natural killer (NK) cells and CD8+ T cells.</p></sec><sec id="s3"><label>3</label><title>Interferons and their regulation by miRNAs during viral infections</title><p>Antiviral mechanisms in vertebrates are fundamentally dependent on the activity of IFNs. IFNs constitute a family of cytokines that play a pivotal role early in the innate immune response, possessing the capacity to induce an antiviral state in both infected and uninfected neighboring cells (<xref rid="B26" ref-type="bibr">26</xref>). In addition to their antiviral functions, interferon cytokines are also integral to the regulation of the ensuing adaptive immune response, thereby facilitating a coordinated defense against viral pathogens (<xref rid="B25" ref-type="bibr">25</xref>).</p><p>The IFN family is categorized into three distinct types. The type I IFN family includes a multi-gene cytokine group, with 13 partially homologous IFN-&#x003b1; subtypes identified in humans and 14 in mice, in addition to a single IFN-&#x003b2; and several less well-characterized gene products (<xref rid="B27" ref-type="bibr">27</xref>, <xref rid="B28" ref-type="bibr">28</xref>). In contrast, the type II IFN (IFN-II) family consists of a singular gene product, IFN-&#x003b3;, predominantly produced by T cells and natural killer (NK) cells. This cytokine interacts with a broad spectrum of cell types expressing the IFN-&#x003b3; receptor (<xref rid="B29" ref-type="bibr">29</xref>). The type III IFN (IFN-III) family includes IFN-&#x003bb;1, IFN-&#x003bb;2, and IFN-&#x003bb;3 (also designated as IL-29, IL-28A, and IL-28B), as well as the recently identified IFN-&#x003bb;4. These cytokines share functional similarities with those of the type I IFN family; however, their activity is more limited due to the restricted expression of their receptor on epithelial cell surfaces (<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B31" ref-type="bibr">31</xref>). It is noteworthy that immune cells tend to exhibit minimal responsiveness to IFN-&#x003bb; (<xref rid="B32" ref-type="bibr">32</xref>&#x02013;<xref rid="B34" ref-type="bibr">34</xref>).</p><p>IFN-&#x003b1; and IFN-&#x003b2; are well-recognized for their capacity to establish an antiviral environment in both infected and unaffected bystander cells. They accomplish this by initiating a gene transcription program that interferes with various stages of the viral replication process through several mechanisms (<xref rid="B35" ref-type="bibr">35</xref>). Beyond their antiviral properties, these cytokines play a significant role in modulating both innate and adaptive immune responses, not only against viral pathogens but also against bacterial and other infectious agents.</p><p>The effectiveness of the IFN response during infectious diseases is highly context-dependent, shaped by factors such as the specific conditions arising from the infection, the timing and site of IFN signal delivery, and the downstream signaling pathways activated by the IFN-I receptor. These variables can result in either beneficial or adverse effects for the host (<xref rid="B24" ref-type="bibr">24</xref>) (<xref rid="f2" ref-type="fig">
<bold>Figure&#x000a0;2</bold>
</xref>).</p><fig position="float" id="f2"><label>Figure&#x000a0;2</label><caption><p>Type I, type II, and type III IFN signaling pathways. Type I and Type III IFNs bind to distinct receptor complexes, triggering the activation of downstream signaling pathways. IFN-I (e.g., IFN-&#x003b1;/&#x003b2;) bind to the IFNAR1/IFNAR2 receptor complex, leading to the phosphorylation of STAT1 and STAT2, which form a trimeric complex called ISGF3. ISGF3 then translocate to the nucleus, binding ISREs and inducing the transcription of various ISGs. Viral miRNAs can target molecules in the IFN signaling pathways, leading to the inhibition of IFN production and reduced antiviral immunity.</p></caption><graphic xlink:href="fimmu-16-1567459-g002" position="float"/></fig><p>Given the critical role of IFNs in antiviral defense, their regulation by miRNAs during viral infections is a key focus of this section. miRNAs fine-tune gene expression, including components of the IFN pathway, either enhancing or suppressing the antiviral response. To improve clarity, this section is structured around the stages of the IFN response modulated by miRNAs, from induction to effector functions and negative regulation.</p><sec id="s3_1"><label>3.1</label><title>Activation of interferons</title><p>The activation of various PRRs such as TLR3, TLR4, TLR7, TLR8, TLR9, and the RIG-I-like receptors (RLRs) such as RIG-I and MDA-5, along with cytosolic DNA sensors, culminates in the production of IFN-I. Typically, virally infected cells activate the cell-intrinsic pathway for IFN-I production through the engagement of RLRs or DNA sensors. In contrast, plasmacytoid dendritic cells (pDCs) are capable of detecting viral genomes within endosomes via the activation of TLR7 or TLR9, which leads to a robust and sustained release of IFN-&#x003b1; and IFN-&#x003b2; (<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B36" ref-type="bibr">36</xref>). pDCs are characterized by their ability to maintain elevated basal levels of interferon regulatory factor 7 (IRF7). They possess a unique capability to directly connect TLR signaling to IRF7, thereby facilitating a rapid and intense transcriptional activation of IFN-I genes. This mechanism underscores their critical role in the early innate immune response to viral infections (<xref rid="B24" ref-type="bibr">24</xref>).</p><p>This activation sets the stage for IFN production, which is tightly regulated by miRNAs, as explored in the following subsections.</p></sec><sec id="s3_2"><label>3.2</label><title>miRNAs modulating the induction of interferons during viral infections</title><p>miRNAs play a crucial role in modulating the initial induction of IFNs by targeting PRRs and their downstream signaling molecules. This regulation can either inhibit or enhance IFN production, influencing the host&#x02019;s ability to mount an effective antiviral response.</p><sec id="s3_2_1"><label>3.2.1</label><title>Targeting RIG-I-like receptors</title><p>RLRs, or retinoic acid-inducible gene I-like receptors, are a group of cytosolic RNA sensors that includes three key members: RIG-I, melanoma differentiation-associated protein 5 (MDA5), and laboratory of genetics and physiology 2 (LGP2). All three proteins share a similar structural design, featuring a central helicase domain and a carboxy-terminal domain (CTD) that collaboratively recognize immunostimulatory RNAs. RIG-I is unique in possessing an additional repressor domain (RD) at its C-terminus, which serves to inhibit its activation when in a resting state. Upon binding to viral RNA, RIG-I undergoes a conformational alteration that uncovers its caspase activation and recruitment domain (CARD), thereby triggering antiviral signaling pathways (<xref rid="B37" ref-type="bibr">37</xref>, <xref rid="B38" ref-type="bibr">38</xref>). RIG-I functions as a vital pattern recognition receptor (PRR) with the ability to detect a diverse array of viruses, such as Sendai virus (SeV), vesicular stomatitis virus (VSV), influenza virus, hepatitis C virus (HCV), Japanese encephalitis virus (JEV), and Epstein-Barr virus (EBV). Notably, EBV has a small RNA genome encoded by its DNA. This extensive recognition capacity underscores RIG-I&#x02019;s important role in the antiviral immune response, enabling it to effectively respond to various viral pathogens. By recognizing viral RNA, RIG-I initiates signaling pathways that lead to the production of type I interferons and other cytokines, ultimately enhancing the host&#x02019;s defense mechanisms against invading viruses (<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B39" ref-type="bibr">39</xref>).</p><p>MDA5 functions as a key sentinel for the detection of picornaviruses and can be activated by cytosolic synthetic dsRNA, including polyinosinic-polycytidylic acid (poly I:C) (<xref rid="B39" ref-type="bibr">39</xref>). There is notable redundancy in the recognition capabilities of MDA5 and RIG-I, as both sensors can induce type I interferon production in response to infections by viruses including dengue virus and West Nile virus. However, MDA5 demonstrates a preference for longer RNA molecules, specifically those exceeding 2 kilobases in length, while RIG-I is activated by a more diverse range of dsRNA sizes, spanning 400 base pairs to 4 kilobases (<xref rid="B39" ref-type="bibr">39</xref>, <xref rid="B40" ref-type="bibr">40</xref>). This differential sensing mechanism enables the immune system to effectively respond to a variety of viral threats, ensuring robust antiviral signaling and the subsequent activation of innate immune responses.</p><p>miRNAs regulate RLR activity during viral infection as follows:</p><p>The discovery of RIG-I and MDA5 as inducers of type I interferons has represented a significant advancement in immunology over the past two decades (<xref rid="B41" ref-type="bibr">41</xref>, <xref rid="B42" ref-type="bibr">42</xref>). Both RIG-I and MDA5, members of the RLR family, play essential roles in the recruitment of IPS-1 (known as Cardif, VISA, or MAVS), a multifunctional adaptor protein located on the outer mitochondrial membrane. This recruitment is a critical step that triggers a signaling cascade, activating key transcription factors such as IRF3, IRF7, and NF-&#x003ba;B. The activation of these transcription factors results in the expression of a broad array of genes, particularly those encoding IFNs-I. IFNs-I are pivotal in modulating immune responses and exerting antiviral effects, as they enhance the antiviral state of neighboring cells, promote the activation of immune cells, and inhibit viral replication. This interplay highlights the important role of RLRs and IPS-1 in orchestrating the host&#x02019;s antiviral defense mechanisms (<xref rid="B43" ref-type="bibr">43</xref>). The intricate antiviral signaling mechanisms are tightly regulated through the activation of RIG-I and other key intermediates within the pathway. Post-translational modifications, particularly ubiquitylation and phosphorylation, have been identified as essential mechanisms that activate RIG-I, helping to enhance its function. Notably, many viruses have evolved strategies to target these modifications, aiming to delay or evade the host immune response. By disrupting these critical signaling pathways, viruses attempt to circumvent the host&#x02019;s defenses, thereby promoting their own survival and replication (<xref rid="B44" ref-type="bibr">44</xref>, <xref rid="B45" ref-type="bibr">45</xref>).</p><p>Rhabdovirus has been shown to induce the overexpression of miR-3570, which promotes viral replication by suppressing the production of IFNs and inhibiting the activation of the NF-&#x003ba;B and IRF3 signaling pathways, primarily through the downregulation of MAVS (<xref rid="B46" ref-type="bibr">46</xref>). Furthermore, the expression of miR-485 is induced in response to infections with various RNA viruses, including Newcastle disease virus (NDV) and influenza virus, as well as during the transfection of cells with poly(I:C), a synthetic mimic of viral dsRNA. Elevated levels of miR-485 have also been observed in human peripheral blood mononuclear cells (PBMCs) following such transfections. Importantly, miR-485 directly targets the 3&#x02019; UTR of the RIG-I gene, which plays a pivotal role in the recognition of viral RNA and the initiation of the antiviral immune response. Ectopic expression of miR-485 in both human and mouse cells has been shown to disrupt the RIG-I-dependent antiviral pathway, resulting in compromised antiviral signaling and increased viral loads. This highlights the critical role of miR-485 as a regulatory molecule that can modulate the host&#x02019;s antiviral response, showcasing how RNA viruses may employ host cellular mechanisms, such as miRNAs, to evade immune detection and promote their replication. Through the regulation of key components like RIG-I, miRNAs such as miR-485 serve as important fine-tuning agents in the host&#x02019;s immune response to viral infections. Ingle et&#x000a0;al. (<xref rid="B11" ref-type="bibr">11</xref>) demonstrated that miR-485 forms a stable complex with human Argonaute 2 (Ago2) protein and is recruited to the RIG-I transcript during viral infections. This interaction suggests a significant role for miR-485 in the post-transcriptional regulation of RIG-I, a key sensor of viral RNA and an important player in the antiviral immune response. Additionally, miR-485 impacts the signaling cascade downstream of RIG-I, influencing the expression of genes encoding type I and III IFNs.</p><p>Overexpression of miR-485 has been shown to significantly inhibit the transcriptional activities of promoters for IFN-&#x003b1;4, IFN-&#x003b2;, ISRE (interferon-stimulated response element), and IL-29 in response to infections with NDV. Notably, infections with highly pathogenic viruses such as H5N1 and NDV have been observed to reduce the levels of IFN-&#x003b1;, IFN-&#x003b2;, IP10, and IL-29 mRNAs in the presence of miR-485 in both human and mouse cell lines.</p><p>Mechanistically, the upregulation of miR-485 by NDV and influenza A virus (IAV) facilitates viral replication by suppressing virus-induced expression of IFN-I and IFN-III through direct targeting of RIG-I. This emphasizes the sophisticated interplay between viral pathogens and host miRNA-mediated regulation. It highlights how viruses can manipulate host cellular pathways, particularly miRNA expression, to evade the immune response. Overall, these findings underscore the potential of miRNAs as critical modulators of antiviral immunity, presenting new avenues for understanding host-pathogen interactions and developing therapeutic strategies against viral infections (<xref rid="B11" ref-type="bibr">11</xref>).</p><p>The intricate dynamics between microRNAs and the immune system are exemplified by the dual roles of miR-92a and miR-218 in facilitating VSV replication. By targeting RIG-I in macrophages, these microRNAs inhibit the production of type I interferons, thereby creating an environment conducive to viral propagation (<xref rid="B47" ref-type="bibr">47</xref>, <xref rid="B48" ref-type="bibr">48</xref>).</p><p>In a separate context, HBV-induced miR146a exhibits a distinct mechanism of action, suppressing the expression of both RIG-I and its enhancer RIG-G, leading to a diminution of IFN-I production and impairment of innate immunity (<xref rid="B49" ref-type="bibr">49</xref>). Furthermore, the studies by Lu et&#x000a0;al. (<xref rid="B50" ref-type="bibr">50</xref>) highlight the intricate relationship between microRNAs and the immune system, particularly in the context of viral infections. Their research demonstrates that EBV-encoded miR-BART6-3p plays a crucial role in inhibiting genes involved in the RLR signaling pathway and the IFN-I response. Notably, this specific microRNA has a preferential effect in suppressing RIG-I-like receptor signaling-mediated production of IFN-&#x003b2;, highlighting its unique function in modulating the immune response during EBV infection (<xref rid="B50" ref-type="bibr">50</xref>). In contrast, miR-136 exhibits a protective effect on host defense against H5N1 IAV replication <italic>in vitro</italic>. Through its mechanism of action as a ligand for RIG-I during infection, miR-136 triggers innate immunity and IFN production, thereby bolstering the host&#x02019;s defense against viral invasion (<xref rid="B51" ref-type="bibr">51</xref>).</p><p>Fibroblast growth factor 2 (FGF2), a multifaceted signaling molecule, has been implicated in a diverse array of biological processes, such as the intricate dynamics of angiogenesis, the complex cascade of embryonic development, and the orchestrated response of wound healing (<xref rid="B52" ref-type="bibr">52</xref>). Furthermore, recent studies have suggested an unexpected role for FGF2 in innate immune signaling, where it interacts with the RIG-I receptor family members MDA5 and RIG-I (<xref rid="B53" ref-type="bibr">53</xref>). Although FGF2 has been shown to bind to both receptors, the majority of research has focused on its interaction with RIG-I, a dsRNA helicase that plays a crucial role in the recognition of viral RNA (<xref rid="B37" ref-type="bibr">37</xref>). The binding of FGF2 to RIG-I&#x02019;s CARD domain stabilizes the protein by preventing its ubiquitination and subsequent proteasomal degradation (<xref rid="B53" ref-type="bibr">53</xref>). Surprisingly, FGF2 has been found to negatively regulate RIG-I functioning by disrupting IPS-1 binding suggesting a complex interplay between FGF2 and RIG-I. This dichotomous behavior highlights the intricate nuances of FGF2&#x02019;s role in innate immunity (<xref rid="B53" ref-type="bibr">53</xref>). In a striking contrast to its negative regulatory effects on RIG-I, administration of recombinant FGF2 protein has been shown to significantly alleviate the severity of IAV-induced lung injury and promote the survival of IAV-infected animals by recruiting neutrophils. These results indicate that FGF2 can play a vital role in modulating the host&#x02019;s response to viral infection, underscoring the importance of further investigation into its immunomodulatory functions (<xref rid="B54" ref-type="bibr">54</xref>).</p><p>A study published by Wang et&#x000a0;al. (<xref rid="B55" ref-type="bibr">55</xref>) has highlighted the complex interaction between FGF2 isoforms and the immune response during IAV infection. They demonstrated that overexpressing high-molecular-weight isoforms of FGF2 in A549 cells results in enhanced production of IFN-I and suppressed viral replication in response to IAV challenge. This suggests that different molecular weight isoforms of FGF2 may have unique functions in modulating antiviral responses (<xref rid="B55" ref-type="bibr">55</xref>). Importantly, the study revealed that miR-194 directly targets FGF2, leading to decreased expression of FGF2 at both mRNA and protein levels. The upregulation of miR-194 was shown to facilitate IAV replication by downregulating IFN-I production. Conversely, reintroducing FGF2 could counteract these effects, demonstrating that FGF2 plays a vital role in the antiviral response. Inhibition of miR-194 was found to mitigate IAV-induced lung injury <italic>in vivo</italic>, likely due to enhanced IFN-I antiviral activities. Further investigation uncovered that FGF2 activates the RIG-I signaling cascade, while miR-194 suppresses the phosphorylation of tank-binding kinase 1 (TBK1) and IFN regulatory factor 3 (IRF3) (<xref rid="B55" ref-type="bibr">55</xref>). Overall, the study suggests that miR-194 downregulates IFN-I production triggered by IAV infection by targeting FGF2, thereby repressing the RIG-I pathway. Notably, FGF2 can block the miR-194-induced decrease in IFN-I, reinforcing its role in activating RIG-I signaling. In a related study, it was also found that miR-21-3p promotes IAV (H5N1) replication through downregulation of IFN-I response via targeting FGF2 (<xref rid="B56" ref-type="bibr">56</xref>) (<xref rid="f3" ref-type="fig">
<bold>Figure&#x000a0;3</bold>
</xref>). This further underscores the role of specific miRNAs in manipulating host immune responses, particularly in the context of viral infections, and illustrates the potential for targeting these pathways in therapeutic strategies against such pathogens.</p><fig position="float" id="f3"><label>Figure&#x000a0;3</label><caption><p>Role of RIG-I-like receptors (RLRs) in viral infection. Schematic representation of viral invasion and RIG-I-like receptor (RLR) activation. Viral replication in the host cell produces pathogen-associated molecular patterns (PAMPs) such as viral dsRNA, which is recognized by RLRs. Upon activation, RLRs induce the expression of type I interferons (IFNs) and pro-inflammatory cytokines through the activation of downstream signaling cascades, including IRF-3/7 and NF-&#x003ba;B. Viral miRNAs can target and inhibit the activation of RLRs and their downstream signaling cascades, leading to decreased expression of IFN-&#x003b2; and other pro-inflammatory cytokines. This diminishes the host&#x02019;s antiviral response and promotes viral evasion of host immunity.</p></caption><graphic xlink:href="fimmu-16-1567459-g003" position="float"/></fig><p>Under normal physiological conditions, the RIG-I/MDA5 pathway is latent, existing in a state of repression within the cytoplasm (<xref rid="B57" ref-type="bibr">57</xref>, <xref rid="B58" ref-type="bibr">58</xref>). However, upon viral infection, RIG-I/MDA5 undergoes a paradigmatic shift, as it recognizes viral RNA and undergoes conformational changes that enable its activation. These alterations promotes the interaction between RIG-I/MDA5 and MAVS, a key adaptor protein localized to the surface of mitochondria (<xref rid="B59" ref-type="bibr">59</xref>). The MAVS-mediated dimerization event initiates a signaling cascade that serves as a hub for complex assembly at the outer mitochondrial membrane. This platform attracts key molecules, including TRAF6, which is recruited to the IRAK1-IRAK4-MyD88 adaptor complex. Upon recruitment, TRAF6 undergoes K63-linked polyubiquitination, thereby creating a binding site for downstream regulators. Specifically, TAK1 and TAB2/3 proteins bind to this ubiquitinated TRAF6, triggering the activation of the TAK1-TAB2/3 complexes. This activation subsequently results in the nuclear translocation of NF-&#x003ba;B, ultimately driving the transcriptional activation of genes involved in producing the inflammatory cytokines (<xref rid="B60" ref-type="bibr">60</xref>, <xref rid="B61" ref-type="bibr">61</xref>).</p><p>The RLRs interact with MAVS, initiating a signaling cascade that recruits various proteins, including TRAF3, TBK1, IKK&#x003f5;, IKK&#x003b3; (also known as NEMO), IKK&#x003b1;, and IKK&#x003b2;. This recruitment culminates in the activation and nuclear translocation of the transcription factors IRF3 and NF-&#x003ba;B, which play pivotal roles in the antiviral response (<xref rid="B62" ref-type="bibr">62</xref>, <xref rid="B63" ref-type="bibr">63</xref>). Research has shown that miRNAs can inhibit the interferon response and suppress the innate immune system during viral infections by regulating the expression of key factors. For instance, miR-200b-3p plays a role in the replication of IAV and VSV by suppressing NF-&#x003ba;B activity and promoting IFN-I production via IRF3-mediated signaling, which is achieved through targeting TBK1 (<xref rid="B64" ref-type="bibr">64</xref>). Similarly, when SCRV is present, miR-15b promotes viral replication by suppressing the production of IFN-I and inflammatory cytokines through the inhibition of TBK1 (<xref rid="B65" ref-type="bibr">65</xref>, <xref rid="B66" ref-type="bibr">66</xref>). Liang et&#x000a0;al. discovered that IKK&#x003b5; is directly targeted by the microRNA miR-K12-11 encoded by Kaposi&#x02019;s sarcoma-associated herpesvirus (KSHV). Their investigation revealed that increased levels of miR-K12-11 led to downregulation of IKK&#x003b5;, whereas inhibiting miR-K12-11 restored IKK&#x003b5; levels in cells infected with KSHV. Additionally, the authors established that the expression of miR-K12-11 disrupts interferon signaling pathways, which in turn diminishes antiviral immune responses (<xref rid="B67" ref-type="bibr">67</xref>). These results illustrate the capacity of viral microRNAs to modulate immune signaling and promote the viral lifecycle. Given that the innate immune response is linked to the reactivation of KSHV, and considering that miR-K12-11 is expressed during both the latent and lytic stages of infection, it is proposed that miR-K12-11 may play a role in preserving KSHV latency by targeting IKK&#x003b5; (<xref rid="B67" ref-type="bibr">67</xref>).</p></sec><sec id="s3_2_2"><label>3.2.2</label><title>Targeting toll-like receptors during viral infections</title><p>TLRs represent the most extensively researched components of the PRR family, serving to identify conserved molecular signatures present across a diverse array of microorganisms. In mice, there are 11 functional TLRs (TLR1-7, 9, 11-13), whereas humans have TLR1-10. All TLRs are characterized as type I transmembrane proteins, featuring leucine-rich repeat (LRR) domains within their ectodomains that facilitate the recognition of PAMPs. Certain TLRs are adept at recognizing bacterial, fungal, and protozoan entities, while others are specifically tailored to identify viral pathogens (<xref rid="B68" ref-type="bibr">68</xref>, <xref rid="B69" ref-type="bibr">69</xref>).</p><p>Upon the detection of a virus, the activation of TLRs initiates a multifaceted signaling cascade that diverges into two primary pathways. This process ultimately culminates in the secretion of pro-inflammatory cytokines through the NF-&#x003ba;B pathway and the production of antiviral cytokines, specifically IFN-I, via the IRF pathway. Moreover, TLR signaling is known to engage mitogen-activated protein kinases (MAPKs). Specific TLRs, including TLR3, TLR7, TLR8, and TLR9, located within the endosomal membrane, are responsible for discriminating viral pathogens. These receptors can interact with viral nucleic acids following the endocytosis of viral particles (<xref rid="B69" ref-type="bibr">69</xref>). The endosomal TLRs, specifically TLR3/7/9 depend on the endoplasmic reticulum membrane protein UNC93B for their trafficking to the endosome. UNC93B forms a physical interaction with these TLRs via their transmembrane domains, facilitating their transport to the endosomal compartment. Upon arrival in the endosome, the TLRs associate with adaptor proteins, namely TRIF and MYD88, which activate interferon regulatory factors IRF3 and IRF7. Once activated, IRF3 and IRF7 bind to the promoter region of the IFN-&#x003b2; gene, triggering its transcription. The consequently released IFN-&#x003b2; initiates paracrine signaling through the IFN&#x003b1;/&#x003b2; receptor, which in turn activates a myriad of interferon-stimulated genes (ISGs). Additionally, phosphorylated IRF3 has the capability to independently activate specific ISGs, including those encoding IFIT and IFITM genes, without reliance on IFN signaling (<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B70" ref-type="bibr">70</xref>).</p><p>During infections caused by viruses or bacteria, as well as during the phagocytosis of apoptotic cells, DNA can be released and found within the cytoplasm and endosomes. Within the endosomal compartment, TLR9 plays a crucial role in recognizing unmethylated CpG DNA, which activates the adaptor protein MYD88. This activation leads to a downstream signaling cascade that promotes pro-inflammatory responses. Conversely, DNA that is present in the cytoplasm can be recognized by other sensors, such as DAI (DNA-dependent activator of interferon-regulatory factors) or IFI16 (interferon gamma-inducible protein 16). This recognition triggers a distinct signaling pathway that is dependent on the activation of STING (Stimulator of Interferon Genes), leading to the activation of both IRF3 and NF-&#x003ba;B. Furthermore, the activated cytoplasmic DNA is transcribed by RNA polymerase III into short RNA molecules that possess a 5&#x02019;-triphosphate (5&#x02019;-ppp) motif. These short RNAs then serve as ligands for the cytosolic receptor RIG-I, triggering antiviral signaling pathways. In addition, helicases such as DHX9 and DHX36 can bind to specific DNA ligands, including CpG-A and CpG-B, within the cytosol. This interaction further induces MYD88 and IRF7-dependent signaling responses, enhancing the host&#x02019;s immune reaction against the infection. This multilayered detection and response system ensures that the immune system effectively recognizes and responds to different forms of pathogenic DNA (<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B62" ref-type="bibr">62</xref>).</p><p>miRNAs modulate TLR signaling during viral infections as follows:</p><p>Various viruses have evolved strategies to evade IFN-I responses by targeting TLR-dependent signaling pathways. They also manipulate host and viral miRNAs that regulate these pathways. For instance, during HCV infection, increased levels of miR-758 suppress the expression of TLR3 and TLR7. This suppression leads to reduced production of IFN-&#x003b1; and IFN-&#x003b2;, weakening the antiviral response. Such tactics highlight the complex interaction between viral evasion mechanisms and host immune regulatory pathways, which is crucial for developing effective antiviral therapies and vaccines (<xref rid="B14" ref-type="bibr">14</xref>). MiR-155 facilitates HIV replication by suppressing the antiviral innate immune response. It targets TLR3, NF-&#x003ba;B, and IRF-3, inhibiting key immune signaling pathways and diminishing the host&#x02019;s ability to combat the virus. This interplay between miR-155 and HIV underscores potential therapeutic targets (<xref rid="B71" ref-type="bibr">71</xref>). The overexpression of let-7a/b in cells infected with JEV exacerbates neuroinflammation and neurodegeneration. This effect is mediated by an increase in TNF-&#x003b1; production and apoptosis, driven by the activation of TLR7 and the Notch signaling pathway (<xref rid="B72" ref-type="bibr">72</xref>). MiR-125b attenuates the innate immune response to HCV infection by downregulating the TLR2/MyD88 signaling pathway. Similarly, miR-140-5p enhances the replication of RSV by decreasing levels of IFN&#x003b1; and inflammatory factors through the inhibition of TLR4 (<xref rid="B73" ref-type="bibr">73</xref>) (<xref rid="T1" ref-type="table">
<bold>Table&#x000a0;1</bold>
</xref>).</p><table-wrap position="float" id="T1"><label>Table&#x000a0;1</label><caption><p>Effect of viral-deregulated cellular miRNAs on the TLR and RLR pathway.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Viral infection</th><th valign="top" align="left" rowspan="1" colspan="1">MicroRNA (Up/Down)</th><th valign="top" align="left" rowspan="1" colspan="1">Target</th><th valign="top" align="left" rowspan="1" colspan="1">Note</th><th valign="top" align="left" rowspan="1" colspan="1">Ref</th></tr></thead><tbody><tr><th valign="top" colspan="5" align="center" rowspan="1">
<italic>Retroviridae</italic>
</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">HIV</td><td valign="top" align="left" rowspan="1" colspan="1">miR-155</td><td valign="top" align="left" rowspan="1" colspan="1">TLR3, NF-&#x003ba;B and IRF-3</td><td valign="top" align="left" rowspan="1" colspan="1">miR-155 promotes HIV replication in HIV progresses by inhibiting anti-viral innate response through targeting TLR3, NF-&#x003ba;B and IRF-3.</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B71" ref-type="bibr">71</xref>)</td></tr><tr><th valign="top" colspan="5" align="center" rowspan="1">
<italic>Flaviviridae</italic>
</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">JEV</td><td valign="top" align="left" rowspan="1" colspan="1">miR-155</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">miR-155 alleviates peripheral nerve injury induced by negatively regulating NF-&#x003ba;B regulated downstream genes.</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B74" ref-type="bibr">74</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">JEV</td><td valign="top" align="left" rowspan="1" colspan="1">let-7a/b</td><td valign="top" align="left" rowspan="1" colspan="1">TLR7</td><td valign="top" align="left" rowspan="1" colspan="1">JEV-overexpressed let-7a/b enhances neuro-inflammation and neurodegeneration by positively regulating TNF-&#x003b1; and apoptosis through targeting TLR7 and NOTCH pathway.</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B72" ref-type="bibr">72</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">JEV</td><td valign="top" align="left" rowspan="1" colspan="1">miR-29b</td><td valign="top" align="left" rowspan="1" colspan="1">TNFIAP3</td><td valign="top" align="left" rowspan="1" colspan="1">miR-29b contributes to JEV pathogenesis by promoting pro-inflammatory cytokines production through targeting TNFIAP3 in microglia cells.</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B75" ref-type="bibr">75</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">JEV</td><td valign="top" align="left" rowspan="1" colspan="1">miR-19b-3p</td><td valign="top" align="left" rowspan="1" colspan="1">RNF11</td><td valign="top" align="left" rowspan="1" colspan="1">JEV-induced miR-19b-3p promotes JEV-mediates inflammatory cytokine by activating NF-kB signaling through targeting RNF11.</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B76" ref-type="bibr">76</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">HCV</td><td valign="top" align="left" rowspan="1" colspan="1">miR-125b</td><td valign="top" align="left" rowspan="1" colspan="1">TLR2/MyD88 signaling</td><td valign="top" align="left" rowspan="1" colspan="1">miR-125b inhibits HCV-induced innate immune responses by negatively regulating TLR2/MyD88 signaling</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B77" ref-type="bibr">77</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ZIKV&#x02003;</td><td valign="top" align="left" rowspan="1" colspan="1">miR-146a</td><td valign="top" align="left" rowspan="1" colspan="1">TRAF6 and STAT-1</td><td valign="top" align="left" rowspan="1" colspan="1">ZIKV NS1-induced miR-146a facilitates viral replication by suppressing pro-inflammatory through negatively regulating TRAF6 and STAT-1.</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B78" ref-type="bibr">78</xref>)</td></tr><tr><th valign="top" colspan="5" align="center" rowspan="1">
<italic>Hepadnaviridae</italic>
</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">HBV</td><td valign="top" align="left" rowspan="1" colspan="1">miR-30e</td><td valign="top" align="left" rowspan="1" colspan="1">TRIM38, TANK, ATG12, BECN1, SOCS3, and SOCS1</td><td valign="top" align="left" rowspan="1" colspan="1">Upregulated miR-30e suppresses viral replication by enhancing innate immunity by targeting TRIM38, TANK, ATG12, BECN1, SOCS3, and SOCS1.</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B79" ref-type="bibr">79</xref>)</td></tr><tr><th valign="top" colspan="5" align="center" rowspan="1">
<italic>Paramyxoviridae</italic>
</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">RSV</td><td valign="top" align="left" rowspan="1" colspan="1">miR&#x02212;140&#x02212;5p</td><td valign="top" align="left" rowspan="1" colspan="1">TLR4</td><td valign="top" align="left" rowspan="1" colspan="1">miR-140-5p contributes to RSV replication by negatively regulating the levels of IFN&#x003b1; and inflammation factors through targeting TLR4.</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B73" ref-type="bibr">73</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NDV</td><td valign="top" align="left" rowspan="1" colspan="1">miR-30e</td><td valign="top" align="left" rowspan="1" colspan="1">TRIM38, TANK, ATG12, BECN1, SOCS3, and SOCS1</td><td valign="top" align="left" rowspan="1" colspan="1">Upregulated miR-30e enhances antiviral innate immunity by suppressing immune regulators (SOCS1, SOCS3, TRIM38, TANK) and autophagy-related genes (ATG12, BECN1), thereby restricting viral replication.</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B79" ref-type="bibr">79</xref>)</td></tr><tr><th valign="top" colspan="5" align="center" rowspan="1">
<italic>Rhabdoviridae</italic>
</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">VSV</td><td valign="top" align="left" rowspan="1" colspan="1">miR-33/33*</td><td valign="top" align="left" rowspan="1" colspan="1">MAVS</td><td valign="top" align="left" rowspan="1" colspan="1">miR-33/33* negatively regulates innate anti-viral responses by targeting MAVS.</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B80" ref-type="bibr">80</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">VSV</td><td valign="top" align="left" rowspan="1" colspan="1">miR-136</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">Innate antiviral responses are enhanced by miR-136 through activation of RIG-I signaling</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B51" ref-type="bibr">51</xref>)</td></tr><tr><th valign="top" colspan="5" align="center" rowspan="1">
<italic>Orthomyxoviridae</italic>
</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">IAV</td><td valign="top" align="left" rowspan="1" colspan="1">miR-125a or -b</td><td valign="top" align="left" rowspan="1" colspan="1">MAVS</td><td valign="top" align="left" rowspan="1" colspan="1">miR-125a or -b contributes to IAV replication by positively regulating inflammatory cytokines and negatively regulating antiviral cytokines through targeting A20 and MAVS, respectively.</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B81" ref-type="bibr">81</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">H5N1</td><td valign="top" align="left" rowspan="1" colspan="1">miR-136</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">miR-136 enhances innate anti-viral responses by activating RIG-I signaling.</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B51" ref-type="bibr">51</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">H5N1</td><td valign="top" align="left" rowspan="1" colspan="1">H5N1 miR-HA-3p</td><td valign="top" align="left" rowspan="1" colspan="1">PCBP2</td><td valign="top" align="left" rowspan="1" colspan="1">H5N1-encoded miRNA-like small RNA, miR-HA-3p, triggers cytokine storm by promoting proinflammatory cytokine production through targeting PCBP2.</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B82" ref-type="bibr">82</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">IVA (H1N1)</td><td valign="top" align="left" rowspan="1" colspan="1">miR-29c</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">IAV-overexpressed miR-29c negatively regulates NF-&#x003ba;B activity and the expression of proinflammatory and antiviral cytokines through increasing A20 levels.</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B83" ref-type="bibr">83</xref>)</td></tr><tr><th valign="top" colspan="5" align="center" rowspan="1">Togaviridae</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CHIKV</td><td valign="top" align="left" rowspan="1" colspan="1">miR-146a</td><td valign="top" align="left" rowspan="1" colspan="1">TRAF6, IRAK1 and IRAK2</td><td valign="top" align="left" rowspan="1" colspan="1">CHIKV-overexpressed miR-146a alleviates pro-inflammatory immune responses by negatively regulating NF-kB through decreasing TRAF6, IRAK1 and IRAK2 levels.</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B84" ref-type="bibr">84</xref>)</td></tr><tr><th valign="top" colspan="5" align="center" rowspan="1">
<italic>Arteriviridae</italic>
</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PRRSV</td><td valign="top" align="left" rowspan="1" colspan="1">miR-125b</td><td valign="top" align="left" rowspan="1" colspan="1">NF-kB</td><td valign="top" align="left" rowspan="1" colspan="1">miR-125b restricts PRRSV replication by negatively regulating NF-kB.</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B85" ref-type="bibr">85</xref>)</td></tr><tr><th valign="top" colspan="5" align="center" rowspan="1">
<italic>Coronaviridae</italic>
</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">OC43</td><td valign="top" align="left" rowspan="1" colspan="1">miR-9</td><td valign="top" align="left" rowspan="1" colspan="1">NFKB1</td><td valign="top" align="left" rowspan="1" colspan="1">N protein of HCoV OC43 control the host inflammatory response by promoting NF-kB1 expression levels through inhibiting miR-9.</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B86" ref-type="bibr">86</xref>)</td></tr><tr><th valign="top" colspan="5" align="center" rowspan="1">
<italic>Picornaviridae</italic>
</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">EV71</td><td valign="top" align="left" rowspan="1" colspan="1">miR-302 cluster</td><td valign="top" align="left" rowspan="1" colspan="1">KPNA2</td><td valign="top" align="left" rowspan="1" colspan="1">Upregulated miR-302 cluster inhibits inflammatory cytokine production by targeting KPNA2, in return, EV71 promotes inflammatory cytokine production by suppressing miR-302 family.</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B87" ref-type="bibr">87</xref>)</td></tr><tr><th valign="top" colspan="5" align="center" rowspan="1">Herpesviridae</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">KSHV</td><td valign="top" align="left" rowspan="1" colspan="1">KSHV- miR-K9</td><td valign="top" align="left" rowspan="1" colspan="1">IRAK1 and MYD88</td><td valign="top" align="left" rowspan="1" colspan="1">KSHV-encoded miR-K9 regulates KSHV reactivation by regulating TLR7/8 signaling through targeting IRAK1 and MYD88.</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B88" ref-type="bibr">88</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">HCMV</td><td valign="top" align="left" rowspan="1" colspan="1">HCMV- miR-UL112-3p</td><td valign="top" align="left" rowspan="1" colspan="1">TLR2</td><td valign="top" align="left" rowspan="1" colspan="1">HCMV-encoded miR-UL112-3p modulates innate immune response by negatively regulating TLR2-dependent activation of NF-&#x003ba;B and IRAK1.</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B89" ref-type="bibr">89</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">EBV</td><td valign="top" align="left" rowspan="1" colspan="1">EBV BHRF1-2-5p</td><td valign="top" align="left" rowspan="1" colspan="1">IL-1 receptor 1 (IL1R1)</td><td valign="top" align="left" rowspan="1" colspan="1">EBV miR-BHRF1-2-5p inhibits inflammatory cytokine expression by targeting IL1R1.</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B90" ref-type="bibr">90</xref>)</td></tr></tbody></table></table-wrap><p>Furthermore, viral-encoded microRNAs have the capacity to modulate the host&#x02019;s innate immune response by TLRs. Specifically, human cytomegalovirus (HCMV)-encoded miR-UL112-3p exerts its effect by inhibiting TLR2-mediated activation of both NF-&#x003ba;B and IRAK1 (<xref rid="B89" ref-type="bibr">89</xref>). KSHV-encoded miR-K9 plays a role in controlling KSHV reactivation by modulating TLR7/8 signaling (<xref rid="B88" ref-type="bibr">88</xref>). HIV-derived miR-88 and miR-99, bind to TLR8 and stimulate the release of pro-inflammatory factors such as TNF&#x003b1;, IL-6, and IL-12 from macrophages. This mechanism may play a role in the chronic abnormal immune activation observed in HIV infection (<xref rid="B91" ref-type="bibr">91</xref>).</p></sec><sec id="s3_2_3"><label>3.2.3</label><title>Targeting signaling molecules</title><sec id="s3_2_3_1"><label>3.2.3.1</label><title>Downstream signaling molecules are also miRNA targets</title><p>IRAK1 has been identified as a negative regulator of RIG-I-mediated IFN-I signaling, exerting a suppressive influence on downstream antiviral responses (<xref rid="B92" ref-type="bibr">92</xref>). In contrast, TRAF6 interacts with phosphorylated IRAK1 to facilitate the activation of NF-&#x003ba;B, which is crucial for the subsequent induction of type I IFN (<xref rid="B93" ref-type="bibr">93</xref>, <xref rid="B94" ref-type="bibr">94</xref>). Dysregulation of the RIG-I pathway and IFN production, particularly through the targeting of MAVS and the TRAF6/IRAK1 complex by aberrant microRNA regulation, has been a subject of investigations in various studies (<xref rid="SM1" ref-type="supplementary-material">
<bold>Supplementary Table&#x000a0;1</bold>
</xref>). For instance, a study by Mo et&#x000a0;al. confirmed that the overexpression of miR-146a-5p during hepatitis A virus (HAV) infection impairs RIG-I/MDA5-mediated IFN-I signaling by promoting the cleavage of TRAF6, a vital adaptor protein in the RIG-I/MDA5-mediated IFN-I signaling cascade (<xref rid="B95" ref-type="bibr">95</xref>). Furthermore, miR-146a has been shown to negatively regulate IFN-I production triggered by vesicular stomatitis virus (VSV) infection in macrophages, thereby enhancing VSV replication through its targeting of TRAF6 and IRAK1/2 (<xref rid="B96" ref-type="bibr">96</xref>). Additionally, IRAK1 and IRAK2 are involved in IFN-I production induced by VSV infection, interacting with Fas-associated death domain protein (FADD), an important adaptor molecule in the RIG-I signaling pathway, in a virus-induced manner (<xref rid="B96" ref-type="bibr">96</xref>). Both miR-146a and miR-125a, which are upregulated during viral infections, function as negative regulators of the RIG-I-dependent antiviral pathway by targeting key components such as TRAF6, IRAK1, and IRAK2. Specifically, miR-146a targets TRAF6, IRAK1, and IRAK2 to suppress the pathway, while miR-125a targets MAVS and TRAF6 to disrupt IFN-I signaling, ultimately promoting viral replication, including that of HCV (<xref rid="B97" ref-type="bibr">97</xref>). Moreover, microRNA-146a has been highlighted as playing a crucial role in enabling viruses to evade the antiviral response by targeting TRAF6 and IRAK2, particularly noted during enterovirus 71 (EV71) infection (<xref rid="B98" ref-type="bibr">98</xref>, <xref rid="B99" ref-type="bibr">99</xref>). This underscores the significance of miR-146a and the associated regulatory pathways in modulating the innate immune response, illustrating how viruses can exploit host cellular mechanisms to enhance their replication and survival.</p><p>Importantly, miRNAs have been evidenced to directly target IFN mRNAs during viral infections. For example, Li et&#x000a0;al. (<xref rid="B13" ref-type="bibr">13</xref>) established that miR-466l directly binds to the 3&#x02019; UTRs of various IFN-&#x003b1; mRNA species, particularly to the AU-rich elements (AREs) in the 3&#x02019; UTRs of multiple IFN-&#x003b1; subtypes. This interaction inhibits IFN-&#x003b1; production and promotes viral replication (<xref rid="B13" ref-type="bibr">13</xref>). Additionally, members of the miR-548 family have been shown to target the 3&#x02019; UTR of IFN-&#x003bb;1 mRNA. Additional research has shown that miR-548 mimics reduce the expression of IFN-&#x003bb;1, whereas complementary inhibitors can increase IFN-&#x003bb;1 levels and induce the expression of ISGs. Significantly, miR-548 mimics promote infections caused by EV71 and VSV, while the application of inhibitors effectively hampers their replication (<xref rid="B100" ref-type="bibr">100</xref>). Overall, miR-548 seems to weaken the host&#x02019;s antiviral response by directly targeting IFN-&#x003bb;1, thereby facilitating the replication of EV71 and VSV, making it a potential candidate for antiviral therapies.</p><p>This modulation of IFN induction by miRNAs directly impacts downstream signaling, as discussed next.</p></sec></sec><sec id="s3_2_4"><label>3.2.4</label><title>Targeting IFN receptors by viral-regulated miRNAs</title><p>IFNs are a class of naturally occurring proteins produced by various cell types, including fibroblasts, NK cells, leukocytes, and epithelial cells, in response to viral infections (<xref rid="B101" ref-type="bibr">101</xref>). The action of IFNs is initiated when they bind to specific receptors on target cells (<xref rid="B102" ref-type="bibr">102</xref>). These receptors are found across different tissues such as the endocrine, immune, and central nervous systems, and they are expressed on the surface of various cells, including monocytes, macrophages, T lymphocytes, glial cells, and neurons. The structure of IFN receptors is characterized by an extracellular domain that interacts with IFNs and an intracellular kinase domain activated upon dimerization induced by ligand binding (<xref rid="B101" ref-type="bibr">101</xref>).</p><p>The IFN-I receptor, comprising IFNAR1 and IFNAR2, is a transmembrane glycoprotein belonging to the class II family of cytokine receptors. In contrast, the IFN-III receptor system comprises two separate proteins: IL-10 receptor-&#x003b2; and IL-28 receptor-&#x003b1;. On the other hand, the type II interferon receptor is formed by the IFN&#x003b3;R1 and IFN&#x003b3;R2 subunits, which possess unique structural and functional characteristics when compared to both type I and type III receptors (<xref rid="B103" ref-type="bibr">103</xref>). Research conducted by Jarret et&#x000a0;al. revealed that HCV infection leads to the aberrant expression of miR-208b and miR-499a-5p, in infected hepatocytes. These microRNAs, which originate from myosin genes, target and inhibit the production of IFNL2/3, members of the IFN-III gene family, thereby facilitating viral persistence. Furthermore, the study indicated that miR-208b and miR-499a-5p also downregulate IFN-I signaling in HCV-infected hepatocytes by reducing the expression of the IFN-I receptor chain, IFNAR1 (<xref rid="B16" ref-type="bibr">16</xref>). In another investigation, Zhang et&#x000a0;al. reported that during RSV infection, levels of miR-29a increase, which subsequently targets the 3&#x02019; UTR of the IFNAR1 gene and leads to diminished expression of IFNAR1. Moreover, the RSV non-structural protein 1 (NS1) has been shown to inhibit the expression of IFNAR1 at both the RNA and protein levels in the A549 human lung adenocarcinoma cell line (<xref rid="B104" ref-type="bibr">104</xref>). MiR-29a functions as a negative regulator of IFNAR1 and plays a significant role in promoting RSV NS1-induced viral replication. Similarly, miR-30c contributes to porcine reproductive and respiratory syndrome virus (PRRSV) evasion of the antiviral innate response by targeting IFNAR2 (<xref rid="B105" ref-type="bibr">105</xref>).</p></sec><sec id="s3_2_5"><label>3.2.5</label><title>Targeting JAK/STAT components by viral-regulated miRNAs</title><p>In the canonical IFN signaling pathway, all types of IFNs activate transcriptionally active STAT1 through phosphorylation at tyrosine 701, a process facilitated by Janus kinases (JAKs) associated with the IFN receptor. Specifically, the IFN&#x003b3; receptor utilizes JAK1 and JAK2 to phosphorylate STAT1, resulting in its homodimerization. The homodimerized form of STAT1, commonly known as gamma interferon-activated factor (GAF), translocates to the nucleus where it binds to gamma interferon-activated sites (GAS) in the promoters of ISGs. This binding promotes the expression of these genes, facilitating the cellular response to gamma interferon (<xref rid="B106" ref-type="bibr">106</xref>). In contrast, stimulation with type I or type III interferons induces the phosphorylation of both STAT1 and STAT2 through the action of TYK2 and JAK1. This leads to the formation of heterodimers that associate with IRF9, resulting in the creation of a transcriptionally active complex known as ISGF3. The ISGF3 complex binds to ISRE located in a different subset of ISGs, thereby regulating their gene expression (<xref rid="B106" ref-type="bibr">106</xref>&#x02013;<xref rid="B108" ref-type="bibr">108</xref>).</p><p>Despite considerable research efforts, the detailed mechanisms governing IFN signaling pathways remain largely elusive. Recent studies have confirmed the role of miRNAs in modulating these pathways, particularly through interaction with the JAK/STAT signaling cascade. For example, Zhao et&#x000a0;al. (<xref rid="B109" ref-type="bibr">109</xref>) demonstrated that miR-93 specifically targets JAK1, inhibiting the antiviral effects of IFN-I against IVA. The inhibition of miR-93 resulted in a marked reduction of IVA replication <italic>in vivo</italic> and contributed to improved survival rates in affected mice. Notably, miR-93 levels were found to be downregulated in patients infected with IVA, and its overexpression was shown to facilitate increased viral replication by negatively regulating the IFN-JAK-STAT pathway (<xref rid="B109" ref-type="bibr">109</xref>, <xref rid="B110" ref-type="bibr">110</xref>). Upon recognizing an RNA virus infection, the host activates the RIG-I/JNK pathway, which correlates with decreased expression of miR-93.</p><p>Additionally, HCV infection induces the upregulation of miR-373, which negatively impacts IFN signaling by directly targeting JAK1 and IRF9. Conversely, silencing miR-373 leads to enhanced expression of IFN-stimulated genes and a reduction in HCV replication (<xref rid="B111" ref-type="bibr">111</xref>). HCV-mediated elevation of miR-373 also prevents the phosphorylation of STAT1, essential for the formation of the ISGF3 complex and the subsequent expression of ISGs (<xref rid="B111" ref-type="bibr">111</xref>). Furthermore, the overexpression of miR-30c, driven by PRRSV, further contributes to viral replication by suppressing IFN-I production through targeting of JAK1 (<xref rid="B112" ref-type="bibr">112</xref>).</p><p>These alterations in signaling influence the expression of IFN-stimulated genes (ISGs), the effector arm of the IFN response.</p></sec></sec><sec id="s3_3"><label>3.3</label><title>miRNAs modulating IFN-stimulated genes</title><p>As previously discussed, the signal transduction that follows the interaction of IFN-I with its receptor, IFNAR, is mediated by JAKs and STAT proteins. This cascade culminates in the nuclear translocation of the transcription factor complex known as ISGF3, which is composed of IRF9, phosphorylated STAT1, and STAT2. This complex plays a critical role in inducing numerous ISGs (<xref rid="B113" ref-type="bibr">113</xref>). The ISGs encode a wide variety of proteins that serve multiple biological functions, which can effectively obstruct various stages of the viral life cycle, including entry, translation, replication, assembly, and dissemination. Moreover, certain ISGs possess immunomodulatory properties, contributing to the recruitment of leukocytes and the priming of the adaptive immune response. These multifaceted roles underscore the significance of ISGs in the host&#x02019;s defense against viral infections. In a broader sense, an ISG is any gene whose expression is induced by the signaling cascade initiated by interferon molecules [for a recent review, see (<xref rid="B114" ref-type="bibr">114</xref>) and (<xref rid="B115" ref-type="bibr">115</xref>)]. Recent breakthroughs in RNA-sequencing (RNA-seq) technology have facilitated the discovery of ISGs across a range of cell lines by quantifying the transcriptomic response to interferon stimulation. The INTERFEROME database has been continuously updated with the findings of these gene profiling studies, providing a comprehensive repository of ISGs (<xref rid="B116" ref-type="bibr">116</xref>). However, the expression of ISGs exhibits a more complex reality. A subset of these genes are direct transcriptional targets of IRF3/7 and can be induced either independently or in conjunction with downstream interferon signaling pathways <bold>
<italic>(</italic>
</bold>
<xref rid="f4" ref-type="fig">
<bold>Figure&#x000a0;4</bold>
</xref>
<bold>
<italic>)</italic>
</bold> (<xref rid="B117" ref-type="bibr">117</xref>). In addition, a distinct subset of ISGs displays both basal expression and interferon-induced upregulation, while others exhibit cell-type-specific regulation, demonstrating the complex and heterogeneous nature of ISG expression (<xref rid="B113" ref-type="bibr">113</xref>, <xref rid="B118" ref-type="bibr">118</xref>). Furthermore, there exist three types of IFNs, with types I and III being the classical antiviral IFNs. Although type I and III IFNs interact with distinct receptors, they converge on the same signaling pathway mediated by JAK-STAT, ultimately inducing a shared repertoire of ISGs. Notably, the type I and III IFN signaling pathways are distinguished by differences in expression kinetics and cell-type specific expression patterns of their cognate receptors (<xref rid="B114" ref-type="bibr">114</xref>). The precise regulation of ISG expression is critical, as imbalances in the IFN-I response can culminate in the development of interferonopathies or systemic inflammation, which can have severe and far-reaching detrimental effects on the organism (<xref rid="B119" ref-type="bibr">119</xref>). miRNAs target specific ISGs, altering their antiviral effects.</p><fig position="float" id="f4"><label>Figure&#x000a0;4</label><caption><p>Role of TLRs in viral infection. A schematic representation of viral invasion and the activation of TLRs. Viruses bind to host cell receptors and are internalized, releasing viral genetic material in the cytoplasm. TLRs detect viral pathogen-associated molecular patterns (PAMPs), leading to the activation of downstream signaling cascades, ultimately inducing the production of pro-inflammatory cytokines and IFN-I. Viral miRNAs can target and inhibit TLR-mediated signal transduction and the subsequent induction of inflammatory cytokines, thereby preventing the development of an effective host immune response.</p></caption><graphic xlink:href="fimmu-16-1567459-g004" position="float"/></fig><sec id="s3_3_1"><label>3.3.1</label><title>Myxovirus resistance</title><p>The Myxovirus resistance (Mx) genes, which are evolutionarily conserved across most vertebrates, are induced by IFN production and serve as antiviral effectors, showcasing a remarkable specificity for inhibiting the replication of RNA viruses (<xref rid="B120" ref-type="bibr">120</xref>). Human cells contain two distinct Mx proteins, Mx1 (commonly referred to as MxA) and Mx2 (MxB), which are members of a specialized family of dynamin-like large GTPases. These proteins are closely related to the dynamin GTPase family, sharing both a common ancestry and structural homology (<xref rid="B113" ref-type="bibr">113</xref>). Mx1 is recognized for its broad-spectrum antiviral activity, which occurs at an early post-entry stage in the viral life cycle, specifically before genome replication takes place. Studies have shown that Mx1 has the ability to sequester incoming viral components, including nucleocapsids, thereby thwarting their progression to designated cellular locations where they could facilitate infection. Recent advancements in unveiling the structure of Mx1 have provided valuable insights into its mechanism of action, enhancing our understanding of the molecular processes that underlie its antiviral capabilities (<xref rid="B113" ref-type="bibr">113</xref>, <xref rid="B121" ref-type="bibr">121</xref>).</p><p>In addition to its direct antiviral properties, Mx1 expression and functionality are modulated by miRNAs, which play a significant role during viral infections. For example, miR-141 has been implicated in the negative regulation of both MxA and STAT3 expressions, thereby promoting the replication of IAV by inhibiting IFN signaling pathways (<xref rid="B122" ref-type="bibr">122</xref>). Similarly, elevated levels of miR-650 have been shown to facilitate IAV replication in primary human monocyte-derived dendritic cells (MDDCs) by negatively influencing the expression of several ISGs, including MxA and IFIT2. Conversely, the downregulation of miR-650 has been associated with an increase in MxA expression, potentially contributing to the establishment of an antiviral state by hindering viral replication (<xref rid="B123" ref-type="bibr">123</xref>). These findings underscore the intricate interplay between Mx proteins, miRNAs, and the host antiviral response, highlighting the potential for targeting these regulatory pathways in developing therapeutics against viral infections.</p></sec><sec id="s3_3_2"><label>3.3.2</label><title>Interferon-induced transmembrane proteins</title><p>The interferon-induced transmembrane (IFITM) proteins represent a key family of antiviral restriction factors that are constitutively expressed across various cell types, particularly in barrier epithelial cells, where they play a crucial role in limiting viral replication. The expression of human IFITM1, IFITM2, and IFITM3 is markedly augmented by both type I and type II interferons, emphasizing their vital contribution to the host&#x02019;s antiviral defenses (<xref rid="B124" ref-type="bibr">124</xref>, <xref rid="B125" ref-type="bibr">125</xref>). Among the IFITM proteins, IFITM1 has demonstrated significant antiviral activity by obstructing the entry of a broad spectrum of RNA viruses, including the H1N1, IAV, Dengue virus, West Nile virus, HCV, and HIV (<xref rid="B126" ref-type="bibr">126</xref>&#x02013;<xref rid="B128" ref-type="bibr">128</xref>). The antiviral mechanisms attributed to IFITM proteins are thought to involve several steps, such as inhibiting viral binding to cellular receptors, blocking endocytosis, and modulating the activity of pattern recognition receptors that initiate downstream signaling pathways upon detecting viral infections (<xref rid="B128" ref-type="bibr">128</xref>). These proteins interfere with the fusion of viral membranes with cellular endosomal vesicular membranes by disrupting hemifusion processes. They reduce membrane fluidity and curvature, which are critical for effective membrane fusion. Additionally, these proteins may alter the balance of intracellular cholesterol, further impacting the ability of viruses to successfully enter and replicate within host cells. As a result, they play a crucial role in the cellular defense against viral infections (<xref rid="B129" ref-type="bibr">129</xref>, <xref rid="B130" ref-type="bibr">130</xref>).</p><p>While IFITM proteins are primarily recognized for their antiviral functions, emerging evidence suggests they may also enhance viral infections under specific conditions. For example, both IFITM1 and IFITM3 can modestly promote the infection of various cell types by human papillomavirus 16 (HPV-16) (<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B131" ref-type="bibr">131</xref>). Additionally, research by Zhao et&#x000a0;al. has shown that interferons (IFN-I IFN-II, and IFN-III) can significantly increase the susceptibility to human coronavirus HCoV-OC43 by upregulating IFITM protein expression. They demonstrated that overexpression of IFITM3 substantially enhances the susceptibility of Huh7.5 cells to HCoV-OC43 infection (<xref rid="B132" ref-type="bibr">132</xref>).</p><p>The IFITM family also influences the infection process of other viruses. For instance, Hussein and Sakula recently highlighted that overexpressing IFITM1 can enhance the infection of target cells by KSHV, whereas silencing IFITM1 results in reduced infection rates. They found that IFITM1 similarly enhances infection by EBV and herpes simplex virus 2 (HSV-2). Notably, they identified that miR-36 targets the 3&#x02019; UTR of IFITM1, with overexpression of miR-36 inhibiting KSHV infection through downregulation of IFITM1. Conversely, inhibiting miR-36 allows enhanced viral infection, pointing to a post-binding regulatory role for miR-36 in viral entry. The regulation of IFITM1 by miR-36 was shown to be conserved across KSHV, EBV, and HSV-2, indicating a shared mechanism of miRNA-mediated regulation that facilitates viral internalization (<xref rid="B133" ref-type="bibr">133</xref>, <xref rid="B134" ref-type="bibr">134</xref>).</p><p>Additionally, a significant subset of ISGs plays a role in inhibiting viral translation, with the IFN-induced protein with tetratricopeptide repeats (IFIT) family representing a notable group (<xref rid="B113" ref-type="bibr">113</xref>). In this regard, Buggele and Horvath (<xref rid="B12" ref-type="bibr">12</xref>) proposed a model regarding the regulation of host miRNA and IFIT1/ISG56 during Sendai virus (SeV) infection. Their findings indicate that SeV infection triggers an antiviral response that leads to IFN-I production, which activates the JAK-STAT-ISGF3 signaling cascade to induce the expression of ISGs, including IFIT1/ISG56 and miR-203. miR-203 can initially be induced by pre-existing proteins under the influence of IFN; however, sustaining its expression may require the ongoing synthesis of new signaling proteins, potentially involving members of the IRF family (<xref rid="B12" ref-type="bibr">12</xref>). Collectively, the elevated levels of miR-203, promoted by IFN-I during SeV infection, can facilitate viral replication by suppressing the antiviral effects of IFIT1/ISG56. Conversely, miR-1307 and miR-130a have been shown to restrict replication of FMDV (<xref rid="B135" ref-type="bibr">135</xref>) and HCV (<xref rid="B136" ref-type="bibr">136</xref>), respectively, by positively regulating the expression of IFN-I and several ISGs. This complex interplay underscores the multifaceted roles of ISGs and miRNAs in the host&#x02019;s antiviral response, emphasizing both their protective and potentially facilitating effects on viral infections.</p></sec><sec id="s3_3_3"><label>3.3.3</label><title>The tripartite motif proteins</title><p>The tripartite motif (TRIM) protein family consists of more than 76 diverse members found in humans and mice, showcasing a wide array of functions, including the activity of E3 ubiquitin ligases (<xref rid="B137" ref-type="bibr">137</xref>). Recent research has demonstrated that TRIM-containing proteins play a vital role in multiple facets of the host immune response. The TRIM protein family, characterized by their function as ubiquitin E3 ligases, possesses a unique tripartite motif at their N-terminus. This motif is composed of three structural domains: a RING domain, one or two B-box domains, and a coiled-coil region (<xref rid="B138" ref-type="bibr">138</xref>). The RING domain equips TRIM proteins with E3 ubiquitin ligase activity, enabling the ubiquitination of target proteins. This post-translational modification affects various protein functions, including movement within the cell, stability, localization, interactions with other proteins, and enzymatic activation (<xref rid="B139" ref-type="bibr">139</xref>). TRIM proteins are essential in the host immune response, as they modulate the activity of important signaling molecules through ubiquitination, which boosts immunity. Moreover, they help hinder viral infections by targeting viral proteins for degradation, preventing their buildup and disrupting the viral lifecycle (<xref rid="B137" ref-type="bibr">137</xref>). Importantly, TRIM25 is a vital contributor to the RIG-I-mediated antiviral pathway, serving as a key component of the host&#x02019;s innate immune defense against viral infections (<xref rid="B140" ref-type="bibr">140</xref>). Upregulation of TRIM25 has been found to significantly repress the replication of Coxsackievirus B3 (CVB3), whereas silencing TRIM25 expression leads to an increase in viral titers (<xref rid="B141" ref-type="bibr">141</xref>). In response to TRIM25-enhanced antiviral immunity, CVB3 has been found to evade this response by upregulating miR-30a expression. This microRNA targets and downregulates TRIM25, thereby disrupting TRIM25-mediated ubiquitination of RIG-I, which in turn impairs IFN-&#x003b2; activation and production. Consequently, the virus is able to enhance its replication by subverting the host&#x02019;s antiviral response (<xref rid="B141" ref-type="bibr">141</xref>). PRRSV infection has been found to downregulate TRIM22 expression by upregulating the miR-376b-3p and miR-136. These miRNAs specifically target TRIM22, thereby negatively regulating the host&#x02019;s innate antiviral responses and promoting PRRSV replication (<xref rid="B15" ref-type="bibr">15</xref>). Furthermore, miR-27a is a great contributor in promoting VSV replication in macrophages by negatively regulating IFN-I production. This is achieved through the targeting of TRIM27 and Siglec1, key components of the innate immune response. Notably, IFN-I induction can downregulate miR-27a expression, leading to an increase in Siglec1 and TRIM27 expression. This feedback loop subsequently inhibits IFN-I production, thereby dampening the antiviral innate response (<xref rid="B142" ref-type="bibr">142</xref>).</p></sec><sec id="s3_3_4"><label>3.3.4</label><title>Oligoadenylate synthetase</title><p>The oligoadenylate synthetase (OAS) family, comprising DNA sensor cGAS and RNA-sensing OAS/OASL proteins, is a critical class of ISGs that plays a key role in the host&#x02019;s antiviral defense through the recognition of viral RNA and DNA (<xref rid="B143" ref-type="bibr">143</xref>). OAS proteins detect cytosolic dsRNA, triggering RNase L activation to halt viral replication and establish an antiviral state. The importance of this pathway is evident from the diverse strategies viruses have developed to evade OAS-mediated antiviral responses (<xref rid="B143" ref-type="bibr">143</xref>). Zhu et&#x000a0;al. (<xref rid="B144" ref-type="bibr">144</xref>)., found that SARS-CoV-2-encoded miR-ORF1ab-2-5p targets and regulates OAS1 and OAS2, antiviral enzymes induced by interferon. The stable binding of miR-ORF1ab-2-5p to the pathogenic risk allele rs7967461(C) of OAS1 leads to a decrease in OAS1 expression. This reduction facilitates SARS-CoV-2 replication by impairing the IFN-I signaling pathway (<xref rid="B144" ref-type="bibr">144</xref>). In a related context, Bouvet et&#x000a0;al. discovered that the EBV-encoded miR-BART1 represses the expression of OAS2, thereby facilitating the development of viral infection (<xref rid="B145" ref-type="bibr">145</xref>). Zhao et&#x000a0;al. demonstrated that the suppression or knockdown of endogenous miR-340 prevents IAV infection, whereas the enforced expression of miR-340 significantly enhances virus replication (<xref rid="B146" ref-type="bibr">146</xref>). Also, they discovered that miR-340 impairs cellular antiviral immunity by targeting OAS2, a crucial component of the antiviral response (<xref rid="B143" ref-type="bibr">143</xref>). Taken together, these findings suggest that host cells may counterbalance viral loads by modulating miRNA pathways, which may offer novel therapeutic opportunities for the treatment of viral infections.</p></sec><sec id="s3_3_5"><label>3.3.5</label><title>ISG15</title><p>ISG15 is a paradigmatic example of an ISG, exhibiting strong induction in response to interferon stimulation. As previously indicated, ISG15 is a ubiquitin-like protein capable of forming covalent bonds with target proteins through a process known as ISGylation (<xref rid="B113" ref-type="bibr">113</xref>). ISG15 appears to have a complex role in regulating various cellular responses, which contributes to the establishment of an antiviral state (<xref rid="B147" ref-type="bibr">147</xref>). It restricts viral replication by disrupting the translation and exocytosis machinery that viruses exploit for their propagation. Additionally, it impedes the budding of virus-like particles by inhibiting essential enzymes involved in this process (<xref rid="B147" ref-type="bibr">147</xref>). Most viral proteins require oligomerization or complex formation to function effectively. ISGylation of these viral proteins acts as an effective antiviral strategy, as the attachment of the ISG15 protein introduces steric hindrance. This steric hindrance prevents further oligomerization of the ISGylated proteins when they are incorporated into complexes. Consequently, the ISGylation of even a limited number of viral proteins can lead to a substantial inhibitory effect on viral replication and activity (<xref rid="B147" ref-type="bibr">147</xref>). Beyond its role in intracellular immune responses, ISG15 is critical for extracellular immune responses, highlighting its multifaceted participation in the immune system (<xref rid="B147" ref-type="bibr">147</xref>).</p><p>Viruses have devised various strategies to evade the antiviral action of ISG15, one of which includes the alteration of host microRNA levels to specifically target ISG15 itself. A notable example is the upregulation of miR-130a, which boosts the expression of IFN-I and ISG15, thereby triggering an innate immune response that restricts HCV replication by restoring a functional innate immune state (<xref rid="B136" ref-type="bibr">136</xref>). Conversely, HCV infection leads to a significant decrease in miR-130a expression in infected cell lines, suggesting that the virus may exploit this downregulation to evade the host&#x02019;s innate immune response (<xref rid="B148" ref-type="bibr">148</xref>). Ectopic miR-130a overexpression suppresses HCV replication by stimulating IFN-I (IFN-&#x003b1;/&#x003b2;) and ISG15 expression, thereby promoting an innate immune response that restricts viral replication (<xref rid="B136" ref-type="bibr">136</xref>).</p></sec><sec id="s3_3_6"><label>3.3.6</label><title>Interferon regulatory factor</title><p>The interferon regulatory factor (IRF) family plays an essential role in regulating type I interferons (IFN-&#x003b1;/&#x003b2;) and ISGs by directly interacting with and binding to the ISRE sequence found in the promoter regions of these genes. Originally recognized as a vital regulator of the IFN-&#x003b1;/&#x003b2; promoter, the binding of IRF to ISRE is important for the transcriptional activation of these genes (<xref rid="B149" ref-type="bibr">149</xref>). The IRF family includes three primary members IRF3, IRF5, and IRF7 which are vital for producing IFN-I following the activation of pathogen recognition receptors that recognize viral RNA and DNA. In contrast, IRF9 is critical for regulation of the expression of genes induced by interferons. Additionally, IRF4, IRF8, and IRF5 play vital parts in the development and differentiation of myeloid cells, thus impacting inflammatory responses (<xref rid="B150" ref-type="bibr">150</xref>). The regulation of IRF levels and activity is crucial, as aberrations in either can lead to imbalanced immune responses and potentially trigger autoimmune diseases. Interestingly, studies have demonstrated that IRF regulation by miRNAs during viral infections can facilitate viral replication by suppressing the IFN pathway. Notably, the upregulation of miR-373 during HCV infection has been shown to impair the IFN antiviral response by targeting IRF5, thereby enabling viral replication (<xref rid="B151" ref-type="bibr">151</xref>) and IRF9 (<xref rid="B111" ref-type="bibr">111</xref>). Similarly, Zhang et&#x000a0;al. (<xref rid="B152" ref-type="bibr">152</xref>) discovered that miR-731 disrupts the IFN-I response induced by megalocytiviruses and suppresses IFN expression at both the mRNA and protein levels. Their findings indicate that miR-731 modulates the IFN-I response by targeting IRF7. Furthermore, they observed that ectopic expression of miR-731 significantly downregulates the expression of IFITIM1, ISG15, Mx, and viperin. Conversely, silencing miR-731 leads to increased expression levels of ISG proteins (<xref rid="B152" ref-type="bibr">152</xref>).</p><p>The Megalocytivirus-induced pol-miR-731 plays a crucial role in facilitating viral replication by suppressing ISG expression levels through the targeted degradation of IRF7. Furthermore, miR-155 has been shown to contribute to HIV&#x02019;s evasion of the host&#x02019;s innate immune response by targeting IRF3. In contrast, miR-722 has been found to restrict CyHV-3 replication by positively regulating IFN expression through the targeted degradation of viral ORF89, which acts as an inhibitor of IRF3 (<xref rid="B153" ref-type="bibr">153</xref>). MiR-34a has been identified as an antiviral microRNA that potentiates the IFN-I response by positively modulating the expression level of IRF3 through the targeting of Wnt signaling during Flavivirus infection (<xref rid="B154" ref-type="bibr">154</xref>). Notably, IRF-3 has been found to interact with the co-activator proteins CREB binding protein (CBP) or p300 (CBP/p300), a mechanism that plays a crucial role in modulating IFN production. Specifically, a compactly folded 46-residue domain within CBP, known as the IRF3 binding domain (IBiD), is responsible for binding to the C-terminal region of IRF-3 (<xref rid="B155" ref-type="bibr">155</xref>). Upon activation, IRF3 forms a complex with the co-activator proteins CBP/p300, leading to the initiation of transcription of the IFN-&#x003b2; gene (<xref rid="B156" ref-type="bibr">156</xref>, <xref rid="B157" ref-type="bibr">157</xref>). Phosphorylation at serine residues 386 and 396 on IRF3 is crucial for its activation and subsequent interaction with the co-activator CBP (<xref rid="B158" ref-type="bibr">158</xref>, <xref rid="B159" ref-type="bibr">159</xref>). Following phosphorylation and dimerization, activated IRF3 undergoes nuclear translocation, where it interacts with and recruits the co-activators CBP and/or p300, thereby achieving full activation (<xref rid="B156" ref-type="bibr">156</xref>, <xref rid="B157" ref-type="bibr">157</xref>, <xref rid="B160" ref-type="bibr">160</xref>). Subsequently, the IRF3-CBP/p300 complex binds to the PRD I/III elements within the IFN-&#x003b2; promoter, thereby triggering transcriptional activation and inducing the production of IFN-I-&#x003b2; (<xref rid="B161" ref-type="bibr">161</xref>).</p><p>Studies have demonstrated that the EBV-encoded BART16 protein suppresses the antiviral IFN response to latent EBV infection by targeting the CBP (<xref rid="B162" ref-type="bibr">162</xref>). The EBV-encoded miR-BART16 directly targets CBP, leading to its downregulation in EBV-transformed B cells and gastric carcinoma cells. Notably, miR-BART16 has been shown to abrogate the production of ISGs in response to IFN-&#x003b1; stimulation by inhibiting CBP activity. Furthermore, miR-BART16 has been found to suppress the anti-proliferative effect of IFN-&#x003b1; on latently infected Burkitt lymphoma (BL) cells. By blocking the IFN-I -induced antiviral response, miR-BART16 creates a mechanism for facilitating the establishment of latent EBV infection and enhancing viral replication (<xref rid="B162" ref-type="bibr">162</xref>).</p><p>Transcriptome analyses have indicated that IRF1 is responsible for regulating a substantial number of genes, including approximately 300 antiviral ISGs such as OAS2, BST2, and RNASEL. The inhibition of IRF1 has been associated with increased susceptibility of cells to various viruses, including HCV and herpes simplex virus-1. Furthermore, previous research has shown that type I interferons are downregulated by miRNAs that target IRF1 during viral infections. For instance, Zhang et&#x000a0;al. demonstrated that IRF1 is a direct target of miR-132-3p during H1N1 IAV infection. Significantly, the antiviral effect of miR-132-3p knockdown on IAV replication was eliminated when IRF1 was inhibited, indicating that the miR-132-3p inhibitor reduces IAV replication by directly targeting IRF1 and elevating the antiviral response (<xref rid="B163" ref-type="bibr">163</xref>). Similarly, overexpression of miR-302 induced by PRRSV negatively regulates IRF1, leading to a reduction in IFN-&#x003b2; production and facilitating PRRSV replication (<xref rid="B164" ref-type="bibr">164</xref>). The inability of the host to effectively generate type I interferons in response to JEV infection is associated with a heightened risk of lethal disease (<xref rid="B165" ref-type="bibr">165</xref>). Hazra and colleagues (<xref rid="B166" ref-type="bibr">166</xref>) demonstrated that JEV-induced expression of miR-301a inhibits IFN-I production by reducing IRF1 levels. In mouse neurons, the neutralization of miR-301a was found to restore the innate immune response by promoting IFN-&#x003b2; production, thereby limiting viral spread. Inhibition of miR-301a in the mouse brain resulted in the restoration of IRF1 levels, increased IFN-&#x003b2; generation, and a reduction in JEV replication, ultimately improving survival outcomes for the mice (<xref rid="B166" ref-type="bibr">166</xref>). Additionally, miR-373 and miR-23a have been shown to enhance HSV-1 replication by specifically suppressing IRF1, a key transcription factor necessary for the induction of antiviral genes.</p></sec></sec><sec id="s3_4"><label>3.4</label><title>miRNAs targeting negative regulators of the IFN pathway</title><p>Negative regulators such as SOCS, CUEDC2, USP18, USP15, and the ATG5-ATG12 complex suppress IFN signaling to prevent excessive immune activation. Notably, miRNAs can counteract this suppression by directly targeting these regulators, thereby enhancing antiviral responses&#x02014;a mechanism explored in detail below.</p><p>The JAK/STAT signaling pathways, which are crucial for mounting antiviral immune responses and maintaining immune balance, are strongly regulated by negative regulators, including SOCS and CUEDC2 to prevent excessive or prolonged activation and ensure optimal viral clearance (<xref rid="B167" ref-type="bibr">167</xref>, <xref rid="B168" ref-type="bibr">168</xref>). The suppressor of cytokine signaling proteins (SOCS) protein family consists of a range of intracellular proteins, including CIS, SOCS1/2/3/4/5/6/7. Upon activation, STATs undergo a process of homodimerization, followed by translocation to the nucleus, where they induce the transcriptional activation of SOCS genes. The resulting SOCS proteins subsequently interact with phosphorylated JAK and its receptor, thereby modulating the JAK/STAT signaling pathway through three distinct mechanisms (<xref rid="B169" ref-type="bibr">169</xref>). It has been observed that certain miRNAs can overcome the inhibitory effect of SOCS proteins on IFN production, thereby leading to an increase in IFN production and subsequently inhibiting viral infection (<xref rid="SM1" ref-type="supplementary-material">
<bold>Supplementary Table&#x000a0;1</bold>
</xref>). MiR-30a-5p has been found to suppress transmissible gastroenteritis coronavirus (TGEV) infection by augmenting the antiviral signaling pathway triggered by IFN production. This is achieved by directly targeting and inhibiting the expression of SOCS1 and SOCS3, two key negative regulators of the IFN signaling pathway (<xref rid="B170" ref-type="bibr">170</xref>). TGEV has been shown to counteract the antiviral effects of miR-30a-5p by suppressing its expression. As a result, the negative regulators of the JAK-STAT signaling pathway, SOCS1 and SOCS3, are upregulated, leading to a blunted antiviral response (<xref rid="B170" ref-type="bibr">170</xref>).</p><p>Recently, Yan et&#x000a0;al. (<xref rid="B171" ref-type="bibr">171</xref>) demonstrated that miR-221 directly targets SOCS1 and suppresses its expression at both the mRNA and protein levels. Notably, the overexpression of miR-221 has been shown to both inhibit replication of HCMV and enhance the production of IFN-I and ISGs. In contrast, the reintroduction of SOCS1 mitigates the effects of miR-221 on HCMV replication, suggesting a role for SOCS1 in counteracting the antiviral effects mediated by miR-221 (<xref rid="B171" ref-type="bibr">171</xref>). Furthermore, miR-221 has been observed to facilitate the phosphorylation and activation of NF-&#x003ba;B by inhibiting the expression of SOCS1. This implies that miR-221 may modulate the NF-&#x003ba;B signaling pathway, which is an essential transcription factor involved in various cellular functions, including inflammation and immune responses (<xref rid="B171" ref-type="bibr">171</xref>). Similarly, miR-155 has demonstrated antiviral effects against VSV in macrophages by promoting the production of IFN-I through the targeting of SOCS1. This data indicates that miR-155 might play a critical role in the host&#x02019;s defense mechanisms against VSV infection (<xref rid="B172" ref-type="bibr">172</xref>). Gao et&#x000a0;al. (<xref rid="B173" ref-type="bibr">173</xref>) further reported that reductions in SOCS3 levels positively influence the antiviral efficacy of endogenous IFN-I against hepatitis B virus (HBV). Furthermore, our research indicates that the downregulation of miR-122 during HBV infection results in the reduced expression of interferons. This reduction promotes HBV replication and may play a role in viral persistence and the development of hepatocellular carcinoma (<xref rid="B173" ref-type="bibr">173</xref>). miR-221 and miR-30c-5p exert a positive regulatory effect on the IFN-I pathway by targeting SOCS1, subsequently suppressing the replication of HPV-16 (<xref rid="B174" ref-type="bibr">174</xref>) and PEDV (<xref rid="B175" ref-type="bibr">175</xref>), respectively. Zhai et&#x000a0;al. (<xref rid="B176" ref-type="bibr">176</xref>) demonstrated that the borna disease virus (BDV) protein directly suppresses miR-155 expression in infected cells, leading to increased inhibition of IFN-Is in these cells. Notably, when miR-155 is overexpressed, this inhibition is further augmented. Additionally, miR-155 is found to promote IFN-I production by targeting SOCS1 and SOCS3, thereby restricting BDV infection. Consequently, the persistent infection with BDV leads to the suppression of IFN-Is through the downregulation of miR-155, underscoring the crucial role of miR-155 in immune regulation during BDV persistent infection (<xref rid="B176" ref-type="bibr">176</xref>). CUEDC2, a negative regulator of the JAK1-STAT3 pathway, has been found to be targeted by miR-324-5p at its 3&#x02019; UTR. The study shows that miR-324-5p enhances the host&#x02019;s antiviral response by inhibiting CUEDC2, thereby limiting H5N1 replication. This highlights the significance of miR-324-5p as a critical contributor in modulating the host&#x02019;s immune response to H5N1 infection (<xref rid="B177" ref-type="bibr">177</xref>). Ubiquitin Specific Peptidase (USP) 18 (<xref rid="B178" ref-type="bibr">178</xref>) and 15 (<xref rid="B179" ref-type="bibr">179</xref>) are additional negative regulators of the type 1 IFN pathway, which can be modulated by miRNAs. In this context, the ectopic expression of miR-130a has been shown to suppress HCV replication by positively regulating IFN-I-&#x003b1;/&#x003b2; production through the negative regulation of USP18 expression levels (<xref rid="B136" ref-type="bibr">136</xref>). Notably, miR-26a has been found to enhance IFN-I production and restrict the replication of various viruses, including HEV, VSV, and SeV, by targeting USP15 (<xref rid="B180" ref-type="bibr">180</xref>).</p><p>The ATG5-ATG12 complex, an essential element of the autophagy machinery, has been reported to negatively regulate IFN-I production in MEFs, thereby facilitating VSV replication (<xref rid="B181" ref-type="bibr">181</xref>). Additionally, the importance of ATG5 in IFN-I production has been highlighted in plasmacytoid dendritic cells (pDCs) infected with VSV, underscoring its role in antiviral responses (<xref rid="B182" ref-type="bibr">182</xref>). Besides, Duan et&#x000a0;al. (<xref rid="B183" ref-type="bibr">183</xref>) found that ATG5 promotes HCV replication by downregulating the expression of ISGs. In an interesting counteraction, the overexpression of miR-130a was shown to decrease ATG5 levels, which in turn disrupts the conjugation of the ATG5-ATG12 protein complex. This disruption ultimately leads to the inhibition of HCV infection through the substantial upregulation of several key ISGs, including MX1 and OAS3 (<xref rid="B183" ref-type="bibr">183</xref>). These findings suggest a complex interplay between autophagy-related proteins, miRNAs, and the antiviral immune response, highlighting the potential for targeted therapeutic strategies in managing viral infections.</p><p>This tight regulation by miRNAs underscores their double-edged role in viral infections: while some miRNAs facilitate immune evasion by suppressing IFN pathways, others reinforce antiviral defenses by enhancing ISG expression&#x02014;a dichotomy that highlights their context-dependent impact on infection outcomes.</p></sec></sec><sec id="s4"><label>4</label><title>Harnessing miRNAs: emerging therapeutic strategies for antiviral immunity</title><p>Recent studies have underscored the promising potential of miRNAs in combating viral infections by enhancing the body&#x02019;s antiviral immune response. Therefore, this section delves into the current applications of miRNAs as therapeutic targets, highlighting three primary strategies: miRNA antagonists (antagomiRs), miRNA mimics, and small-molecule miRNA modulators. These approaches hold significant promise for advancing antiviral treatment paradigms.</p><p>AntagomiRs are chemically modified oligonucleotides designed to block specific miRNAs that help viruses replicate or weaken the immune response (<xref rid="B184" ref-type="bibr">184</xref>). For example, miravirsen targets miR-122, which is essential for hepatitis C virus (HCV) stability, and has shown promise in clinical studies by forming a stable complex that prevents the virus from thriving (<xref rid="B185" ref-type="bibr">185</xref>). Another example is miR-146a antagomirs, which have been used in mouse models to reduce influenza A virus (IAV) infection and mitigate severe immune reactions (<xref rid="B186" ref-type="bibr">186</xref>), like cytokine storms seen in diseases such as COVID-19. These antagomiRs are effective at low doses and.</p><sec id="s4_1"><label>4.1</label><title>miRNA antagonists (AntagomiRs): detailed mechanisms and applications</title><p>AntagomiRs are chemically modified antisense oligonucleotides designed to specifically inhibit the function of target miRNAs (<xref rid="B184" ref-type="bibr">184</xref>). Their role in antiviral therapy by targeting miRNAs that facilitate viral replication or suppress host immunity has been highlighted. For instance, miR-122 is noted as a critical miRNA for HCV replication, stabilizing the viral genome. Miravirsen, a locked nucleic acid (LNA)-modified DNA phosphorothioate antisense oligonucleotide, is cited as an example that binds to mature miR-122, forming a stable heteroduplex that impedes its function, thereby inhibiting HCV infection (<xref rid="B185" ref-type="bibr">185</xref>, <xref rid="B187" ref-type="bibr">187</xref>). This approach has been explored in clinical settings, demonstrating efficacy in reducing viral load.</p></sec><sec id="s4_2"><label>4.2</label><title>miRNA mimics: enhancing host antiviral defenses</title><p>MiRNA mimics are synthetic RNA molecules designed to replicate the function of endogenous miRNAs that suppress viral replication, thereby enhancing the host&#x02019;s antiviral defense mechanisms (<xref rid="B188" ref-type="bibr">188</xref>&#x02013;<xref rid="B190" ref-type="bibr">190</xref>). One strategy involves utilizing miRNA mimics to boost the levels of natural miRNAs that naturally inhibit viral activity. For example, Ivacik et&#x000a0;al. (<xref rid="B191" ref-type="bibr">191</xref>), demonstrated that lentiviral vectors carrying miRNAs derived from pri-miR-31, under the control of a liver-specific promoter, efficiently suppress HBV replication by targeting host pathways that limit viral spread (<xref rid="B191" ref-type="bibr">191</xref>). This approach leverages gene delivery systems to ensure effective expression of the mimic at the site of infection (<xref rid="B184" ref-type="bibr">184</xref>).</p><p>Additionally, HBV-miR-3, an HBV-specific miRNA, inhibits HBV replication by downregulating SOCS5 and activating the JAK/STAT signaling pathway and interferon-induced antiviral effects (<xref rid="B192" ref-type="bibr">192</xref>). This mechanism enhances the host&#x02019;s innate immune response, offering a targeted strategy to combat HBV. Therefore, miRNA mimics provide a precise way to modulate host-virus interactions, reinforcing natural antiviral capabilities. However, challenges such as delivery efficiency and potential off-target effects are acknowledged, requiring innovative solutions like viral vectors, liposomes, and nanoparticles to ensure mimics reach infected cells without triggering adverse immune responses (<xref rid="B184" ref-type="bibr">184</xref>).</p></sec><sec id="s4_3"><label>4.3</label><title>Small-molecule miRNA modulators: emerging but understudied</title><p>Small-molecule miRNA modulators represent an innovative and promising strategy in the realm of miRNA-based therapeutics, particularly for antiviral immunity. These compounds are designed to either enhance or inhibit the expression of specific miRNAs by interacting with their biogenesis pathways or directly modulating their activity (<xref rid="B193" ref-type="bibr">193</xref>). This approach leverages the unique ability of small molecules to cross cell membranes via free diffusion, making them more accessible to intracellular targets compared to traditional nucleic acid-based therapies (<xref rid="B194" ref-type="bibr">194</xref>).</p><p>Small-molecule modulators function through various mechanisms to influence miRNA pathways. One primary method involves transcriptional activation, where these molecules can upregulate the expression of tumor-suppressive miRNAs that have been downregulated in disease states. Conversely, small-molecule inhibitors can suppress the activity of overexpressed oncogenic miRNAs. By blocking the pathways responsible for miRNA maturation or binding directly to mature miRNAs, these inhibitors can prevent the miRNAs from exerting their effects on target mRNAs (<xref rid="B193" ref-type="bibr">193</xref>&#x02013;<xref rid="B195" ref-type="bibr">195</xref>). This dual capability&#x02014;activation and inhibition&#x02014;makes small molecules highly versatile tools in therapeutic development.</p><p>The advantages of using small-molecule modulators include their stability, ease of synthesis, and potential for oral administration, which collectively contribute to better patient compliance and reduced treatment costs (<xref rid="B193" ref-type="bibr">193</xref>). Additionally, their ability to permeate cell membranes without the need for complex delivery systems circumvents many of the challenges associated with nucleic acid-based therapies, such as poor cell-permeability and susceptibility to degradation (<xref rid="B194" ref-type="bibr">194</xref>). However, several challenges remain. The multifaceted roles of miRNAs in cellular processes mean that modulation can lead to unintended off-target effects, affecting multiple pathways and potentially causing adverse reactions (<xref rid="B194" ref-type="bibr">194</xref>). Furthermore, ensuring the specificity and selectivity of small molecules is crucial to avoid disrupting non-targeted miRNAs, which could exacerbate disease conditions or trigger new pathologies (<xref rid="B196" ref-type="bibr">196</xref>&#x02013;<xref rid="B198" ref-type="bibr">198</xref>).</p><p>Despite these challenges, the exploration of small-molecule miRNA modulators has opened new avenues for treating viral infections, including those caused by emerging viruses like SARS-CoV-2 (<xref rid="B194" ref-type="bibr">194</xref>). Understanding the precise roles of specific miRNAs in viral pathogenesis is essential for developing targeted therapies that can inhibit viral replication and mitigate disease severity (<xref rid="B193" ref-type="bibr">193</xref>, <xref rid="B194" ref-type="bibr">194</xref>).</p><p>Future research should focus on refining the specificity of these modulators and exploring combination therapies that integrate small molecules with other therapeutic modalities, such as miRNA mimics or antagomirs (<xref rid="B194" ref-type="bibr">194</xref>). Advances in computational modeling and high-throughput screening technologies will further facilitate the discovery of novel small-molecule modulators with enhanced efficacy and safety profiles (<xref rid="B193" ref-type="bibr">193</xref>).</p></sec><sec id="s4_4"><label>4.4</label><title>Challenges and future directions</title><p>Despite these promising therapeutic potentials, challenges remain. The inherent instability of RNA molecules and the need for targeted delivery systems complicate the direct translatability of these approaches, especially in the context of pandemics like COVID-19 (<xref rid="B194" ref-type="bibr">194</xref>). Additionally, off-target effects and immunogenicity must be carefully evaluated to ensure safety and efficacy (<xref rid="B199" ref-type="bibr">199</xref>). Nevertheless, ongoing advancements in delivery mechanisms, such as hydrogel-based systems and nanocell technologies, hold promise for overcoming these hurdles (<xref rid="B200" ref-type="bibr">200</xref>). Delivery technologies such as viral vectors, liposomes, and nanoparticles are suggested as potential solutions, but their development requires further optimization to minimize off-target effects and immune responses (<xref rid="B184" ref-type="bibr">184</xref>).</p><p>Another challenge is inter-individual variability in miRNA expression, which may affect therapeutic efficacy, necessitating personalized approaches. The study also notes the risk of off-target effects, where miRNA therapies could disrupt normal cellular functions, highlighting the need for specificity in targeting (<xref rid="B184" ref-type="bibr">184</xref>, <xref rid="B201" ref-type="bibr">201</xref>).</p><p>Overall, miRNAs offer novel and emerging targets for therapeutic intervention in viral infections. Current strategies employing miRNA antagonists, mimics, and small-molecule modulators illustrate the versatility and potential of miRNA-based therapies (<xref rid="B199" ref-type="bibr">199</xref>). Continued research is essential to fully harness the therapeutic capabilities of miRNAs and translate these findings into effective clinical applications.</p></sec></sec><sec sec-type="conclusions" id="s5"><label>5</label><title>Conclusion</title><p>During the past decade, considerable progress has been achieved in understanding the complex network through which miRNAs regulate the development and functioning of the immune system. Innovative approaches to deliver miRNA mimics and antagonists <italic>in vivo</italic>, particularly through viral vectors and nanoparticles, have opened new avenues for therapeutic interventions aimed at modulating pathological hematopoiesis (<xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B202" ref-type="bibr">202</xref>, <xref rid="B203" ref-type="bibr">203</xref>). Moreover, techniques for genetically modifying miRNAs using transcription activator-like effector nucleases (TALENs) (<xref rid="B204" ref-type="bibr">204</xref>, <xref rid="B205" ref-type="bibr">205</xref>) and CRISPR&#x02013;Cas9-mediated cleavage (<xref rid="B206" ref-type="bibr">206</xref>, <xref rid="B207" ref-type="bibr">207</xref>) in mammalian cells hold great promise for both elucidating fundamental miRNA mechanisms and developing novel therapeutics (<xref rid="B208" ref-type="bibr">208</xref>, <xref rid="B209" ref-type="bibr">209</xref>).</p><p>Given the critical role of the interferon (IFN) pathway in combating viral infections, alongside miRNAs&#x02019; significant influence on the activation or repression of this pathway, we explored how miRNAs can modulate viral replication by targeting the IFN pathway (<xref rid="B210" ref-type="bibr">210</xref>). Selecting appropriate miRNAs for modulation&#x02014;either through enhancement or inhibition&#x02014;could represent a novel therapeutic strategy for addressing viral infections. Achieving effective miRNA-based interventions will necessitate a comprehensive understanding of miRNA action mechanisms in regulating the IFN pathway and the broader innate immune response.</p><p>Furthermore, the potential of miRNA-based drug delivery, especially in conjunction with IFN therapies, could provide additional tools for controlling viral infections. However, despite the promising prospects of miRNA therapeutics, several practical challenges remain. These include determining optimal administration routes, ensuring stability within the body, targeting specific tissues and cell types, and achieving the desired intracellular effects (<xref rid="B211" ref-type="bibr">211</xref>). As a result, only a limited number of miRNA-based drugs have progressed to clinical testing. Additionally, a thorough risk assessment of miRNA therapeutics is essential prior to <italic>in vivo</italic> applications to mitigate off-target effects and avoid potential miRNA overdosing. Ultimately, addressing these challenges will be crucial for translating miRNA-based approaches into effective clinical therapies.</p></sec></body><back><ack><title>Acknowledgments</title><p>We extend our gratitude to the Research Ethics Committees of the Vice-Chancellor in Research Affairs at Tabriz University of Medical Sciences for approving our proposal (IR.TBZMED.VCR.REC.1404.011) and ensuring its compliance with ethical standards for medical research in Iran. Tabriz University of Medical Sciences supported this work under grant number 76057.</p></ack><sec sec-type="author-contributions" id="s6"><title>Author contributions</title><p>MB: Writing &#x02013; review &#x00026; editing. RN-S: Visualization, Writing &#x02013; review &#x00026; editing. JS: Project administration, Validation, Writing &#x02013; original draft. BN: Visualization, Writing &#x02013; original draft.</p></sec><sec sec-type="COI-statement" id="s8"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="ai-statement" id="s9"><title>Generative AI statement</title><p>The author(s) declare that Generative AI was used in the creation of this manuscript. During the preparation of this work the authors used DeepAI chat GPT in order to improve the writing process and to enhance the readability and language of the manuscript. After using this tool/service, the authors reviewed and edited the content as needed and takes full responsibility for the content of the published article.</p></sec><sec sec-type="disclaimer" id="s10"><title>Publisher&#x02019;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><sec sec-type="supplementary-material" id="s11"><title>Supplementary material</title><p>The Supplementary Material for this article can be found online at: <ext-link xlink:href="https://www.frontiersin.org/articles/10.3389/fimmu.2025.1567459/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fimmu.2025.1567459/full#supplementary-material</ext-link>
</p><supplementary-material id="SM1" position="float" content-type="local-data"><media xlink:href="Table1.docx"/></supplementary-material></sec><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>ZJ</given-names></name></person-group>. <article-title>Innate immune sensing and signaling of cytosolic nucleic acids</article-title>. <source>Annu Rev Immunol</source>. (<year>2014</year>) <volume>32</volume>:<page-range>461&#x02013;88</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1146/annurev-immunol-032713-120156</pub-id>
</mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rojas</surname><given-names>JM</given-names></name><name><surname>Alejo</surname><given-names>A</given-names></name><name><surname>Mart&#x000ed;n</surname><given-names>V</given-names></name><name><surname>Sevilla</surname><given-names>N</given-names></name></person-group>. <article-title>Viral pathogen-induced mechanisms to antagonize mammalian interferon (IFN) signaling pathway</article-title>. <source>Cell Mol Life Sci</source>. (<year>2021</year>) <volume>78</volume>:<page-range>1423&#x02013;44</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s00018-020-03671-z</pub-id>
</mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stark</surname><given-names>GR</given-names></name><name><surname>Kerr</surname><given-names>IM</given-names></name><name><surname>Williams</surname><given-names>BR</given-names></name><name><surname>Silverman</surname><given-names>RH</given-names></name><name><surname>Schreiber</surname><given-names>RD</given-names></name></person-group>. <article-title>How cells respond to interferons</article-title>. <source>Annu Rev Biochem</source>. (<year>1998</year>) <volume>67</volume>:<page-range>227&#x02013;64</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1146/annurev.biochem.67.1.227</pub-id>
</mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Durbin</surname><given-names>JE</given-names></name><name><surname>Fernandez-Sesma</surname><given-names>AF</given-names></name><name><surname>Lee</surname><given-names>CK</given-names></name><name><surname>Rao</surname><given-names>TD</given-names></name><name><surname>Frey</surname><given-names>AB</given-names></name><name><surname>Moran</surname><given-names>TM</given-names></name><etal/></person-group>. <article-title>Type I IFN modulates innate and specific antiviral immunity</article-title>. <source>J Immunol</source>. (<year>2000</year>) <volume>164</volume>:<page-range>4220&#x02013;8</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.4049/jimmunol.164.8.4220</pub-id>
</mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Mirzaei</surname><given-names>H</given-names></name><name><surname>Rahimian</surname><given-names>N</given-names></name><name><surname>Mirzaei</surname><given-names>HR</given-names></name><name><surname>Nahand</surname><given-names>JS</given-names></name><name><surname>Hamblin</surname><given-names>MR</given-names></name></person-group>. <article-title>MicroRNA Biogenesis and Function, in <italic>Exosomes and MicroRNAs</italic>
</article-title>. In: <person-group person-group-type="editor"><name><surname>Mirzaei</surname><given-names>H</given-names></name><name><surname>Rahimian</surname><given-names>N</given-names></name><name><surname>Mirzaei</surname><given-names>HR</given-names></name><name><surname>Nahand</surname><given-names>JS</given-names></name><name><surname>Hamblin</surname><given-names>MR</given-names></name></person-group>, editors. <source>Biomedical Science</source>. <publisher-name>Springer International Publishing</publisher-name>, <publisher-loc>Cham</publisher-loc> (<year>2022</year>). p. <fpage>1</fpage>&#x02013;<lpage>9</lpage>.</mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Mirzaei</surname><given-names>H</given-names></name><name><surname>Rahimian</surname><given-names>N</given-names></name><name><surname>Mirzaei</surname><given-names>HR</given-names></name><name><surname>Nahand</surname><given-names>JS</given-names></name><name><surname>Hamblin</surname><given-names>MR</given-names></name></person-group>. <source>Exosomes and microRNAs in biomedical science</source>. <publisher-loc>San Rafael, CA, USA</publisher-loc>: <publisher-name>Morgan &#x00026; Claypool Publishers</publisher-name> (<year>2022</year>).</mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rahimian</surname><given-names>N</given-names></name><name><surname>Nahand</surname><given-names>JS</given-names></name><name><surname>Hamblin</surname><given-names>MR</given-names></name><name><surname>Mirzaei</surname><given-names>H</given-names></name></person-group>. <article-title>Exosomal microRNA profiling</article-title>. <source>Methods Mol Biol (Clifton N.J.)</source>. (<year>2023</year>) <volume>2595</volume>:<fpage>13</fpage>&#x02013;<lpage>47</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/978-1-0716-2823-2_2</pub-id>
</mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sadri Nahand</surname><given-names>J</given-names></name><name><surname>Salmaninejad</surname><given-names>A</given-names></name><name><surname>Mollazadeh</surname><given-names>S</given-names></name><name><surname>Tamehri Zadeh</surname><given-names>SST</given-names></name><name><surname>Rezaee</surname><given-names>M</given-names></name><name><surname>Sheida</surname><given-names>AH</given-names></name><etal/></person-group>. <article-title>Virus, exosome, and microRNA: new insights into autophagy</article-title>. <source>Adv Exp Med Biol</source>. (<year>2022</year>) <volume>1401</volume>:<fpage>97</fpage>&#x02013;<lpage>162</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/5584_2022_715</pub-id>
<pub-id pub-id-type="pmid">35781219</pub-id>
</mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chandan</surname><given-names>K</given-names></name><name><surname>Gupta</surname><given-names>M</given-names></name><name><surname>Sarwat</surname><given-names>M</given-names></name></person-group>. <article-title>Role of host and pathogen-derived microRNAs in immune regulation during infectious and inflammatory diseases</article-title>. <source>Front Immunol</source>. (<year>2020</year>) <volume>10</volume>:<elocation-id>3081</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fimmu.2019.03081</pub-id>
<pub-id pub-id-type="pmid">32038627</pub-id>
</mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bayat</surname><given-names>M</given-names></name><name><surname>Sadri Nahand</surname><given-names>J</given-names></name></person-group>. <article-title>Exosomal miRNAs: the tumor's trojan horse in selective metastasis</article-title>. <source>Mol Cancer</source>. (<year>2024</year>) <volume>23</volume>:<fpage>167</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s12943-024-02081-0</pub-id>
<pub-id pub-id-type="pmid">39164756</pub-id>
</mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ingle</surname><given-names>H</given-names></name><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Raut</surname><given-names>AA</given-names></name><name><surname>Mishra</surname><given-names>A</given-names></name><name><surname>Kulkarni</surname><given-names>DD</given-names></name><name><surname>Kameyama</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>The microRNA miR-485 targets host and influenza virus transcripts to regulate antiviral immunity and restrict viral replication</article-title>. <source>Sci Signaling</source>. (<year>2015</year>) <volume>8</volume>:<page-range>ra126&#x02013;6</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1126/scisignal.aab3183</pub-id>
</mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Buggele</surname><given-names>WA</given-names></name><name><surname>Horvath</surname><given-names>CM</given-names></name></person-group>. <article-title>MicroRNA profiling of Sendai virus-infected A549 cells identifies miR-203 as an interferon-inducible regulator of IFIT1/ISG56</article-title>. <source>J Virol</source>. (<year>2013</year>) <volume>87</volume>:<page-range>9260&#x02013;70</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1128/JVI.01064-13</pub-id>
</mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Fan</surname><given-names>X</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Zou</surname><given-names>Z</given-names></name><name><surname>Yuan</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>MicroRNA-466l inhibits antiviral innate immune response by targeting interferon-alpha</article-title>. <source>Cell Mol Immunol</source>. (<year>2012</year>) <volume>9</volume>:<fpage>497</fpage>&#x02013;<lpage>502</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/cmi.2012.35</pub-id>
<pub-id pub-id-type="pmid">23042536</pub-id>
</mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Fu</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name></person-group>. <article-title>Hepatitis C virus infection decreases the expression of Toll-like receptors 3 and 7 via upregulation of miR-758</article-title>. <source>Arch Virol</source>. (<year>2014</year>) <volume>159</volume>:<fpage>2997</fpage>&#x02013;<lpage>3003</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s00705-014-2167-3</pub-id>
<pub-id pub-id-type="pmid">25008898</pub-id>
</mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>S</given-names></name><name><surname>Cui</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Xu</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>MicroRNA-376b-3p promotes porcine reproductive and respiratory syndrome virus replication by targeting viral restriction factor TRIM22</article-title>. <source>J Virol</source>. (<year>2022</year>) <volume>96</volume>:<page-range>e01597&#x02013;01521</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1128/JVI.01597-21</pub-id>
</mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jarret</surname><given-names>A</given-names></name><name><surname>McFarland</surname><given-names>AP</given-names></name><name><surname>Horner</surname><given-names>SM</given-names></name><name><surname>Kell</surname><given-names>A</given-names></name><name><surname>Schwerk</surname><given-names>J</given-names></name><name><surname>Hong</surname><given-names>MA</given-names></name><etal/></person-group>. <article-title>Hepatitis-C-virus-induced microRNAs dampen interferon-mediated antiviral signaling</article-title>. <source>Nat Med</source>. (<year>2016</year>) <volume>22</volume>:<page-range>1475&#x02013;81</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/nm.4211</pub-id>
</mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barbu</surname><given-names>MG</given-names></name><name><surname>Condrat</surname><given-names>CE</given-names></name><name><surname>Thompson</surname><given-names>DC</given-names></name><name><surname>Bugnar</surname><given-names>OL</given-names></name><name><surname>Cretoiu</surname><given-names>D</given-names></name><name><surname>Toader</surname><given-names>OD</given-names></name><etal/></person-group>. <article-title>MicroRNA involvement in signaling pathways during viral infection</article-title>. <source>Front Cell Dev Biol</source>. (<year>2020</year>) <volume>8</volume>:<elocation-id>143</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fcell.2020.00143</pub-id>
<pub-id pub-id-type="pmid">32211411</pub-id>
</mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mishra</surname><given-names>R</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Ingle</surname><given-names>H</given-names></name><name><surname>Kumar</surname><given-names>H</given-names></name></person-group>. <article-title>The interplay between viral-derived miRNAs and host immunity during infection</article-title>. <source>Front Immunol</source>. (<year>2020</year>) <volume>10</volume>:<elocation-id>3079</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fimmu.2019.03079</pub-id>
<pub-id pub-id-type="pmid">32038626</pub-id>
</mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Amjad</surname><given-names>ZS</given-names></name><name><surname>Shojaeian</surname><given-names>A</given-names></name><name><surname>Sadri Nahand</surname><given-names>J</given-names></name><name><surname>Bayat</surname><given-names>M</given-names></name><name><surname>Taghizadieh</surname><given-names>MT</given-names></name><name><surname>Rostamian</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Oncoviruses: Induction of cancer development and metastasis by increasing anoikis resistance</article-title>. <source>Heliyon</source>. (<year>2023</year>) <volume>9</volume>:<elocation-id>e22598</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.heliyon.2023.e22598</pub-id>
<pub-id pub-id-type="pmid">38144298</pub-id>
</mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bayat</surname><given-names>M</given-names></name><name><surname>Golestani</surname><given-names>S</given-names></name><name><surname>Motlaghzadeh</surname><given-names>S</given-names></name><name><surname>Bannazadeh Baghi</surname><given-names>H</given-names></name><name><surname>Lalehzadeh</surname><given-names>A</given-names></name><name><surname>Sadri Nahand</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>War or peace: Viruses and metastasis</article-title>. <source>Biochim Biophys Acta (BBA) - Rev Cancer</source>. (<year>2024</year>) <volume>1879</volume>:<fpage>189179</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.bbcan.2024.189179</pub-id>
</mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mobini Kesheh</surname><given-names>M</given-names></name><name><surname>Bayat</surname><given-names>M</given-names></name><name><surname>Kobravi</surname><given-names>S</given-names></name><name><surname>Lotfalizadeh</surname><given-names>MH</given-names></name><name><surname>Heydari</surname><given-names>A</given-names></name><name><surname>Memar</surname><given-names>MY</given-names></name><etal/></person-group>. <article-title>MicroRNAs and human viral diseases: A focus on the role of microRNA-29</article-title>. <source>Biochim Biophys Acta (BBA) - Mol Basis Dis</source>. (<year>2025</year>) <volume>1871</volume>:<fpage>167500</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.bbadis.2024.167500</pub-id>
</mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Marshall</surname><given-names>JS</given-names></name><name><surname>Warrington</surname><given-names>R</given-names></name><name><surname>Watson</surname><given-names>W</given-names></name><name><surname>Kim</surname><given-names>HL</given-names></name></person-group>. <article-title>An introduction to immunology and immunopathology</article-title>. <source>Allergy Asthma Clin Immunol</source>. (<year>2018</year>) <volume>14</volume>:<fpage>49</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s13223-018-0278-1</pub-id>
<pub-id pub-id-type="pmid">30263032</pub-id>
</mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Siavosh Haghighi</surname><given-names>ZM</given-names></name><name><surname>Tabatabaei</surname><given-names>T</given-names></name><name><surname>Rafigh</surname><given-names>M</given-names></name><name><surname>Karampour</surname><given-names>R</given-names></name><name><surname>Babaei</surname><given-names>F</given-names></name><name><surname>Amjad</surname><given-names>ZS</given-names></name><etal/></person-group>. <article-title>Human papillomavirus maybe is a critical player in the regulation of chemoresistance related factors (P53, Rb, TWIST, Bcl-2, Bcl-XL, c-IAP2, cytochrome C, and caspase 3) in breast cancer</article-title>. <source>Pathol - Res Pract</source>. (<year>2023</year>) <volume>248</volume>:<fpage>154653</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.prp.2023.154653</pub-id>
<pub-id pub-id-type="pmid">37454490</pub-id>
</mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Fields</surname><given-names>BN</given-names></name></person-group>. <source>Fields' virology</source> Vol. <volume>1</volume>. <publisher-loc>Lausanne, Switzerland</publisher-loc>: <publisher-name>Frontiers Media</publisher-name> (<year>2007</year>).</mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Weber</surname><given-names>F</given-names></name></person-group>. <article-title>Antiviral innate immunity: introduction</article-title>. <source>Encyclopedia Virol</source>. (<year>2021</year>) <volume>577</volume>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/B978-0-12-809633-8.21290-9</pub-id>
</mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Isaacs</surname><given-names>A</given-names></name><name><surname>Lindenmann</surname><given-names>J</given-names></name></person-group>. <article-title>Virus interference. I. The interferon</article-title>. <source>J Interferon Res</source>. (<year>1987</year>) <volume>7</volume>:<page-range>429&#x02013;38</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1089/jir.1987.7.429</pub-id>
</mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pestka</surname><given-names>S</given-names></name><name><surname>Krause</surname><given-names>CD</given-names></name><name><surname>Walter</surname><given-names>MR</given-names></name></person-group>. <article-title>Interferons, interferon-like cytokines, and their receptors</article-title>. <source>Immunological Rev</source>. (<year>2004</year>) <volume>202</volume>:<fpage>8</fpage>&#x02013;<lpage>32</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1111/j.0105-2896.2004.00204.x</pub-id>
</mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bj&#x000f6;rkstr&#x000f6;m</surname><given-names>NK</given-names></name><name><surname>Strunz</surname><given-names>B</given-names></name><name><surname>Ljunggren</surname><given-names>H-G</given-names></name></person-group>. <article-title>Natural killer cells in antiviral immunity</article-title>. <source>Nat Rev Immunol</source>. (<year>2022</year>) <volume>22</volume>:<page-range>112&#x02013;23</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41577-021-00558-3</pub-id>
</mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schoenborn</surname><given-names>JR</given-names></name><name><surname>Wilson</surname><given-names>CB</given-names></name></person-group>. <article-title>Regulation of interferon-&#x003b3; during innate and adaptive immune responses</article-title>. <source>Adv Immunol</source>. (<year>2007</year>) <volume>96</volume>:<fpage>41</fpage>&#x02013;<lpage>101</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/S0065-2776(07)96002-2</pub-id>
<pub-id pub-id-type="pmid">17981204</pub-id>
</mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Prokunina-Olsson</surname><given-names>L</given-names></name><name><surname>Muchmore</surname><given-names>B</given-names></name><name><surname>Tang</surname><given-names>W</given-names></name><name><surname>Pfeiffer</surname><given-names>RM</given-names></name><name><surname>Park</surname><given-names>HY</given-names></name><name><surname>Dickensheets</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus</article-title>. <source>Nat Genet</source>. (<year>2013</year>) <volume>45</volume>:<page-range>164&#x02013;71</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/ng.2521</pub-id>
</mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>O'Brien</surname><given-names>TR</given-names></name><name><surname>Prokunina-Olsson</surname><given-names>L</given-names></name><name><surname>Donnelly</surname><given-names>RP</given-names></name></person-group>. <article-title>IFN-&#x003bb;4: the paradoxical new member of the interferon lambda family</article-title>. <source>J Interferon Cytokine Res</source>. (<year>2014</year>) <volume>34</volume>:<page-range>829&#x02013;38</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1089/jir.2013.0136</pub-id>
</mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Durbin</surname><given-names>RK</given-names></name><name><surname>Kotenko</surname><given-names>SV</given-names></name><name><surname>Durbin</surname><given-names>JE</given-names></name></person-group>. <article-title>Interferon induction and function at the mucosal surface</article-title>. <source>Immunological Rev</source>. (<year>2013</year>) <volume>255</volume>:<fpage>25</fpage>&#x02013;<lpage>39</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1111/imr.2013.255.issue-1</pub-id>
</mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Witte</surname><given-names>K</given-names></name><name><surname>Witte</surname><given-names>E</given-names></name><name><surname>Sabat</surname><given-names>R</given-names></name><name><surname>Wolk</surname><given-names>K</given-names></name></person-group>. <article-title>IL-28A, IL-28B, and IL-29: promising cytokines with type I interferon-like properties</article-title>. <source>Cytokine Growth factor Rev</source>. (<year>2010</year>) <volume>21</volume>:<page-range>237&#x02013;51</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.cytogfr.2010.04.002</pub-id>
</mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lee</surname><given-names>JS</given-names></name><name><surname>Shin</surname><given-names>E-C</given-names></name></person-group>. <article-title>The type I interferon response in COVID-19: implications for treatment</article-title>. <source>Nat Rev Immunol</source>. (<year>2020</year>) <volume>20</volume>:<page-range>585&#x02013;6</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41577-020-00429-3</pub-id>
</mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yan</surname><given-names>N</given-names></name><name><surname>Chen</surname><given-names>ZJ</given-names></name></person-group>. <article-title>Intrinsic antiviral immunity</article-title>. <source>Nat Immunol</source>. (<year>2012</year>) <volume>13</volume>:<page-range>214&#x02013;22</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/ni.2229</pub-id>
</mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Walker</surname><given-names>FC</given-names></name><name><surname>Sridhar</surname><given-names>PR</given-names></name><name><surname>Baldridge</surname><given-names>MT</given-names></name></person-group>. <article-title>Differential roles of interferons in innate responses to mucosal viral infections</article-title>. <source>Trends Immunol</source>. (<year>2021</year>) <volume>42</volume>:<page-range>1009&#x02013;23</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.it.2021.09.003</pub-id>
</mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Loo</surname><given-names>YM</given-names></name><name><surname>Gale</surname><given-names>M</given-names><suffix>Jr</suffix></name></person-group>. <article-title>Immune signaling by RIG-I-like receptors</article-title>. <source>Immunity</source>. (<year>2011</year>) <volume>34</volume>:<page-range>680&#x02013;92</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.immuni.2011.05.003</pub-id>
</mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kawai</surname><given-names>T</given-names></name><name><surname>Akira</surname><given-names>S</given-names></name></person-group>. <article-title>Toll-like receptor and RIG-1-like receptor signaling</article-title>. <source>Ann New York Acad Sci</source>. (<year>2008</year>) <volume>1143</volume>:<fpage>1</fpage>&#x02013;<lpage>20</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1196/nyas.2008.1143.issue-1</pub-id>
<pub-id pub-id-type="pmid">19076341</pub-id>
</mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Takeuchi</surname><given-names>O</given-names></name><name><surname>Akira</surname><given-names>S</given-names></name></person-group>. <article-title>MDA5/RIG-I and virus recognition</article-title>. <source>Curr Opin Immunol</source>. (<year>2008</year>) <volume>20</volume>:<fpage>17</fpage>&#x02013;<lpage>22</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.coi.2008.01.002</pub-id>
<pub-id pub-id-type="pmid">18272355</pub-id>
</mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brisse</surname><given-names>M</given-names></name><name><surname>Ly</surname><given-names>H</given-names></name></person-group>. <article-title>Comparative structure and function analysis of the RIG-I-like receptors: RIG-I and MDA5</article-title>. <source>Front Immunol</source>. (<year>2019</year>) <volume>10</volume>:<elocation-id>1586</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fimmu.2019.01586</pub-id>
<pub-id pub-id-type="pmid">31379819</pub-id>
</mixed-citation></ref><ref id="B41"><label>41</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yoneyama</surname><given-names>M</given-names></name><name><surname>Kikuchi</surname><given-names>M</given-names></name><name><surname>Natsukawa</surname><given-names>T</given-names></name><name><surname>Shinobu</surname><given-names>N</given-names></name><name><surname>Imaizumi</surname><given-names>T</given-names></name><name><surname>Miyagishi</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses</article-title>. <source>Nat Immunol</source>. (<year>2004</year>) <volume>5</volume>:<page-range>730&#x02013;7</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/ni1087</pub-id>
</mixed-citation></ref><ref id="B42"><label>42</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Andrejeva</surname><given-names>J</given-names></name><name><surname>Childs</surname><given-names>KS</given-names></name><name><surname>Young</surname><given-names>DF</given-names></name><name><surname>Carlos</surname><given-names>TS</given-names></name><name><surname>Stock</surname><given-names>N</given-names></name><name><surname>Goodbourn</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>The V proteins of paramyxoviruses bind the IFN-inducible RNA helicase, mda-5, and inhibit its activation of the IFN-&#x003b2; promoter</article-title>. <source>Proc Natl Acad Sci</source>. (<year>2004</year>) <volume>101</volume>:<page-range>17264&#x02013;9</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1073/pnas.0407639101</pub-id>
</mixed-citation></ref><ref id="B43"><label>43</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Monie</surname><given-names>TP</given-names></name></person-group>. <article-title>Section 2 - Immune Cells and the Process of Pattern Recognition</article-title>. In: <person-group person-group-type="editor"><name><surname>Monie</surname><given-names>TP</given-names></name></person-group>, editor. <source>The Innate Immune System</source>. <publisher-loc>London, UK</publisher-loc>: <publisher-name>Nature Publishing Group</publisher-name> (<year>2017</year>). p. <fpage>41</fpage>&#x02013;<lpage>82</lpage>.</mixed-citation></ref><ref id="B44"><label>44</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Reikine</surname><given-names>S</given-names></name><name><surname>Nguyen</surname><given-names>JB</given-names></name><name><surname>Modis</surname><given-names>Y</given-names></name></person-group>. <article-title>Pattern recognition and signaling mechanisms of RIG-I and MDA5</article-title>. <source>Front Immunol</source>. (<year>2014</year>) <volume>5</volume>:<elocation-id>342</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fimmu.2014.00342</pub-id>
<pub-id pub-id-type="pmid">25101084</pub-id>
</mixed-citation></ref><ref id="B45"><label>45</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bowie</surname><given-names>AG</given-names></name><name><surname>Unterholzner</surname><given-names>L</given-names></name></person-group>. <article-title>Viral evasion and subversion of pattern-recognition receptor signaling</article-title>. <source>Nat Rev Immunol</source>. (<year>2008</year>) <volume>8</volume>:<page-range>911&#x02013;22</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/nri2436</pub-id>
</mixed-citation></ref><ref id="B46"><label>46</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xu</surname><given-names>T</given-names></name><name><surname>Chu</surname><given-names>Q</given-names></name><name><surname>Cui</surname><given-names>J</given-names></name><name><surname>Bi</surname><given-names>D</given-names></name></person-group>. <article-title>Inducible microRNA-3570 feedback inhibits the RIG-I-dependent innate immune response to rhabdovirus in teleost fish by targeting MAVS/IPS-1</article-title>. <source>J Virol</source>. (<year>2018</year>) <volume>92</volume>:<page-range>e01594&#x02013;17</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1128/JVI.01594-17</pub-id>
</mixed-citation></ref><ref id="B47"><label>47</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Qiu</surname><given-names>Y</given-names></name><name><surname>Geng</surname><given-names>X</given-names></name><name><surname>Ban</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name></person-group>. <article-title>MicroRNA-218 inhibits type I interferon production and facilitates virus immune evasion via targeting RIG-I</article-title>. <source>Biotechnol Appl Biochem</source>. (<year>2020</year>) <volume>67</volume>:<fpage>396</fpage>&#x02013;<lpage>403</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1002/bab.1882</pub-id>
<pub-id pub-id-type="pmid">31912548</pub-id>
</mixed-citation></ref><ref id="B48"><label>48</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sheng</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>W</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Dong</surname><given-names>G</given-names></name><name><surname>Ge</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>MicroRNA-92a inhibits macrophage antiviral response by targeting retinoic acid inducible gene-I</article-title>. <source>Microbiol Immunol</source>. (<year>2018</year>) <volume>62</volume>:<page-range>585&#x02013;93</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1111/1348-0421.12640</pub-id>
</mixed-citation></ref><ref id="B49"><label>49</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hou</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Han</surname><given-names>Q</given-names></name><name><surname>Su</surname><given-names>C</given-names></name><name><surname>Qu</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Hepatitis B virus inhibits intrinsic RIG-I and RIG-G immune signaling via inducing miR146a</article-title>. <source>Sci Rep</source>. (<year>2016</year>) <volume>6</volume>:<fpage>26150</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/srep26150</pub-id>
<pub-id pub-id-type="pmid">27210312</pub-id>
</mixed-citation></ref><ref id="B50"><label>50</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Qin</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Zheng</surname><given-names>X</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Epstein-Barr virus miR-BART6-3p inhibits the RIG-I pathway</article-title>. <source>J innate Immun</source>. (<year>2017</year>) <volume>9</volume>:<page-range>574&#x02013;86</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1159/000479749</pub-id>
</mixed-citation></ref><ref id="B51"><label>51</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>HB</given-names></name><name><surname>Zhao</surname><given-names>ZZ</given-names></name><name><surname>Zou</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>XK</given-names></name><etal/></person-group>. <article-title>Identification of cellular microRNA-136 as a dual regulator of RIG-I-mediated innate immunity that antagonizes H5N1 IAV replication in A549 cells</article-title>. <source>Sci Rep</source>. (<year>2015</year>) <volume>5</volume>:<fpage>14991</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/srep14991</pub-id>
<pub-id pub-id-type="pmid">26450567</pub-id>
</mixed-citation></ref><ref id="B52"><label>52</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sluzalska</surname><given-names>KD</given-names></name><name><surname>Slawski</surname><given-names>J</given-names></name><name><surname>Sochacka</surname><given-names>M</given-names></name><name><surname>Lampart</surname><given-names>A</given-names></name><name><surname>Otlewski</surname><given-names>J</given-names></name><name><surname>Zakrzewska</surname><given-names>MG</given-names></name><etal/></person-group>. <article-title>Intracellular partners of fibroblast growth factors 1 and 2 - implications for functions</article-title>. <source>Cytokine Growth Factor Rev</source>. (<year>2021</year>) <volume>57</volume>:<fpage>93</fpage>&#x02013;<lpage>111</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.cytogfr.2020.05.004</pub-id>
<pub-id pub-id-type="pmid">32475760</pub-id>
</mixed-citation></ref><ref id="B53"><label>53</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Luo</surname><given-names>D</given-names></name><name><surname>Yang</surname><given-names>N</given-names></name></person-group>. <article-title>Cytosolic low molecular weight FGF2 orchestrates RIG-I-mediated innate immune response</article-title>. <source>J Immunol (Baltimore Md: 1950)</source>. (<year>2015</year>) <volume>195</volume>:<page-range>4943&#x02013;52</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.4049/jimmunol.1501503</pub-id>
</mixed-citation></ref><ref id="B54"><label>54</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Lai</surname><given-names>CC</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Ni</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Basic fibroblast growth factor protects against influenza A virus-induced acute lung injury by recruiting neutrophils</article-title>. <source>J Mol Cell Biol</source>. (<year>2018</year>) <volume>10</volume>:<page-range>573&#x02013;85</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1093/jmcb/mjx047</pub-id>
</mixed-citation></ref><ref id="B55"><label>55</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Lai</surname><given-names>CC</given-names></name><name><surname>Gu</surname><given-names>HJ</given-names></name><name><surname>Zhao</surname><given-names>LN</given-names></name><name><surname>Xia</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>PH</given-names></name><etal/></person-group>. <article-title>miR-194 inhibits innate antiviral immunity by targeting FGF2 in influenza H1N1 virus infection</article-title>. <source>Front Microbiol</source>. (<year>2017</year>) <volume>8</volume>:<elocation-id>2187</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fmicb.2017.02187</pub-id>
<pub-id pub-id-type="pmid">29163456</pub-id>
</mixed-citation></ref><ref id="B56"><label>56</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Feng</surname><given-names>P</given-names></name><name><surname>Gu</surname><given-names>T</given-names></name></person-group>. <article-title>MicroRNA-21-3p modulates FGF2 to facilitate influenza A virus H5N1 replication by refraining type I interferon response</article-title>. <source>Bioscience Rep</source>. (<year>2020</year>) <volume>40</volume>:<fpage>BSR20200158</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1042/BSR20200158</pub-id>
</mixed-citation></ref><ref id="B57"><label>57</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kolakofsky</surname><given-names>D</given-names></name><name><surname>Kowalinski</surname><given-names>E</given-names></name><name><surname>Cusack</surname><given-names>S</given-names></name></person-group>. <article-title>A structure-based model of RIG-I activation</article-title>. <source>Rna</source>. (<year>2012</year>) <volume>18</volume>:<page-range>2118&#x02013;27</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1261/rna.035949.112</pub-id>
</mixed-citation></ref><ref id="B58"><label>58</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Leung</surname><given-names>DW</given-names></name><name><surname>Amarasinghe</surname><given-names>GK</given-names></name></person-group>. <article-title>Structural insights into RNA recognition and activation of RIG-I-like receptors</article-title>. <source>Curr Opin Struct Biol</source>. (<year>2012</year>) <volume>22</volume>:<fpage>297</fpage>&#x02013;<lpage>303</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.sbi.2012.03.011</pub-id>
<pub-id pub-id-type="pmid">22560447</pub-id>
</mixed-citation></ref><ref id="B59"><label>59</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>RB</surname><given-names>S</given-names></name></person-group>. <article-title>Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF3</article-title>. <source>Cell</source>. (<year>2005</year>) <volume>122</volume>:<page-range>669&#x02013;82</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.cell.2005.08.012</pub-id>
</mixed-citation></ref><ref id="B60"><label>60</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Ji</surname><given-names>QL</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>F</given-names></name><name><surname>Zheng</surname><given-names>JS</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>MicroRNAs in the regulation of RIG-I-like receptor signaling pathway: possible strategy for viral infection and cancer</article-title>. <source>Biomolecules</source>. (<year>2023</year>) <volume>13</volume>:<fpage>1344</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/biom13091344</pub-id>
<pub-id pub-id-type="pmid">37759744</pub-id>
</mixed-citation></ref><ref id="B61"><label>61</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Van Dam</surname><given-names>H</given-names></name><name><surname>Ten Dijke</surname><given-names>P</given-names></name></person-group>. <article-title>UBE2O negatively regulates TRAF6-mediated NF-&#x003ba;B activation by inhibiting TRAF6 polyubiquitination</article-title>. <source>Cell Res</source>. (<year>2013</year>) <volume>23</volume>:<page-range>366&#x02013;77</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/cr.2013.21</pub-id>
</mixed-citation></ref><ref id="B62"><label>62</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Diamond</surname><given-names>MS</given-names></name><name><surname>Farzan</surname><given-names>M</given-names></name></person-group>. <article-title>The broad-spectrum antiviral functions of IFIT and IFITM proteins</article-title>. <source>Nat Rev Immunol</source>. (<year>2013</year>) <volume>13</volume>:<fpage>46</fpage>&#x02013;<lpage>57</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/nri3344</pub-id>
<pub-id pub-id-type="pmid">23237964</pub-id>
</mixed-citation></ref><ref id="B63"><label>63</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Minkoff</surname><given-names>JM</given-names></name><name><surname>tenOever</surname><given-names>B</given-names></name></person-group>. <article-title>Innate immune evasion strategies of SARS-CoV-2</article-title>. <source>Nat Rev Microbiol</source>. (<year>2023</year>) <volume>21</volume>:<page-range>178&#x02013;94</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41579-022-00839-1</pub-id>
</mixed-citation></ref><ref id="B64"><label>64</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fang</surname><given-names>A</given-names></name><name><surname>Yuan</surname><given-names>Y</given-names></name><name><surname>Sui</surname><given-names>BK</given-names></name><name><surname>Wang</surname><given-names>ZH</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Inhibition of miR-200b-3p confers broad-spectrum resistance to viral infection by targeting TBK1</article-title>. <source>mBio</source>. (<year>2023</year>) <volume>14</volume>:<page-range>e00867&#x02013;00823</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1128/mbio.00867-23</pub-id>
</mixed-citation></ref><ref id="B65"><label>65</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chang</surname><given-names>R</given-names></name><name><surname>Chu</surname><given-names>Q</given-names></name><name><surname>Zheng</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>T</given-names></name></person-group>. <article-title>The sp1-responsive microRNA-15b negatively regulates rhabdovirus-triggered innate immune responses in lower vertebrates by targeting TBK1</article-title>. <source>Front Immunol</source>. (<year>2021</year>) <volume>11</volume>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fimmu.2020.625828</pub-id>
</mixed-citation></ref><ref id="B66"><label>66</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Paludan</surname><given-names>SR</given-names></name><name><surname>Pradeu</surname><given-names>T</given-names></name><name><surname>Masters</surname><given-names>SL</given-names></name><name><surname>Mogensen</surname><given-names>TH</given-names></name></person-group>. <article-title>Constitutive immune mechanisms: mediators of host defense and immune regulation</article-title>. <source>Nat Rev Immunol</source>. (<year>2021</year>) <volume>21</volume>:<page-range>137&#x02013;50</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41577-020-0391-5</pub-id>
</mixed-citation></ref><ref id="B67"><label>67</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liang</surname><given-names>D</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>He</surname><given-names>ZH</given-names></name><name><surname>Zhao</surname><given-names>QL</given-names></name><name><surname>Deng</surname><given-names>Q</given-names></name><etal/></person-group>. <article-title>A human herpesvirus miRNA attenuates interferon signaling and contributes to maintenance of viral latency by targeting IKK&#x003b5;</article-title>. <source>Cell Res</source>. (<year>2011</year>) <volume>21</volume>:<fpage>793</fpage>&#x02013;<lpage>806</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/cr.2011.5</pub-id>
<pub-id pub-id-type="pmid">21221132</pub-id>
</mixed-citation></ref><ref id="B68"><label>68</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fitzgerald</surname><given-names>KA</given-names></name><name><surname>Kagan</surname><given-names>JC</given-names></name></person-group>. <article-title>Toll-like receptors and the control of immunity</article-title>. <source>Cell</source>. (<year>2020</year>) <volume>180</volume>:<page-range>1044&#x02013;66</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.cell.2020.02.041</pub-id>
</mixed-citation></ref><ref id="B69"><label>69</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Carty</surname><given-names>M</given-names></name><name><surname>Bowie</surname><given-names>AG</given-names></name></person-group>. <article-title>Recent insights into the role of Toll-like receptors in viral infection</article-title>. <source>Clin Exp Immunol</source>. (<year>2010</year>) <volume>161</volume>:<fpage>397</fpage>&#x02013;<lpage>406</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1111/j.1365-2249.2010.04196.x</pub-id>
<pub-id pub-id-type="pmid">20560984</pub-id>
</mixed-citation></ref><ref id="B70"><label>70</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Iannacone</surname><given-names>M</given-names></name><name><surname>Guidotti</surname><given-names>LG</given-names></name></person-group>. <article-title>Immunobiology and pathogenesis of hepatitis B virus infection</article-title>. <source>Nat Rev Immunol</source>. (<year>2022</year>) <volume>22</volume>:<fpage>19</fpage>&#x02013;<lpage>32</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41577-021-00549-4</pub-id>
<pub-id pub-id-type="pmid">34002067</pub-id>
</mixed-citation></ref><ref id="B71"><label>71</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pawar</surname><given-names>P</given-names></name><name><surname>Gokavi</surname><given-names>J</given-names></name><name><surname>Wakhare</surname><given-names>S</given-names></name><name><surname>Bagul</surname><given-names>R</given-names></name><name><surname>Ghule</surname><given-names>U</given-names></name><name><surname>Khan</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>MiR-155 Negatively Regulates Anti-Viral Innate Responses among HIV-Infected Progressors</article-title>. <source>Viruses</source>. (<year>2023</year>) <volume>15</volume>(<issue>11</issue>). doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/v15112206</pub-id>
</mixed-citation></ref><ref id="B72"><label>72</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mukherjee</surname><given-names>S</given-names></name><name><surname>Akbar</surname><given-names>I</given-names></name><name><surname>Kumari</surname><given-names>B</given-names></name><name><surname>Vrati</surname><given-names>S</given-names></name><name><surname>Basu</surname><given-names>A</given-names></name><name><surname>Banerjee</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Japanese Encephalitis Virus-induced let-7a/b interacted with the NOTCH-TLR 7 pathway in microglia and facilitated neuronal death via caspase activation</article-title>. <source>J neurochemistry</source>. (<year>2019</year>) <volume>149</volume>:<page-range>518&#x02013;34</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1111/jnc.2019.149.issue-4</pub-id>
</mixed-citation></ref><ref id="B73"><label>73</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Shao</surname><given-names>L</given-names></name></person-group>. <article-title>Decreased microRNA&#x02212;140&#x02212;5p contributes to respiratory syncytial virus disease through targeting Toll&#x02212;like receptor 4</article-title>. <source>Exp Ther Med</source>. (<year>2018</year>) <volume>16</volume>:<page-range>993&#x02013;9</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3892/etm.2018.6272</pub-id>
</mixed-citation></ref><ref id="B74"><label>74</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pareek</surname><given-names>S</given-names></name><name><surname>Roy</surname><given-names>S</given-names></name><name><surname>Kumari</surname><given-names>B</given-names></name><name><surname>Jain</surname><given-names>P</given-names></name><name><surname>Banerjee</surname><given-names>A</given-names></name><name><surname>Vrati</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>miR-155 induction in microglial cells suppresses Japanese encephalitis virus replication and negatively modulates innate immune responses</article-title>. <source>J Neuroinflammation</source>. (<year>2014</year>) <volume>11</volume>:<fpage>97</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/1742-2094-11-97</pub-id>
<pub-id pub-id-type="pmid">24885259</pub-id>
</mixed-citation></ref><ref id="B75"><label>75</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Thounaojam</surname><given-names>MC</given-names></name><name><surname>Kaushik</surname><given-names>DK</given-names></name><name><surname>Kundu</surname><given-names>K</given-names></name><name><surname>Basu</surname><given-names>A</given-names></name></person-group>. <article-title>MicroRNA-29b modulates Japanese encephalitis virus-induced microglia activation by targeting tumor necrosis factor alpha-induced protein 3</article-title>. <source>J Neurochem</source>. (<year>2014</year>) <volume>129</volume>:<page-range>143&#x02013;54</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1111/jnc.2014.129.issue-1</pub-id>
</mixed-citation></ref><ref id="B76"><label>76</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ashraf</surname><given-names>U</given-names></name><name><surname>Zhu</surname><given-names>B</given-names></name><name><surname>Ye</surname><given-names>J</given-names></name><name><surname>Wan</surname><given-names>S</given-names></name><name><surname>Nie</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>MicroRNA-19b-3p modulates Japanese encephalitis virus-mediated inflammation via targeting RNF11</article-title>. <source>J Virol</source>. (<year>2016</year>) <volume>90</volume>:<page-range>4780&#x02013;95</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1128/JVI.02586-15</pub-id>
</mixed-citation></ref><ref id="B77"><label>77</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Peng</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>WJ</given-names></name><name><surname>Jie</surname><given-names>SH</given-names></name><name><surname>Tong</surname><given-names>QX</given-names></name><name><surname>Lu</surname><given-names>MJ</given-names></name><etal/></person-group>. <article-title>Inhibitory effect of miR-125b on hepatitis C virus core protein-induced TLR2/MyD88 signaling in THP-1 cells</article-title>. <source>World J gastroenterology</source>. (<year>2016</year>) <volume>22</volume>:<page-range>4354&#x02013;61</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3748/wjg.v22.i17.4354</pub-id>
</mixed-citation></ref><ref id="B78"><label>78</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shukla</surname><given-names>A</given-names></name><name><surname>Rastogi</surname><given-names>M</given-names></name><name><surname>Singh</surname><given-names>SK</given-names></name></person-group>. <article-title>Zika virus NS1 suppresses the innate immune responses via miR-146a in human microglial cells</article-title>. <source>Int J Biol Macromolecules</source>. (<year>2021</year>) <volume>193</volume>:<page-range>2290&#x02013;6</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.ijbiomac.2021.11.061</pub-id>
</mixed-citation></ref><ref id="B79"><label>79</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mishra</surname><given-names>R</given-names></name><name><surname>Bhattacharya</surname><given-names>S</given-names></name><name><surname>Rawat</surname><given-names>BS</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Kumar</surname><given-names>AK</given-names></name><name><surname>Niraj</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>MicroRNA-30e-5p has an Integrated Role in the Regulation of the Innate Immune Response during Virus Infection and Systemic Lupus Erythematosus</article-title>. <source>iScience</source>. (<year>2020</year>) <volume>23</volume>:<fpage>101322</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.isci.2020.101322</pub-id>
<pub-id pub-id-type="pmid">32688283</pub-id>
</mixed-citation></ref><ref id="B80"><label>80</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Tan</surname><given-names>QC</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>YY</given-names></name><name><surname>Xue</surname><given-names>Y</given-names></name><name><surname>Song</surname><given-names>YJ</given-names></name><etal/></person-group>. <article-title>MicroRNA-33/33* inhibit the activation of MAVS through AMPK in antiviral innate immunity</article-title>. <source>Cell Mol Immunol</source>. (<year>2021</year>) <volume>18</volume>:<page-range>1450&#x02013;62</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41423-019-0326-x</pub-id>
</mixed-citation></ref><ref id="B81"><label>81</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hsu</surname><given-names>AC</given-names></name><name><surname>Dua</surname><given-names>K</given-names></name><name><surname>Starkey</surname><given-names>MR</given-names></name><name><surname>Haw</surname><given-names>TJ</given-names></name><name><surname>Nair</surname><given-names>PM</given-names></name><name><surname>Nichol</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>MicroRNA-125a and-b inhibit A20 and MAVS to promote inflammation and impair antiviral response in COPD</article-title>. <source>JCI insight</source>. (<year>2017</year>) <volume>2</volume>:<elocation-id>e90443</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1172/jci.insight.90443</pub-id>
<pub-id pub-id-type="pmid">28405612</pub-id>
</mixed-citation></ref><ref id="B82"><label>82</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Fu</surname><given-names>Z</given-names></name><name><surname>Liang</surname><given-names>HW</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Qi</surname><given-names>X</given-names></name><name><surname>Ding</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>H5N1 influenza virus-specific miRNA-like small RNA increases cytokine production and mouse mortality via targeting poly(rC)-binding protein 2</article-title>. <source>Cell Res</source>. (<year>2018</year>) <volume>28</volume>:<page-range>157&#x02013;71</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/cr.2018.3</pub-id>
</mixed-citation></ref><ref id="B83"><label>83</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Dong</surname><given-names>CY</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>ML</given-names></name><name><surname>Guan</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>Induction of the cellular miR-29c by influenza virus inhibits the innate immune response through protection of A20 mRNA</article-title>. <source>Biochem Biophys Res Commun</source>. (<year>2014</year>) <volume>450</volume>:<page-range>755&#x02013;61</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.bbrc.2014.06.059</pub-id>
</mixed-citation></ref><ref id="B84"><label>84</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Selvamani</surname><given-names>SP</given-names></name><name><surname>Mishra</surname><given-names>R</given-names></name><name><surname>Singh</surname><given-names>SK</given-names></name></person-group>. <article-title>Chikungunya virus exploits miR-146a to regulate NF-&#x003ba;B pathway in human synovial fibroblasts</article-title>. <source>PloS One</source>. (<year>2014</year>) <volume>9</volume>:<elocation-id>e103624</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1371/journal.pone.0103624</pub-id>
<pub-id pub-id-type="pmid">25083878</pub-id>
</mixed-citation></ref><ref id="B85"><label>85</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Cao</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Fang</surname><given-names>LR</given-names></name><name><surname>Zhong</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><etal/></person-group>. <article-title>MiR-125b reduces porcine reproductive and respiratory syndrome virus replication by negatively regulating the NF-&#x003ba;B pathway</article-title>. <source>PloS One</source>. (<year>2013</year>) <volume>8</volume>:<elocation-id>e55838</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1371/journal.pone.0055838</pub-id>
<pub-id pub-id-type="pmid">23409058</pub-id>
</mixed-citation></ref><ref id="B86"><label>86</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lai Frances</surname><given-names>W</given-names></name><name><surname>Stephenson Kyle</surname><given-names>B</given-names></name><name><surname>Mahony</surname><given-names>J</given-names></name><name><surname>Lichty Brian</surname><given-names>D</given-names></name></person-group>. <article-title>Human coronavirus OC43 nucleocapsid protein binds microRNA 9 and potentiates NF-&#x003ba;B activation</article-title>. <source>J Virol</source>. (<year>2014</year>) <volume>88</volume>:<fpage>54</fpage>&#x02013;<lpage>65</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1128/JVI.02678-13</pub-id>
<pub-id pub-id-type="pmid">24109243</pub-id>
</mixed-citation></ref><ref id="B87"><label>87</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Peng</surname><given-names>N</given-names></name><name><surname>Yang</surname><given-names>XC</given-names></name><name><surname>Zhu</surname><given-names>CL</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>HS</given-names></name><name><surname>Li</surname><given-names>MQ</given-names></name><etal/></person-group>. <article-title>MicroRNA-302 cluster downregulates enterovirus 71&#x02013;induced innate immune response by targeting KPNA2</article-title>. <source>J Immunol</source>. (<year>2018</year>) <volume>201</volume>:<page-range>145&#x02013;56</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.4049/jimmunol.1701692</pub-id>
</mixed-citation></ref><ref id="B88"><label>88</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Abend</surname><given-names>JR</given-names></name><name><surname>Ramalingam</surname><given-names>D</given-names></name><name><surname>Kieffer-Kwon</surname><given-names>PK</given-names></name><name><surname>Uldrick</surname><given-names>TS</given-names></name><name><surname>Yarchoan</surname><given-names>R</given-names></name><name><surname>Ziegelbauer</surname><given-names>JM</given-names></name><etal/></person-group>. <article-title>Kaposi's sarcoma-associated herpesvirus microRNAs target IRAK1 and MYD88, two components of the toll-like receptor/interleukin-1R signaling cascade, to reduce inflammatory-cytokine expression</article-title>. <source>J Virol</source>. (<year>2012</year>) <volume>86</volume>:<page-range>11663&#x02013;74</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1128/JVI.01147-12</pub-id>
</mixed-citation></ref><ref id="B89"><label>89</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Landais</surname><given-names>I</given-names></name><name><surname>Pelton</surname><given-names>C</given-names></name><name><surname>Streblow</surname><given-names>D</given-names></name><name><surname>DeFilippis</surname><given-names>V</given-names></name><name><surname>McWeeney</surname><given-names>S</given-names></name><name><surname>Nelson</surname><given-names>JA</given-names></name></person-group>. <article-title>Human cytomegalovirus miR-UL112-3p targets TLR2 and modulates the TLR2/IRAK1/NF&#x003ba;B signaling pathway</article-title>. <source>PloS Pathog</source>. (<year>2015</year>) <volume>11</volume>:<elocation-id>e1004881</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1371/journal.ppat.1004881</pub-id>
<pub-id pub-id-type="pmid">25955717</pub-id>
</mixed-citation></ref><ref id="B90"><label>90</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Skinner Camille</surname><given-names>M</given-names></name><name><surname>Ivanov Nikita</surname><given-names>S</given-names></name><name><surname>Barr Sarah</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Skalsky Rebecca</surname><given-names>L</given-names></name></person-group>. <article-title>An epstein-barr virus microRNA blocks interleukin-1 (IL-1) signaling by targeting IL-1 receptor 1</article-title>. <source>J Virol</source>. (<year>2017</year>) <volume>91</volume>:<elocation-id>e00530&#x02013;17</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1128/JVI.00530-17</pub-id>
<pub-id pub-id-type="pmid">28794034</pub-id>
</mixed-citation></ref><ref id="B91"><label>91</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Sun</surname><given-names>ZM</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Zhi</surname><given-names>S</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>ZH</given-names></name><etal/></person-group>. <article-title>HIV-1-derived exosomal microRNAs miR88 and miR99 promote the release of cytokines from human alveolar macrophages by binding to TLR8</article-title>. <source>Eur J Inflammation</source>. (<year>2019</year>) <volume>17</volume>:<fpage>2058739219870434</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1177/2058739219870434</pub-id>
</mixed-citation></ref><ref id="B92"><label>92</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>An</surname><given-names>H</given-names></name><name><surname>Hou</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>W</given-names></name><name><surname>Xu</surname><given-names>HM</given-names></name><name><surname>Zheng</surname><given-names>YJ</given-names></name><etal/></person-group>. <article-title>Phosphatase SHP-1 promotes TLR-and RIG-I-activated production of type I interferon by inhibiting the kinase IRAK1</article-title>. <source>Nat Immunol</source>. (<year>2008</year>) <volume>9</volume>:<page-range>542&#x02013;50</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/ni.1604</pub-id>
</mixed-citation></ref><ref id="B93"><label>93</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Konno</surname><given-names>H</given-names></name><name><surname>Yamamoto</surname><given-names>T</given-names></name><name><surname>Yamazaki</surname><given-names>K</given-names></name><name><surname>Gohda</surname><given-names>J</given-names></name><name><surname>Akiyama</surname><given-names>T</given-names></name><name><surname>Semba</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>TRAF6 establishes innate immune responses by activating NF-&#x003ba;B and IRF7 upon sensing cytosolic viral RNA and DNA</article-title>. <source>PloS One</source>. (<year>2009</year>) <volume>4</volume>:<elocation-id>e5674</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1371/journal.pone.0005674</pub-id>
<pub-id pub-id-type="pmid">19479062</pub-id>
</mixed-citation></ref><ref id="B94"><label>94</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bhaumik</surname><given-names>D</given-names></name><name><surname>Scott</surname><given-names>GK</given-names></name><name><surname>Schokrpur</surname><given-names>S</given-names></name><name><surname>Patil</surname><given-names>CK</given-names></name><name><surname>Campisi</surname><given-names>J</given-names></name><name><surname>Benz</surname><given-names>CC</given-names></name></person-group>. <article-title>Expression of microRNA-146 suppresses NF-&#x003ba;B activity with reduction of metastatic potential in breast cancer cells</article-title>. <source>Oncogene</source>. (<year>2008</year>) <volume>27</volume>:<page-range>5643&#x02013;7</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/onc.2008.171</pub-id>
</mixed-citation></ref><ref id="B95"><label>95</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mo</surname><given-names>L</given-names></name><name><surname>Zeng</surname><given-names>Z</given-names></name><name><surname>Deng</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Hepatitis A virus-induced hsa-miR-146a-5p attenuates IFN-&#x003b2; signaling by targeting adaptor protein TRAF6</article-title>. <source>Arch Virol</source>. (<year>2021</year>) <volume>166</volume>:<page-range>789&#x02013;99</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s00705-021-04952-z</pub-id>
</mixed-citation></ref><ref id="B96"><label>96</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hou</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>XG</given-names></name><name><surname>Ma</surname><given-names>F</given-names></name><name><surname>An</surname><given-names>HZ</given-names></name><etal/></person-group>. <article-title>MicroRNA-146a feedback inhibits RIG-I-dependent Type I IFN production in macrophages by targeting TRAF6, IRAK1, and IRAK2</article-title>. <source>J Immunol</source>. (<year>2009</year>) <volume>183</volume>:<page-range>2150&#x02013;8</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.4049/jimmunol.0900707</pub-id>
</mixed-citation></ref><ref id="B97"><label>97</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yan</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>YT</given-names></name><name><surname>Su</surname><given-names>Y</given-names></name><name><surname>Tian</surname><given-names>LL</given-names></name><name><surname>Qin</surname><given-names>PF</given-names></name><name><surname>Xu</surname><given-names>XF</given-names></name><etal/></person-group>. <article-title>microRNA-125a targets MAVS and TRAF6 to modulate interferon signaling and promote HCV infection</article-title>. <source>Virus Res</source>. (<year>2021</year>) <volume>296</volume>:<fpage>198336</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.virusres.2021.198336</pub-id>
<pub-id pub-id-type="pmid">33577860</pub-id>
</mixed-citation></ref><ref id="B98"><label>98</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ho</surname><given-names>BC</given-names></name><name><surname>Yu</surname><given-names>IS</given-names></name><name><surname>Lu</surname><given-names>LF</given-names></name><name><surname>Rudensky</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>HY</given-names></name><name><surname>Tsai</surname><given-names>CW</given-names></name></person-group>. <article-title>Inhibition of miR-146a prevents enterovirus-induced death by restoring the production of type I interferon</article-title>. <source>Nat Commun</source>. (<year>2014</year>) <volume>5</volume>:<fpage>3344</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/ncomms4344</pub-id>
<pub-id pub-id-type="pmid">24561744</pub-id>
</mixed-citation></ref><ref id="B99"><label>99</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Tang</surname><given-names>T</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Feng</surname><given-names>CH</given-names></name><etal/></person-group>. <article-title>Exosome-mediated miR-146a transfer suppresses type I interferon response and facilitates EV71 infection</article-title>. <source>PloS Pathog</source>. (<year>2017</year>) <volume>13</volume>:<elocation-id>e1006611</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1371/journal.ppat.1006611</pub-id>
<pub-id pub-id-type="pmid">28910400</pub-id>
</mixed-citation></ref><ref id="B100"><label>100</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Xie</surname><given-names>JJ</given-names></name><name><surname>Xu</surname><given-names>XP</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Ao</surname><given-names>F</given-names></name><name><surname>Wan</surname><given-names>YS</given-names></name><etal/></person-group>. <article-title>MicroRNA-548 down-regulates host antiviral response via direct targeting of IFN-&#x003bb;1</article-title>. <source>Protein Cell</source>. (<year>2013</year>) <volume>4</volume>:<page-range>130&#x02013;41</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s13238-012-2081-y</pub-id>
</mixed-citation></ref><ref id="B101"><label>101</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dafny</surname><given-names>N</given-names></name><name><surname>Lincoln</surname><given-names>J</given-names></name></person-group>. <article-title>Interferon and the central nervous system</article-title>. <source>Eur J Pharmacol</source>. (<year>2016</year>) <volume>523</volume>(<issue>1-3</issue>):<page-range>1&#x02013;15</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.ejphar.2005.08.029</pub-id>
</mixed-citation></ref><ref id="B102"><label>102</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Razzuoli</surname><given-names>E</given-names></name><name><surname>Zanotti</surname><given-names>C</given-names></name><name><surname>Amadori</surname><given-names>M</given-names></name></person-group>. <article-title>Modulation of the interferon response by environmental, noninfectious stressors</article-title>. In: <source>The Innate Immune Response to Noninfectious Stressors</source>. (<year>2016</year>) <fpage>191</fpage>&#x02013;<lpage>207</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/B978-0-12-801968-9.00008-8</pub-id>
</mixed-citation></ref><ref id="B103"><label>103</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Odendall</surname><given-names>C</given-names></name><name><surname>Kagan</surname><given-names>JC</given-names></name></person-group>. <article-title>The unique regulation and functions of type III interferons in antiviral immunity</article-title>. <source>Curr Opin Virol</source>. (<year>2015</year>) <volume>12</volume>:<fpage>47</fpage>&#x02013;<lpage>52</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.coviro.2015.02.003</pub-id>
<pub-id pub-id-type="pmid">25771505</pub-id>
</mixed-citation></ref><ref id="B104"><label>104</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>G</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name></person-group>. <article-title>Respiratory syncytial virus non-structural protein 1 facilitates virus replication through miR-29a-mediated inhibition of interferon-&#x003b1; receptor</article-title>. <source>Biochem Biophys Res Commun</source>. (<year>2016</year>) <volume>478</volume>:<page-range>1436&#x02013;41</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.bbrc.2016.08.142</pub-id>
</mixed-citation></ref><ref id="B105"><label>105</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>HL</given-names></name><name><surname>Du</surname><given-names>L</given-names></name><name><surname>Wei</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Feng</surname><given-names>WH</given-names></name><etal/></person-group>. <article-title>MicroRNA-30c targets the interferon&#x02013;alpha/beta receptor beta chain to promote type 2 PRRSV infection</article-title>. <source>J Gen Virol</source>. (<year>2018</year>) <volume>99</volume>:<page-range>1671&#x02013;80</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1099/jgv.0.001166</pub-id>
</mixed-citation></ref><ref id="B106"><label>106</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Majoros</surname><given-names>A</given-names></name><name><surname>Platanitis</surname><given-names>E</given-names></name><name><surname>Kernbauer-H&#x000f6;lzl</surname><given-names>E</given-names></name><name><surname>Rosebrock</surname><given-names>F</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>M</given-names></name><name><surname>Decker</surname><given-names>T</given-names></name></person-group>. <article-title>Canonical and non-canonical aspects of JAK&#x02013;STAT signaling: lessons from interferons for cytokine responses</article-title>. <source>Front Immunol</source>. (<year>2017</year>) <volume>8</volume>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fimmu.2017.00029</pub-id>
</mixed-citation></ref><ref id="B107"><label>107</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Borden</surname><given-names>EC</given-names></name><name><surname>Sen</surname><given-names>GC</given-names></name><name><surname>Uze</surname><given-names>G</given-names></name><name><surname>Silverman</surname><given-names>RH</given-names></name><name><surname>Ransohoff</surname><given-names>RM</given-names></name><name><surname>Foster</surname><given-names>GR</given-names></name><etal/></person-group>. <article-title>Interferons at age 50: past, current and future impact on biomedicine</article-title>. <source>Nat Rev Drug Discov</source>. (<year>2007</year>) <volume>6</volume>:<page-range>975&#x02013;90</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/nrd2422</pub-id>
</mixed-citation></ref><ref id="B108"><label>108</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Levy</surname><given-names>DE</given-names></name><name><surname>Darnell</surname><given-names>J</given-names><suffix>Jr</suffix></name></person-group>. <article-title>Stats: transcriptional control and biological impact</article-title>. <source>Nat Rev Mol Cell Biol</source>. (<year>2002</year>) <volume>3</volume>:<page-range>651&#x02013;62</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/nrm909</pub-id>
</mixed-citation></ref><ref id="B109"><label>109</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Dong</surname><given-names>J</given-names></name><name><surname>Fu</surname><given-names>H</given-names></name><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Ji</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Inducible downregulation of miR-93 feedback promotes innate responses against RNA virus by amplifying interferon signaling</article-title>. <source>Am J Trans Res</source>. (<year>2022</year>) <volume>14</volume>:<page-range>7689&#x02013;704</page-range>.</mixed-citation></ref><ref id="B110"><label>110</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Guo</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Ji</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Inhibition of miR-93 promotes interferon effector signaling to suppress influenza A infection by upregulating JAK1</article-title>. <source>Int Immunopharmacol</source>. (<year>2020</year>) <volume>86</volume>:<fpage>106754</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.intimp.2020.106754</pub-id>
<pub-id pub-id-type="pmid">32652502</pub-id>
</mixed-citation></ref><ref id="B111"><label>111</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mukherjee</surname><given-names>A</given-names></name><name><surname>Bisceglie</surname><given-names>AMD</given-names></name><name><surname>Ray</surname><given-names>RB</given-names></name></person-group>. <article-title>Hepatitis C virus-mediated enhancement of microRNA miR-373 impairs the JAK/STAT signaling pathway</article-title>. <source>J Virol</source>. (<year>2015</year>) <volume>89</volume>:<page-range>3356&#x02013;65</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1128/JVI.03085-14</pub-id>
</mixed-citation></ref><ref id="B112"><label>112</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Gao</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>HC</given-names></name><name><surname>Tang</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>MicroRNA-30c modulates type I IFN responses to facilitate porcine reproductive and respiratory syndrome virus infection by targeting JAK1</article-title>. <source>J Immunol (Baltimore Md: 1950)</source>. (<year>2016</year>) <volume>196</volume>:<page-range>2272&#x02013;82</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.4049/jimmunol.1502006</pub-id>
</mixed-citation></ref><ref id="B113"><label>113</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schneider</surname><given-names>WM</given-names></name><name><surname>Chevillotte</surname><given-names>MD</given-names></name><name><surname>Rice</surname><given-names>CM</given-names></name></person-group>. <article-title>Interferon-stimulated genes: a complex web of host defenses</article-title>. <source>Annu Rev Immunol</source>. (<year>2014</year>) <volume>32</volume>:<page-range>513&#x02013;45</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1146/annurev-immunol-032713-120231</pub-id>
</mixed-citation></ref><ref id="B114"><label>114</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lazear</surname><given-names>HM</given-names></name><name><surname>Schoggins</surname><given-names>JW</given-names></name><name><surname>Diamond</surname><given-names>MS</given-names></name></person-group>. <article-title>Shared and distinct functions of type I and type III interferons</article-title>. <source>Immunity</source>. (<year>2019</year>) <volume>50</volume>:<page-range>907&#x02013;23</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.immuni.2019.03.025</pub-id>
</mixed-citation></ref><ref id="B115"><label>115</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>E</given-names></name><name><surname>Li</surname><given-names>MMH</given-names></name></person-group>. <article-title>All about the RNA: interferon-stimulated genes that interfere&#x000a0;with viral RNA processes</article-title>. <source>Front Immunol</source>. (<year>2020</year>) <volume>11</volume>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fimmu.2020.605024</pub-id>
</mixed-citation></ref><ref id="B116"><label>116</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rusinova</surname><given-names>I</given-names></name><name><surname>Forster</surname><given-names>S</given-names></name><name><surname>Yu</surname><given-names>S</given-names></name><name><surname>Kannan</surname><given-names>A</given-names></name><name><surname>Masse</surname><given-names>M</given-names></name><name><surname>Cumming</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Interferome v2. 0: an updated database of annotated interferon-regulated genes</article-title>. <source>Nucleic Acids Res</source>. (<year>2012</year>) <volume>41</volume>:<page-range>D1040&#x02013;6</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1093/nar/gks1215</pub-id>
</mixed-citation></ref><ref id="B117"><label>117</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Au-Yeung</surname><given-names>N</given-names></name><name><surname>Horvath</surname><given-names>CM</given-names></name></person-group>. <article-title>Transcriptional and chromatin regulation in interferon and innate antiviral gene expression</article-title>. <source>Cytokine Growth factor Rev</source>. (<year>2018</year>) <volume>44</volume>:<page-range>11&#x02013;7</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.cytogfr.2018.10.003</pub-id>
</mixed-citation></ref><ref id="B118"><label>118</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schoggins</surname><given-names>JW</given-names></name></person-group>. <article-title>Interferon-stimulated genes: what do they all do</article-title>? <source>Annu Rev Virol</source>. (<year>2019</year>) <volume>6</volume>:<page-range>567&#x02013;84</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1146/annurev-virology-092818-015756</pub-id>
</mixed-citation></ref><ref id="B119"><label>119</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Melki</surname><given-names>I</given-names></name><name><surname>Fr&#x000e9;mond</surname><given-names>M-L</given-names></name></person-group>. <article-title>Type I interferonopathies: from a novel concept to targeted therapeutics</article-title>. <source>Curr Rheumatol Rep</source>. (<year>2020</year>) <volume>22</volume>:<fpage>1</fpage>&#x02013;<lpage>14</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s11926-020-00909-4</pub-id>
</mixed-citation></ref><ref id="B120"><label>120</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Carty</surname><given-names>M</given-names></name><name><surname>Guy</surname><given-names>C</given-names></name><name><surname>Bowie</surname><given-names>AG</given-names></name></person-group>. <article-title>Detection of viral infections by innate immunity</article-title>. <source>Biochem Pharmacol</source>. (<year>2021</year>) <volume>183</volume>:<fpage>114316</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.bcp.2020.114316</pub-id>
<pub-id pub-id-type="pmid">33152343</pub-id>
</mixed-citation></ref><ref id="B121"><label>121</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gao</surname><given-names>S</given-names></name><name><surname>von der Malsburg</surname><given-names>A</given-names></name><name><surname>Paeschke</surname><given-names>S</given-names></name><name><surname>Behlke</surname><given-names>J</given-names></name><name><surname>Haller</surname><given-names>O</given-names></name><name><surname>Kochs</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Structural basis of oligomerization in the stalk region of dynamin-like MxA</article-title>. <source>Nature</source>. (<year>2010</year>) <volume>465</volume>:<page-range>502&#x02013;6</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/nature08972</pub-id>
</mixed-citation></ref><ref id="B122"><label>122</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Alalem</surname><given-names>M</given-names></name><name><surname>Dabous</surname><given-names>E</given-names></name><name><surname>Awad</surname><given-names>AM</given-names></name><name><surname>Alalem</surname><given-names>N</given-names></name><name><surname>Guirgis</surname><given-names>AA</given-names></name><name><surname>El-Masry</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Influenza a virus regulates interferon signaling and its associated genes; MxA and STAT3 by cellular miR-141 to ensure viral replication</article-title>. <source>Virol J</source>. (<year>2023</year>) <volume>20</volume>:<fpage>183</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s12985-023-02146-4</pub-id>
<pub-id pub-id-type="pmid">37596622</pub-id>
</mixed-citation></ref><ref id="B123"><label>123</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pichulik</surname><given-names>T</given-names></name><name><surname>Khatamzas</surname><given-names>E</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Brain</surname><given-names>O</given-names></name><name><surname>Garcia</surname><given-names>MD</given-names></name><name><surname>Leslie</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Pattern recognition receptor mediated downregulation of microRNA-650 fine-tunes MxA expression in dendritic cells infected with influenza A virus</article-title>. <source>Eur J Immunol</source>. (<year>2016</year>) <volume>46</volume>:<page-range>167&#x02013;77</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1002/eji.2016.46.issue-1</pub-id>
</mixed-citation></ref><ref id="B124"><label>124</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Reid</surname><given-names>LE</given-names></name><name><surname>Brasnett</surname><given-names>AH</given-names></name><name><surname>Gilbert</surname><given-names>CS</given-names></name><name><surname>Porter</surname><given-names>AC</given-names></name><name><surname>Gewert</surname><given-names>DR</given-names></name><name><surname>Stark</surname><given-names>GR</given-names></name><etal/></person-group>. <article-title>A single DNA response element can confer inducibility by both alpha- and gamma-interferons</article-title>. <source>Proc Natl Acad Sci United States America</source>. (<year>1989</year>) <volume>86</volume>:<page-range>840&#x02013;4</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1073/pnas.86.3.840</pub-id>
</mixed-citation></ref><ref id="B125"><label>125</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Friedman</surname><given-names>RL</given-names></name><name><surname>Manly</surname><given-names>SP</given-names></name><name><surname>McMahon</surname><given-names>M</given-names></name><name><surname>Kerr</surname><given-names>IM</given-names></name><name><surname>Stark</surname><given-names>GR</given-names></name></person-group>. <article-title>Transcriptional and posttranscriptional regulation of interferon-induced gene expression in human cells</article-title>. <source>Cell</source>. (<year>1984</year>) <volume>38</volume>:<page-range>745&#x02013;55</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/0092-8674(84)90270-8</pub-id>
</mixed-citation></ref><ref id="B126"><label>126</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Narayana</surname><given-names>SK</given-names></name><name><surname>Helbig</surname><given-names>KJ</given-names></name><name><surname>McCartney</surname><given-names>EM</given-names></name><name><surname>Eyre</surname><given-names>NS</given-names></name><name><surname>Bull</surname><given-names>RA</given-names></name><name><surname>Eltahla</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>The interferon-induced transmembrane proteins, IFITM1, IFITM2, and IFITM3 inhibit hepatitis C virus entry</article-title>. <source>J Biol Chem</source>. (<year>2015</year>) <volume>290</volume>:<page-range>25946&#x02013;59</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1074/jbc.M115.657346</pub-id>
</mixed-citation></ref><ref id="B127"><label>127</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Wilkins</surname><given-names>J</given-names></name><name><surname>Ding</surname><given-names>S</given-names></name><name><surname>Swartz</surname><given-names>TH</given-names></name><name><surname>Esposito</surname><given-names>AM</given-names></name><etal/></person-group>. <article-title>IFITM proteins restrict HIV-1 infection by antagonizing the envelope glycoprotein</article-title>. <source>Cell Rep</source>. (<year>2015</year>) <volume>13</volume>:<page-range>145&#x02013;56</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.celrep.2015.08.055</pub-id>
</mixed-citation></ref><ref id="B128"><label>128</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brass</surname><given-names>AL</given-names></name><name><surname>Huang</surname><given-names>I-C</given-names></name><name><surname>Yair Benita</surname><given-names>Y</given-names></name><name><surname>John</surname><given-names>SP</given-names></name><name><surname>Krishnan</surname><given-names>MN</given-names></name><name><surname>Feeley</surname><given-names>EM</given-names></name><etal/></person-group>. <article-title>The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus</article-title>. <source>Cell</source>. (<year>2009</year>) <volume>139</volume>:<page-range>1243&#x02013;54</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.cell.2009.12.017</pub-id>
</mixed-citation></ref><ref id="B129"><label>129</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Amini-Bavil-Olyaee</surname><given-names>S</given-names></name><name><surname>Choi</surname><given-names>YJ</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Shi</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>IC</given-names></name><name><surname>Farzan</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>The antiviral effector IFITM3 disrupts intracellular cholesterol homeostasis to block viral entry</article-title>. <source>Cell host Microbe</source>. (<year>2013</year>) <volume>13</volume>:<page-range>452&#x02013;64</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.chom.2013.03.006</pub-id>
</mixed-citation></ref><ref id="B130"><label>130</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Markosyan</surname><given-names>RM</given-names></name><name><surname>Zheng</surname><given-names>YM</given-names></name><name><surname>Golfetto</surname><given-names>O</given-names></name><name><surname>Bungart</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>IFITM proteins restrict viral membrane hemifusion</article-title>. <source>PloS Pathog</source>. (<year>2013</year>) <volume>9</volume>:<elocation-id>e1003124</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1371/journal.ppat.1003124</pub-id>
<pub-id pub-id-type="pmid">23358889</pub-id>
</mixed-citation></ref><ref id="B131"><label>131</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Warren</surname><given-names>CJ</given-names></name><name><surname>Griffin</surname><given-names>LM</given-names></name><name><surname>Little</surname><given-names>AS</given-names></name><name><surname>Huang</surname><given-names>IC</given-names></name><name><surname>Farzan</surname><given-names>M</given-names></name><name><surname>Pyeon</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>The antiviral restriction factors IFITM1, 2 and 3 do not inhibit infection of human papillomavirus, cytomegalovirus and adenovirus</article-title>. <source>PloS One</source>. (<year>2014</year>) <volume>9</volume>:<elocation-id>e96579</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1371/journal.pone.0096579</pub-id>
<pub-id pub-id-type="pmid">24827144</pub-id>
</mixed-citation></ref><ref id="B132"><label>132</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Guo</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Cuconati</surname><given-names>A</given-names></name><name><surname>Chang</surname><given-names>J</given-names></name><name><surname>Block</surname><given-names>TM</given-names></name><etal/></person-group>. <article-title>Interferon induction of IFITM proteins promotes infection by human coronavirus OC43</article-title>. <source>Proc Natl Acad Sci</source>. (<year>2014</year>) <volume>111</volume>:<page-range>6756&#x02013;61</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1073/pnas.1320856111</pub-id>
</mixed-citation></ref><ref id="B133"><label>133</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hussein</surname><given-names>HAM</given-names></name><name><surname>Akula</surname><given-names>SM</given-names></name></person-group>. <article-title>miRNA-36 inhibits KSHV, EBV, HSV-2 infection of cells via stifling expression of interferon induced transmembrane protein 1 (IFITM1)</article-title>. <source>Sci Rep</source>. (<year>2017</year>) <volume>7</volume>:<fpage>17972</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41598-017-18225-w</pub-id>
<pub-id pub-id-type="pmid">29269892</pub-id>
</mixed-citation></ref><ref id="B134"><label>134</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mohamadi</surname><given-names>S</given-names></name><name><surname>Mehrasa</surname><given-names>P</given-names></name><name><surname>Mehramuz</surname><given-names>B</given-names></name><name><surname>Kobravi</surname><given-names>S</given-names></name><name><surname>Taghizadieh</surname><given-names>M</given-names></name><name><surname>Salmaninejad</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>The tumor microenvironment's gambit: Exosomal pawns on the board of head and neck cancer</article-title>. <source>Biochim Biophys Acta (BBA) - Rev Cancer</source>. (<year>2024</year>) <volume>1879</volume>:<fpage>189189</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.bbcan.2024.189189</pub-id>
</mixed-citation></ref><ref id="B135"><label>135</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Qi</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Lv</surname><given-names>J</given-names></name><name><surname>Hou</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Host microRNA miR-1307 suppresses foot-and-mouth disease virus replication by promoting VP3 degradation and enhancing innate immune response</article-title>. <source>Virology</source>. (<year>2019</year>) <volume>535</volume>:<page-range>162&#x02013;70</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.virol.2019.07.009</pub-id>
</mixed-citation></ref><ref id="B136"><label>136</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Duan</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>McGilvray</surname><given-names>I</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Micro RNA-130a inhibits HCV replication by restoring the innate immune response</article-title>. <source>J viral hepatitis</source>. (<year>2014</year>) <volume>21</volume>:<page-range>121&#x02013;8</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1111/jvh.2013.21.issue-2</pub-id>
</mixed-citation></ref><ref id="B137"><label>137</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Patil</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>S</given-names></name></person-group>. <article-title>Tripartite motif proteins: an emerging antiviral protein family</article-title>. <source>Future Virol</source>. (<year>2019</year>) <volume>14</volume>:<page-range>107&#x02013;22</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.2217/fvl-2018-0161</pub-id>
</mixed-citation></ref><ref id="B138"><label>138</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Meroni</surname><given-names>G</given-names></name><name><surname>Diez-Roux</surname><given-names>G</given-names></name></person-group>. <article-title>TRIM/RBCC, a novel class of &#x02018;single protein RING finger&#x02019;E3 ubiquitin ligases</article-title>. <source>Bioessays</source>. (<year>2005</year>) <volume>27</volume>:<page-range>1147&#x02013;57</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1002/bies.v27:11</pub-id>
</mixed-citation></ref><ref id="B139"><label>139</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yau</surname><given-names>R</given-names></name><name><surname>Rape</surname><given-names>M</given-names></name></person-group>. <article-title>The increasing complexity of the ubiquitin code</article-title>. <source>Nat Cell Biol</source>. (<year>2016</year>) <volume>18</volume>:<page-range>579&#x02013;86</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/ncb3358</pub-id>
</mixed-citation></ref><ref id="B140"><label>140</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gack</surname><given-names>MU</given-names></name><name><surname>Shin</surname><given-names>YC</given-names></name><name><surname>Joo</surname><given-names>CH</given-names></name><name><surname>Urano</surname><given-names>T</given-names></name><name><surname>Liang</surname><given-names>C</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity</article-title>. <source>Nature</source>. (<year>2007</year>) <volume>446</volume>:<page-range>916&#x02013;20</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/nature05732</pub-id>
</mixed-citation></ref><ref id="B141"><label>141</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Xie</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Shen</surname><given-names>L</given-names></name><name><surname>Gong</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>MicroRNA-30a modulates type I interferon responses to facilitate coxsackievirus B3 replication via targeting tripartite motif protein 25</article-title>. <source>Front Immunol</source>. (<year>2021</year>) <volume>11</volume>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fimmu.2020.603437</pub-id>
</mixed-citation></ref><ref id="B142"><label>142</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zheng</surname><given-names>Q</given-names></name><name><surname>Hou</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name></person-group>. <article-title>Type I IFN&#x02013;inducible downregulation of microRNA-27a feedback inhibits antiviral innate response by upregulating siglec1/TRIM27</article-title>. <source>J Immunol</source>. (<year>2016</year>) <volume>196</volume>:<page-range>1317&#x02013;26</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.4049/jimmunol.1502134</pub-id>
</mixed-citation></ref><ref id="B143"><label>143</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schwartz</surname><given-names>SL</given-names></name><name><surname>Conn</surname><given-names>GL</given-names></name></person-group>. <article-title>RNA regulation of the antiviral protein 2&#x02032;-5&#x02032;-oligoadenylate synthetase</article-title>. <source>Wiley Interdiscip Reviews: RNA</source>. (<year>2019</year>) <volume>10</volume>:<fpage>e1534</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1002/wrna.2019.10.issue-4</pub-id>
<pub-id pub-id-type="pmid">30989826</pub-id>
</mixed-citation></ref><ref id="B144"><label>144</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Qian</surname><given-names>W</given-names></name><name><surname>Gu</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>SARS-coV-2-encoded miRNAs inhibit host type I interferon pathway and mediate allelic differential expression of susceptible gene</article-title>. <source>Front Immunol</source>. (<year>2021</year>) <volume>12</volume>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fimmu.2021.767726</pub-id>
</mixed-citation></ref><ref id="B145"><label>145</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bouvet</surname><given-names>M</given-names></name><name><surname>Voigt</surname><given-names>S</given-names></name><name><surname>Tagawa</surname><given-names>T</given-names></name><name><surname>Albanese</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>YF</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Multiple viral microRNAs regulate interferon release and signaling early during infection with Epstein-Barr virus</article-title>. <source>MBio</source>. (<year>2021</year>) <volume>12</volume>:<page-range>03440&#x02013;20</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1128/mBio.03440-20</pub-id>
</mixed-citation></ref><ref id="B146"><label>146</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>XH</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Huang</surname><given-names>K</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>The downregulation of microRNA hsa-miR-340-5p in IAV-infected A549 cells suppresses viral replication by targeting RIG-I and OAS2</article-title>. <source>Mol Therapy-Nucleic Acids</source>. (<year>2019</year>) <volume>14</volume>:<page-range>509&#x02013;19</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.omtn.2018.12.014</pub-id>
</mixed-citation></ref><ref id="B147"><label>147</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Freitas</surname><given-names>BT</given-names></name><name><surname>Scholte</surname><given-names>FEM</given-names></name><name><surname>Bergeron</surname><given-names>&#x000c9;</given-names></name><name><surname>Pegan</surname><given-names>SD</given-names></name></person-group>. <article-title>How ISG15 combats viral infection</article-title>. <source>Virus Res</source>. (<year>2020</year>) <volume>286</volume>:<fpage>198036</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.virusres.2020.198036</pub-id>
<pub-id pub-id-type="pmid">32492472</pub-id>
</mixed-citation></ref><ref id="B148"><label>148</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Lowey</surname><given-names>B</given-names></name><name><surname>Sodroski</surname><given-names>C</given-names></name><name><surname>Krishnamurthy</surname><given-names>S</given-names></name><name><surname>Alao</surname><given-names>H</given-names></name><name><surname>Cha</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Cellular microRNA networks regulate host dependency of hepatitis C virus infection</article-title>. <source>Nat Commun</source>. (<year>2017</year>) <volume>8</volume>:<fpage>1789</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41467-017-01954-x</pub-id>
<pub-id pub-id-type="pmid">29176620</pub-id>
</mixed-citation></ref><ref id="B149"><label>149</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Gong</surname><given-names>Z</given-names></name><name><surname>Xie</surname><given-names>J</given-names></name></person-group>. <article-title>Role of ISG15 post-translational modification in immunity against Mycobacterium tuberculosis infection</article-title>. <source>Cell Signaling</source>. (<year>2022</year>) <volume>94</volume>:<fpage>110329</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.cellsig.2022.110329</pub-id>
</mixed-citation></ref><ref id="B150"><label>150</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jefferies</surname><given-names>CA</given-names></name></person-group>. <article-title>Regulating IRFs in IFN driven disease</article-title>. <source>Front Immunol</source>. (<year>2019</year>) <volume>10</volume>:<elocation-id>325</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fimmu.2019.00325</pub-id>
<pub-id pub-id-type="pmid">30984161</pub-id>
</mixed-citation></ref><ref id="B151"><label>151</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gong</surname><given-names>W</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name></person-group>. <article-title>Depletion of microRNA-373 represses the replication of hepatitis C virus via activation of type 1 interferon response by targeting IRF5</article-title>. <source>Yonsei Med J</source>. (<year>2018</year>) <volume>59</volume>:<page-range>1181&#x02013;9</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3349/ymj.2018.59.10.1181</pub-id>
</mixed-citation></ref><ref id="B152"><label>152</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>B-C</given-names></name><name><surname>Zhou</surname><given-names>Z-J</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name></person-group>. <article-title>pol-miR-731, a teleost miRNA upregulated by megalocytivirus, negatively regulates virus-induced type I interferon response, apoptosis and cell cycle arrest</article-title>. <source>Sci Rep</source>. (<year>2016</year>) <volume>6</volume>:<fpage>28354</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/srep28354</pub-id>
<pub-id pub-id-type="pmid">27311682</pub-id>
</mixed-citation></ref><ref id="B153"><label>153</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>AQ</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>LH</given-names></name><name><surname>Su</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>YA</given-names></name><etal/></person-group>. <article-title>MicroRNA miR-722 Inhibits Cyprinid Herpesvirus 3 Replication via Targeting the Viral Immune Evasion Protein ORF89, Which Negatively Regulates IFN by Degrading IRF3</article-title>. <source>J Immunol</source>. (<year>2022</year>) <volume>209</volume>:<page-range>1918&#x02013;29</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.4049/jimmunol.2200025</pub-id>
</mixed-citation></ref><ref id="B154"><label>154</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Smith</surname><given-names>JL</given-names></name><name><surname>Jeng</surname><given-names>S</given-names></name><name><surname>McWeeney</surname><given-names>SK</given-names></name><name><surname>Hirsch</surname><given-names>AJ</given-names></name></person-group>. <article-title>A microRNA screen identifies the wnt signaling pathway as a regulator of the interferon response during flavivirus infection</article-title>. <source>J Virol</source>. (<year>2017</year>) <volume>91</volume>:<page-range>e02388&#x02013;16</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1128/JVI.02388-16</pub-id>
</mixed-citation></ref><ref id="B155"><label>155</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lin</surname><given-names>R</given-names></name><name><surname>Mamane</surname><given-names>Y</given-names></name><name><surname>Hiscott</surname><given-names>J</given-names></name></person-group>. <article-title>Structural and functional analysis of interferon regulatory factor 3: localization of the transactivation and autoinhibitory domains</article-title>. <source>Mol Cell Biol</source>. (<year>1999</year>) <volume>19</volume>(<issue>4</issue>):<page-range>2465&#x02013;74</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1128/mcb.19.4.2465</pub-id>
</mixed-citation></ref><ref id="B156"><label>156</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ysebrant de Lendonck</surname><given-names>L</given-names></name><name><surname>Martinet</surname><given-names>V</given-names></name><name><surname>Goriely</surname><given-names>S</given-names></name></person-group>. <article-title>Interferon regulatory factor 3 in adaptive immune responses</article-title>. <source>Cell Mol Life Sci</source>. (<year>2014</year>) <volume>71</volume>:<page-range>3873&#x02013;83</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s00018-014-1653-9</pub-id>
</mixed-citation></ref><ref id="B157"><label>157</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Suhara</surname><given-names>W</given-names></name><name><surname>Yoneyama</surname><given-names>M</given-names></name><name><surname>Kitabayashi</surname><given-names>I</given-names></name><name><surname>Fujita</surname><given-names>T</given-names></name></person-group>. <article-title>Direct involvement of CREB-binding protein/p300 in sequence-specific DNA binding of virus-activated interferon regulatory factor-3 holocomplex</article-title>. <source>J Biol Chem</source>. (<year>2002</year>) <volume>277</volume>:<page-range>22304&#x02013;13</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1074/jbc.M200192200</pub-id>
</mixed-citation></ref><ref id="B158"><label>158</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cheng</surname><given-names>N</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Han</surname><given-names>Z-G</given-names></name></person-group>. <article-title>Argonaute2 promotes tumor metastasis by way of up-regulating focal adhesion kinase expression in hepatocellular carcinoma</article-title>. <source>Hepatology</source>. (<year>2013</year>) <volume>57</volume>:<page-range>1906&#x02013;18</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1002/hep.26202</pub-id>
</mixed-citation></ref><ref id="B159"><label>159</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Takahasi</surname><given-names>K</given-names></name><name><surname>Horiuchi</surname><given-names>M</given-names></name><name><surname>Fujii</surname><given-names>K</given-names></name><name><surname>Nakamura</surname><given-names>S</given-names></name><name><surname>Noda</surname><given-names>NN</given-names></name><name><surname>Yoneyama</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Ser386 phosphorylation of transcription factor IRF-3 induces dimerization and association with CBP/p300 without overall conformational change</article-title>. <source>Genes to Cells</source>. (<year>2010</year>) <volume>15</volume>:<page-range>901&#x02013;10</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1111/j.1365-2443.2010.01427.x</pub-id>
</mixed-citation></ref><ref id="B160"><label>160</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Song</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>JJ</given-names></name><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>Lee</surname><given-names>JY</given-names></name><name><surname>Chang</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>KJ</given-names></name><etal/></person-group>. <article-title>Fas-associated factor 1 negatively regulates the antiviral immune response by inhibiting translocation of interferon regulatory factor 3 to the nucleus</article-title>. <source>Mol Cell Biol</source>. (<year>2016</year>) <volume>36</volume>(<issue>7</issue>):<page-range>1136&#x02013;51</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1128/MCB.00744-15</pub-id>
</mixed-citation></ref><ref id="B161"><label>161</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Weaver</surname><given-names>BK</given-names></name><name><surname>Kumar</surname><given-names>KP</given-names></name><name><surname>Reich</surname><given-names>NC</given-names></name></person-group>. <article-title>Interferon regulatory factor 3 and CREB-binding protein/p300 are subunits of double-stranded RNA-activated transcription factor DRAF1</article-title>. <source>Mol Cell Biol</source>. (<year>1998</year>) <volume>18</volume>:<page-range>1359&#x02013;68</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1128/MCB.18.3.1359</pub-id>
</mixed-citation></ref><ref id="B162"><label>162</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hooykaas</surname><given-names>MJ</given-names></name><name><surname>van Gent</surname><given-names>M</given-names></name><name><surname>Soppe</surname><given-names>JA</given-names></name><name><surname>Kruse</surname><given-names>E</given-names></name><name><surname>Boer</surname><given-names>IGJ</given-names></name><name><surname>van Leenen</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>EBV microrna BART16 suppresses type I ifn signaling</article-title>. <source>J Immunol</source>. (<year>2017</year>) <volume>198</volume>:<page-range>4062&#x02013;73</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.4049/jimmunol.1501605</pub-id>
</mixed-citation></ref><ref id="B163"><label>163</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Lu</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>QM</given-names></name><name><surname>Zhang</surname><given-names>CX</given-names></name></person-group>. <article-title>MicroRNA-132-3p suppresses type I IFN response through targeting IRF1 to facilitate H1N1 influenza A virus infection</article-title>. <source>Bioscience Rep</source>. (<year>2019</year>) <volume>39</volume>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1042/BSR20192769</pub-id>
</mixed-citation></ref><ref id="B164"><label>164</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Shi</surname><given-names>XB</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>YY</given-names></name><etal/></person-group>. <article-title>MicroRNA 373 facilitates the replication of porcine reproductive and respiratory syndrome virus by its negative regulation of type I interferon induction</article-title>. <source>J Virol</source>. (<year>2017</year>) <volume>91</volume>:<page-range>e01311&#x02013;16</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1128/JVI.01311-16</pub-id>
</mixed-citation></ref><ref id="B165"><label>165</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yadav</surname><given-names>P</given-names></name><name><surname>Chakraborty</surname><given-names>P</given-names></name><name><surname>Jha</surname><given-names>NK</given-names></name><name><surname>Dewanjee</surname><given-names>S</given-names></name><name><surname>Jha</surname><given-names>AK</given-names></name><name><surname>Panda</surname><given-names>SP</given-names></name><etal/></person-group>. <article-title>Molecular mechanism and role of Japanese encephalitis virus infection in central nervous system-mediated diseases</article-title>. <source>Viruses</source>. (<year>2022</year>) <volume>14</volume>:<fpage>2686</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/v14122686</pub-id>
<pub-id pub-id-type="pmid">36560690</pub-id>
</mixed-citation></ref><ref id="B166"><label>166</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hazra</surname><given-names>B</given-names></name><name><surname>Kumawat</surname><given-names>KL</given-names></name><name><surname>Basu</surname><given-names>A</given-names></name></person-group>. <article-title>The host microRNA miR-301a blocks the IRF1-mediated neuronal innate immune response to Japanese encephalitis virus infection</article-title>. <source>Sci Signaling</source>. (<year>2017</year>) <volume>10</volume>:<elocation-id>eaaf5185</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1126/scisignal.aaf5185</pub-id>
</mixed-citation></ref><ref id="B167"><label>167</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>WN</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Luo</surname><given-names>X</given-names></name><name><surname>Fang</surname><given-names>DF</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>CUEDC2 (CUE domain-containing 2) and SOCS3 (suppressors of cytokine signaling 3) cooperate to negatively regulate Janus kinase 1/signal transducers and activators of transcription 3 signaling</article-title>. <source>J Biol Chem</source>. (<year>2012</year>) <volume>287</volume>:<page-range>382&#x02013;92</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1074/jbc.M111.276832</pub-id>
</mixed-citation></ref><ref id="B168"><label>168</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yoshimura</surname><given-names>A</given-names></name><name><surname>Suzuki</surname><given-names>M</given-names></name><name><surname>Sakaguchi</surname><given-names>R</given-names></name><name><surname>Hanada</surname><given-names>T</given-names></name></person-group>. <article-title>&#x00026; Yasukawa, H. SOCS, inflammation, and autoimmunity</article-title>. <source>Front Immunol</source>. (<year>2012</year>) <volume>3</volume>:<elocation-id>20</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fimmu.2012.00020</pub-id>
<pub-id pub-id-type="pmid">22566904</pub-id>
</mixed-citation></ref><ref id="B169"><label>169</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Fu</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name></person-group>. <article-title>The JAK/STAT signaling pathway: from bench to clinic</article-title>. <source>Signal transduction targeted Ther</source>. (<year>2021</year>) <volume>6</volume>:<fpage>402</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41392-021-00791-1</pub-id>
</mixed-citation></ref><ref id="B170"><label>170</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>CL</given-names></name><name><surname>Xue</surname><given-names>M</given-names></name><name><surname>Fu</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>The Coronavirus Transmissible Gastroenteritis Virus Evades the Type I Interferon Response through IRE1&#x003b1;-Mediated Manipulation of the MicroRNA miR-30a-5p/SOCS1/3 Axis</article-title>. <source>J Virol</source>. (<year>2018</year>) <volume>92</volume>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1128/JVI.00728-18</pub-id>
</mixed-citation></ref><ref id="B171"><label>171</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yan</surname><given-names>B</given-names></name><name><surname>Ma</surname><given-names>H</given-names></name><name><surname>Jiang</surname><given-names>S</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Zhu</surname><given-names>WY</given-names></name><etal/></person-group>. <article-title>microRNA-221 restricts human cytomegalovirus replication via promoting type I IFN production by targeting SOCS1/NF-&#x003ba;B pathway</article-title>. <source>Cell Cycle</source>. (<year>2019</year>) <volume>18</volume>:<page-range>3072&#x02013;84</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1080/15384101.2019.1667706</pub-id>
</mixed-citation></ref><ref id="B172"><label>172</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Hou</surname><given-names>J</given-names></name><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>CM</given-names></name><name><surname>Liu</surname><given-names>XG</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Inducible microRNA-155 feedback promotes type I IFN signaling in antiviral innate immunity by targeting suppressor of cytokine signaling 1</article-title>. <source>J Immunol</source>. (<year>2010</year>) <volume>185</volume>:<page-range>6226&#x02013;33</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.4049/jimmunol.1000491</pub-id>
</mixed-citation></ref><ref id="B173"><label>173</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gao</surname><given-names>D</given-names></name><name><surname>Zhai</surname><given-names>AX</given-names></name><name><surname>Qian</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Song</surname><given-names>WQ</given-names></name><etal/></person-group>. <article-title>Down-regulation of suppressor of cytokine signaling 3 by miR-122 enhances interferon-mediated suppression of hepatitis B virus</article-title>. <source>Antiviral Res</source>. (<year>2015</year>) <volume>118</volume>:<page-range>20&#x02013;8</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.antiviral.2015.03.001</pub-id>
</mixed-citation></ref><ref id="B174"><label>174</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lu</surname><given-names>H</given-names></name><name><surname>Gu</surname><given-names>X</given-names></name></person-group>. <article-title>MicroRNA-221 inhibits human papillomavirus 16 E1-E2 mediated DNA replication through activating SOCS1/Type I IFN signaling pathway</article-title>. <source>Int J Clin Exp Pathol</source>. (<year>2019</year>) <volume>12</volume>:<page-range>1518&#x02013;28</page-range>.</mixed-citation></ref><ref id="B175"><label>175</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Shan</surname><given-names>LL</given-names></name><name><surname>Qu</surname><given-names>SX</given-names></name><name><surname>Xue</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>KL</given-names></name><name><surname>Fu</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>The coronavirus PEDV evades type III interferon response through the miR-30c-5p/SOCS1 axis</article-title>. <source>Front Microbiol</source>. (<year>2020</year>) <volume>11</volume>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fmicb.2020.01180</pub-id>
</mixed-citation></ref><ref id="B176"><label>176</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhai</surname><given-names>A</given-names></name><name><surname>Qian</surname><given-names>J</given-names></name><name><surname>Kao</surname><given-names>WP</given-names></name><name><surname>Li</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>JM</given-names></name><etal/></person-group>. <article-title>Borna disease virus encoded phosphoprotein inhibits host innate immunity by regulating miR-155</article-title>. <source>Antiviral Res</source>. (<year>2013</year>) <volume>98</volume>:<fpage>66</fpage>&#x02013;<lpage>75</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.antiviral.2013.02.009</pub-id>
<pub-id pub-id-type="pmid">23428672</pub-id>
</mixed-citation></ref><ref id="B177"><label>177</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Ingle</surname><given-names>H</given-names></name><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Mishra</surname><given-names>R</given-names></name><name><surname>Verma</surname><given-names>MK</given-names></name><etal/></person-group>. <article-title>MicroRNA hsa-miR-324-5p suppresses H5N1 virus replication by targeting the viral PB1 and host CUEDC2</article-title>. <source>J Virol</source>. (<year>2018</year>) <volume>92</volume>:<page-range>e01057&#x02013;18</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1128/JVI.01057-18</pub-id>
</mixed-citation></ref><ref id="B178"><label>178</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gu</surname><given-names>T</given-names></name><name><surname>Lu</surname><given-names>L</given-names></name><name><surname>An</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>XS</given-names></name><name><surname>Xu</surname><given-names>Q</given-names></name><etal/></person-group>. <article-title>Negative regulation of the RLR-mediated IFN signaling pathway by duck ubiquitin-specific protease 18 (USP18)</article-title>. <source>J Cell Physiol</source>. (<year>2019</year>) <volume>234</volume>:<fpage>3995</fpage>&#x02013;<lpage>4004</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1002/jcp.v234.4</pub-id>
<pub-id pub-id-type="pmid">30256391</pub-id>
</mixed-citation></ref><ref id="B179"><label>179</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Zhong</surname><given-names>H</given-names></name><name><surname>Luo</surname><given-names>R</given-names></name><name><surname>Shang</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Ubiquitin-specific protease 15 negatively regulates virus-induced type I interferon signaling via catalytically-dependent and -independent mechanisms</article-title>. <source>Sci Rep</source>. (<year>2015</year>) <volume>5</volume>:<fpage>11220</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/srep11220</pub-id>
<pub-id pub-id-type="pmid">26061460</pub-id>
</mixed-citation></ref><ref id="B180"><label>180</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>CY</given-names></name><name><surname>Hou</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>ZJ</given-names></name><etal/></person-group>. <article-title>miR-26a exerts broad-spectrum antiviral effects via the enhancement of RIG-I-mediated type I interferon response by targeting USP15</article-title>. <source>Microbiol Spectr</source>. (<year>2023</year>) <volume>12</volume>:<page-range>e03124&#x02013;03123</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1128/spectrum.03124-23</pub-id>
</mixed-citation></ref><ref id="B181"><label>181</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jounai</surname><given-names>N</given-names></name><name><surname>Takeshita</surname><given-names>F</given-names></name><name><surname>Kobiyama</surname><given-names>K</given-names></name><name><surname>Sawano</surname><given-names>A</given-names></name><name><surname>Miyawaki</surname><given-names>A</given-names></name><name><surname>Xin</surname><given-names>KQ</given-names></name><etal/></person-group>. <article-title>The Atg5&#x02013;Atg12 conjugate associates with innate antiviral immune responses</article-title>. <source>Proc Natl Acad Sci</source>. (<year>2007</year>) <volume>104</volume>:<page-range>14050&#x02013;5</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1073/pnas.0704014104</pub-id>
</mixed-citation></ref><ref id="B182"><label>182</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lee</surname><given-names>HK</given-names></name><name><surname>Lund</surname><given-names>JM</given-names></name><name><surname>Ramanathan</surname><given-names>B</given-names></name><name><surname>Mizushima</surname><given-names>N</given-names></name><name><surname>Iwasaki</surname><given-names>A</given-names></name></person-group>. <article-title>Autophagy-dependent viral recognition by plasmacytoid dendritic cells</article-title>. <source>Science</source>. (<year>2007</year>) <volume>315</volume>:<page-range>1398&#x02013;401</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1126/science.1136880</pub-id>
</mixed-citation></ref><ref id="B183"><label>183</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Duan</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>WT</given-names></name><name><surname>Holmes</surname><given-names>JA</given-names></name><name><surname>Kruger</surname><given-names>AJ</given-names></name><name><surname>Yang</surname><given-names>CH</given-names></name><etal/></person-group>. <article-title>Microrna-130a Downregulates HCV Replication through an atg5-Dependent Autophagy Pathway</article-title>. <source>Cells</source>. (<year>2019</year>) <volume>8</volume>:<fpage>338</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/cells8040338</pub-id>
<pub-id pub-id-type="pmid">30974864</pub-id>
</mixed-citation></ref><ref id="B184"><label>184</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>G</given-names></name><name><surname>Lv</surname><given-names>X</given-names></name><name><surname>Ren</surname><given-names>L</given-names></name></person-group>. <article-title>Critical role of cellular microRNAs in virus infection: decades of progress</article-title>. <source>Anim Zoonoses</source>. (<year>2025</year>). doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.azn.2025.01.002</pub-id>
</mixed-citation></ref><ref id="B185"><label>185</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Van der Ree</surname><given-names>M</given-names></name><name><surname>van der Meer</surname><given-names>AJ</given-names></name><name><surname>van Nuenen</surname><given-names>AC</given-names></name><name><surname>de Bruijne</surname><given-names>J</given-names></name><name><surname>Ottosen</surname><given-names>S</given-names></name><name><surname>Janssen</surname><given-names>HL</given-names></name><etal/></person-group>. <article-title>Miravirsen dosing in chronic hepatitis C patients results in decreased micro RNA-122 levels without affecting other micro RNA s in plasma</article-title>. <source>Alimentary Pharmacol Ther</source>. (<year>2016</year>) <volume>43</volume>:<page-range>102&#x02013;13</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1111/apt.2016.43.issue-1</pub-id>
</mixed-citation></ref><ref id="B186"><label>186</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Qin</surname><given-names>W</given-names></name></person-group>. <article-title>Downregulation of miR-146a inhibits influenza&#x000a0;A virus replication by enhancing the type I interferon response <italic>in vitro</italic> and in <italic>vivo</italic>
</article-title>. <source>Biomedicine Pharmacotherapy</source>. (<year>2019</year>) <volume>111</volume>:<page-range>740&#x02013;50</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.biopha.2018.12.103</pub-id>
</mixed-citation></ref><ref id="B187"><label>187</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Janssen</surname><given-names>HL</given-names></name><name><surname>Reesink</surname><given-names>HW</given-names></name><name><surname>Lawitz</surname><given-names>EJ</given-names></name><name><surname>Zeuzem</surname><given-names>S</given-names></name><name><surname>Rodriguez-Torres</surname><given-names>M</given-names></name><name><surname>Patel</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Treatment of HCV infection by targeting microRNA</article-title>. <source>New Engl J Med</source>. (<year>2013</year>) <volume>368</volume>:<page-range>1685&#x02013;94</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1056/NEJMoa1209026</pub-id>
</mixed-citation></ref><ref id="B188"><label>188</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Austin</surname><given-names>T</given-names></name></person-group>. <article-title>First microRNA mimic enters clinic</article-title>. <source>Nat Biotechnol</source>. (<year>2013</year>) <volume>31</volume>:<fpage>577</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/nbt0713-577</pub-id>
<pub-id pub-id-type="pmid">23839128</pub-id>
</mixed-citation></ref><ref id="B189"><label>189</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>DY</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Wei</surname><given-names>XJ</given-names></name><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>YP</given-names></name><etal/></person-group>. <article-title>Host-virus interaction: the antiviral defense function of small interfering RNAs can be enhanced by host microRNA-7</article-title>. <source>vitro Sci Rep</source>. (<year>2015</year>) <volume>5</volume>:<fpage>9722</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/srep09722</pub-id>
<pub-id pub-id-type="pmid">26067353</pub-id>
</mixed-citation></ref><ref id="B190"><label>190</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Arbuthnot</surname><given-names>P</given-names></name></person-group>. <article-title>MicroRNA-like antivirals</article-title>. <source>Biochim Biophys Acta (BBA)-Gene Regul Mech</source>. (<year>2011</year>) <volume>1809</volume>:<page-range>746&#x02013;55</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.bbagrm.2011.05.006</pub-id>
</mixed-citation></ref><ref id="B191"><label>191</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ivacik</surname><given-names>D</given-names></name><name><surname>Ely</surname><given-names>A</given-names></name><name><surname>Ferry</surname><given-names>N</given-names></name><name><surname>Arbuthnot</surname><given-names>P</given-names></name></person-group>. <article-title>Sustained inhibition of hepatitis B virus replication <italic>in vivo</italic> using RNAi-activating lentiviruses</article-title>. <source>Gene Ther</source>. (<year>2015</year>) <volume>22</volume>:<page-range>163&#x02013;71</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/gt.2014.94</pub-id>
</mixed-citation></ref><ref id="B192"><label>192</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Mu</surname><given-names>T</given-names></name><name><surname>Yi</surname><given-names>JY</given-names></name><name><surname>Ma</surname><given-names>CQ</given-names></name><name><surname>Xie</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>An HBV-encoded miRNA activates innate immunity to restrict HBV replication</article-title>. <source>J Mol Cell Biol</source>. (<year>2020</year>) <volume>12</volume>:<page-range>263&#x02013;76</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1093/jmcb/mjz104</pub-id>
</mixed-citation></ref><ref id="B193"><label>193</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chakraborty</surname><given-names>C</given-names></name><name><surname>Sharma</surname><given-names>AR</given-names></name><name><surname>Sharma</surname><given-names>G</given-names></name><name><surname>Doss</surname><given-names>CGP</given-names></name><name><surname>Lee</surname><given-names>S-S</given-names></name></person-group>. <article-title>Therapeutic miRNA and siRNA: moving from bench to clinic as next generation medicine</article-title>. <source>Mol Ther Nucleic Acids</source>. (<year>2017</year>) <volume>8</volume>:<page-range>132&#x02013;43</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.omtn.2017.06.005</pub-id>
</mixed-citation></ref><ref id="B194"><label>194</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hum</surname><given-names>C</given-names></name><name><surname>Loiselle</surname><given-names>J</given-names></name><name><surname>Ahmed</surname><given-names>N</given-names></name><name><surname>Shaw</surname><given-names>TA</given-names></name><name><surname>Toudic</surname><given-names>C</given-names></name><name><surname>Pezacki</surname><given-names>JP</given-names></name><etal/></person-group>. <article-title>MicroRNA mimics or inhibitors as antiviral therapeutic approaches against COVID-19</article-title>. <source>Drugs</source>. (<year>2021</year>) <volume>81</volume>:<page-range>517&#x02013;31</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s40265-021-01474-5</pub-id>
</mixed-citation></ref><ref id="B195"><label>195</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pamarthy</surname><given-names>D</given-names></name><name><surname>Chowdhury</surname><given-names>D</given-names></name><name><surname>Bhadra</surname><given-names>U</given-names></name><name><surname>Bhadra</surname><given-names>MP</given-names></name></person-group>. <article-title>Small molecule modulators of micro RNA and their role in cancer therapy</article-title>. <source>Biotechnol Bioeng</source>. (<year>2016</year>) <volume>3</volume>:<fpage>1070</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.47739/2333-7117/1070</pub-id>
</mixed-citation></ref><ref id="B196"><label>196</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhao</surname><given-names>R</given-names></name><name><surname>Fu</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name></person-group>. <article-title>Designing strategies of small-molecule compounds for modulating non-coding RNAs in cancer therapy</article-title>. <source>J Hematol Oncol</source>. (<year>2022</year>) <volume>15</volume>:<fpage>14</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s13045-022-01230-6</pub-id>
<pub-id pub-id-type="pmid">35123522</pub-id>
</mixed-citation></ref><ref id="B197"><label>197</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Peng</surname><given-names>LH</given-names></name><name><surname>Tian</surname><given-names>G</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>Q</given-names></name><etal/></person-group>. <article-title>Identifying small molecule-miRNA associations based on credible negative sample selection and random walk</article-title>. <source>Front Bioengineering Biotechnol</source>. (<year>2020</year>) <volume>8</volume>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fbioe.2020.00131</pub-id>
</mixed-citation></ref><ref id="B198"><label>198</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>LD</given-names></name><name><surname>Wei</surname><given-names>Z</given-names></name><name><surname>Silva</surname><given-names>MC</given-names></name><name><surname>Barber&#x000e1;n-Soler</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>JR</given-names></name><name><surname>Rabinovsky</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Small molecule regulators of microRNAs identified by high-throughput screen coupled with high-throughput sequencing</article-title>. <source>Nat Commun</source>. (<year>2023</year>) <volume>14</volume>:<fpage>7575</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41467-023-43293-0</pub-id>
<pub-id pub-id-type="pmid">37989753</pub-id>
</mixed-citation></ref><ref id="B199"><label>199</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McDermott</surname><given-names>AM</given-names></name><name><surname>Heneghan</surname><given-names>HM</given-names></name><name><surname>Miller</surname><given-names>N</given-names></name><name><surname>Kerin</surname><given-names>MJ</given-names></name></person-group>. <article-title>The therapeutic potential of microRNAs: disease modulators and drug targets</article-title>. <source>Pharmaceutical Res</source>. (<year>2011</year>) <volume>28</volume>:<page-range>3016&#x02013;29</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s11095-011-0550-2</pub-id>
</mixed-citation></ref><ref id="B200"><label>200</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hu</surname><given-names>S</given-names></name><name><surname>Liang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>JX</given-names></name><name><surname>Gao</surname><given-names>XJ</given-names></name><name><surname>Zheng</surname><given-names>YK</given-names></name><name><surname>Wang</surname><given-names>LQ</given-names></name><etal/></person-group>. <article-title>Mechanisms of hydrogel-based microRNA delivery systems and its application strategies in targeting inflammatory diseases</article-title>. <source>J Tissue Eng</source>. (<year>2024</year>) <volume>15</volume>:<fpage>20417314241265897</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1177/20417314241265897</pub-id>
<pub-id pub-id-type="pmid">39092451</pub-id>
</mixed-citation></ref><ref id="B201"><label>201</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ho</surname><given-names>PT</given-names></name><name><surname>Clark</surname><given-names>IM</given-names></name><name><surname>Le</surname><given-names>LT</given-names></name></person-group>. <article-title>MicroRNA-based diagnosis and therapy</article-title>. <source>Int J Mol Sci</source>. (<year>2022</year>) <volume>23</volume>:<fpage>7167</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/ijms23137167</pub-id>
<pub-id pub-id-type="pmid">35806173</pub-id>
</mixed-citation></ref><ref id="B202"><label>202</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>D-Y</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name></person-group>. <article-title>
<italic>In vivo</italic> delivery of miRNAs for cancer therapy: challenges and strategies</article-title>. <source>Advanced Drug delivery Rev</source>. (<year>2015</year>) <volume>81</volume>:<page-range>128&#x02013;41</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.addr.2014.05.009</pub-id>
</mixed-citation></ref><ref id="B203"><label>203</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Rana</surname><given-names>TM</given-names></name></person-group>. <article-title>Therapeutic targeting of microRNAs: current status and future challenges</article-title>. <source>Nat Rev Drug Discov</source>. (<year>2014</year>) <volume>13</volume>:<page-range>622&#x02013;38</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/nrd4359</pub-id>
</mixed-citation></ref><ref id="B204"><label>204</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hu</surname><given-names>R</given-names></name><name><surname>Wallace</surname><given-names>J</given-names></name><name><surname>Dahlem</surname><given-names>TJ</given-names></name><name><surname>Grunwald</surname><given-names>DJ</given-names></name><name><surname>O'Connell</surname><given-names>RM</given-names></name></person-group>. <article-title>Targeting human microRNA genes using engineered Tal-effector nucleases (TALENs)</article-title>. <source>PloS One</source>. (<year>2013</year>) <volume>8</volume>:<elocation-id>e63074</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1371/journal.pone.0063074</pub-id>
<pub-id pub-id-type="pmid">23667577</pub-id>
</mixed-citation></ref><ref id="B205"><label>205</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kim</surname><given-names>Y-K</given-names></name><name><surname>Wee</surname><given-names>G</given-names></name><name><surname>Park</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>JK</given-names></name><name><surname>Baek</surname><given-names>DH</given-names></name><name><surname>Kim</surname><given-names>JS</given-names></name><etal/></person-group>. <article-title>TALEN-based knockout library for human microRNAs</article-title>. <source>Nat Struct Mol Biol</source>. (<year>2013</year>) <volume>20</volume>:<page-range>1458&#x02013;64</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/nsmb.2701</pub-id>
</mixed-citation></ref><ref id="B206"><label>206</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Dai</surname><given-names>Z</given-names></name><name><surname>Liang</surname><given-names>Y</given-names></name><name><surname>Yin</surname><given-names>M</given-names></name><name><surname>Ma</surname><given-names>KY</given-names></name><name><surname>He</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Sequence-specific inhibition of microRNA via CRISPR/CRISPRi system</article-title>. <source>Sci Rep</source>. (<year>2014</year>) <volume>4</volume>:<fpage>3943</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/srep03943</pub-id>
<pub-id pub-id-type="pmid">24487629</pub-id>
</mixed-citation></ref><ref id="B207"><label>207</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ho</surname><given-names>T-T</given-names></name><name><surname>Zhou</surname><given-names>NJ</given-names></name><name><surname>Huang</surname><given-names>JG</given-names></name><name><surname>Koirala</surname><given-names>PK</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Fung</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Targeting non-coding RNAs with the CRISPR/Cas9 system in human cell lines</article-title>. <source>Nucleic Acids Res</source>. (<year>2015</year>) <volume>43</volume>:<page-range>e17&#x02013;7</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1093/nar/gku1198</pub-id>
</mixed-citation></ref><ref id="B208"><label>208</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mehta</surname><given-names>A</given-names></name><name><surname>Baltimore</surname><given-names>D</given-names></name></person-group>. <article-title>MicroRNAs as regulatory elements in immune system logic</article-title>. <source>Nat Rev Immunol</source>. (<year>2016</year>) <volume>16</volume>:<page-range>279&#x02013;94</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/nri.2016.40</pub-id>
</mixed-citation></ref><ref id="B209"><label>209</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bayat</surname><given-names>M</given-names></name><name><surname>Nahand</surname><given-names>JS</given-names></name></person-group>. <article-title>Let&#x02019;s make it personal: CRISPR tools in manipulating cell death pathways for cancer treatment</article-title>. <source>Cell Biol Toxicol</source>. (<year>2024</year>) <volume>40</volume>:<fpage>61</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s10565-024-09907-z</pub-id>
<pub-id pub-id-type="pmid">39075259</pub-id>
</mixed-citation></ref><ref id="B210"><label>210</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bannazadeh Baghi</surname><given-names>H</given-names></name><name><surname>Bayat</surname><given-names>M</given-names></name><name><surname>Mehrasa</surname><given-names>P</given-names></name><name><surname>Alavi</surname><given-names>SMA</given-names></name><name><surname>Lotfalizadeh</surname><given-names>MH</given-names></name></person-group>. <article-title>Regulatory role of microRNAs in virus-mediated inflammation</article-title>. <source>J Inflammation</source>. (<year>2024</year>) <volume>21</volume>:<fpage>43</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s12950-024-00417-7</pub-id>
</mixed-citation></ref><ref id="B211"><label>211</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Diener</surname><given-names>C</given-names></name><name><surname>Keller</surname><given-names>A</given-names></name><name><surname>Meese</surname><given-names>E</given-names></name></person-group>. <article-title>Emerging concepts of miRNA therapeutics: from&#x000a0;cells to clinic</article-title>. <source>Trends Genet</source>. (<year>2022</year>) <volume>38</volume>:<page-range>613&#x02013;26</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.tig.2022.02.006</pub-id>
</mixed-citation></ref></ref-list></back></article>